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The global prevalence of obesity and type 2 diabetes (T2D) continues to rise 
at an alarming rate. Despite the well-established association between obesity 
and an increased risk of developing T2D, the mechanisms underlying the 
pathogenesis of T2D with obesity remain unclear. Skeletal muscle is a major 
site for the disposal of ingested carbohydrate in healthy individuals. It is 
generally accepted that chronic overnutrition leads to accumulation of fat and 
fatty acid metabolites within the skeletal muscle which are believed to play a 
pivotal role in the progression of insulin resistance to carbohydrate metabolism 
which is one of the pathological hallmarks of T2D. Whilst several metabolites 
have been implicated, there appears to be no consensus over which 
metabolite is mediating skeletal muscle insulin resistance. 
In recent years, circulating concentrations of acylcarnitines, which are 
intermediates in glucose, fatty acid and branched chain amino acids (BCAAs) 
metabolism have been identified as potential novel biomarkers of insulin 
resistance and T2D. Furthermore, fatty acid derived acylcarnitines have since 
been shown to impair insulin signalling in vitro. Interestingly, BCAAs and their 
associated short-chain acylcarnitines appear to be more closely associated 
with insulin resistance than any marker of fatty acid metabolism, giving rise to 
the hypothesis that BCAAs and their catabolites may also play a causative role 
in the development of skeletal muscle insulin resistance. However, the 
simultaneous and quantitative assessment of acylcarnitines, BCAAs and 
related metabolites in human skeletal muscle is lacking or limited to one 
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metabolite group. Therefore, the main aim of this this thesis was to develop a 
quantitative analytical method for the assessment of BCAAs and 
acylcarnitines in human muscle to extend upon much of published literature 
which has been limited to investigations in fasting plasma samples and to 
explore their role in the development of insulin resistance and T2D. 
In Chapter 3 a novel liquid chromatography coupled to high resolution mass 
spectrometry method was developed and optimised to enable the quantitative 
assessment of a full range of BCAA and fatty acid derived acylcarnitines, 
BCAAs and related catabolites in both human plasma and muscle samples. 
The commonly cited challenges of metabolite quantification from biological 
tissues were systematically addressed using stable isotope internal standards 
allowing metabolite concentrations to be determined with a high degree of 
confidence.  
In Chapter 4, the method was validated by quantitatively assessing BCAAs 
and acylcarnitine concentrations in fasting plasma and skeletal muscle 
samples of patients with T2D and an age matched obese control subjects. The 
results revealed striking elevations of BCAAs and BCAA derived acylcarnitines 
in both plasma and muscle of patients with T2D compared to control subjects. 
Furthermore, these metabolites were significantly correlated with fasting blood 
glucose. Surprisingly, no significant differences in fatty acid derived 
acylcarnitines were observed between groups in either plasma or muscle. 
These data show that plasma profiles may not always reflect muscle profiles 
as suggested by previous reports. 
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In Chapter 5, skeletal muscle BCAA and acylcarnitine metabolism was 
investigated in the fasted and insulin stimulated state. In order to determine if 
the elevations observed in fasting state in the previous persist in the face of 
insulin thereby allowing some indication of whether they could be causative of 
insulin resistance. A  group of young and old lean, and old overweight/obese 
individuals was investigated in a cross sectional design. Ageing was 
associated with a (30%) decline in muscle BCAA content and decreased 
insulin sensitivity. And increased adiposity was associated with a (20%) 
increase in BCAA content. In response to insulin infusion, there was an 
attenuated decline in muscle BCAA and BCAA catabolite content in the old 
lean group only. In addition, fatty acid derived acylcarnitines were suppressed 
in all groups despite differing glucose disposal during insulin infusion. These 
findings appear to dissociate muscle BCAA content, ageing and insulin 
resistance and suggest fatty acid derived acylcarnitnes may not be associated 
with insulin resistance.  
In Chapter 6, the potential interactions of BCAA and fatty acid metabolism 
were explored in a group of middle aged and older aged patients with T2D. 
Middle aged T2D patients had elevated meal derived fatty acid oxidation and 
endogenous fatty acid delivery to muscle during an oral glucose tolerance test 
(OGTT) when compared to age and BMI matched control subjects. This was 
associated with elevated fasting muscle BCAA content and an attenuated 
suppression of plasma BCAA and BCAA catabolites during the OGTT. 
Remarkably, these metabolic perturbations were absent in the older aged T2D 
patients, despite a similar duration of diabetes and insulinaemic responses to 
OGTT. 
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Collectively, the work in this thesis provides quantitative assessment of muscle 
BCAA catabolism and fatty acid metabolism in humans. T2D and obesity-
induced insulin resistance are characterised by elevated BCAAs and BCAA 
derived acylcarnitines but ageing per se exerts the opposite effects. In 
addition, the results of this thesis suggest that fatty acid derived acylcarnitines 
may not be associated with muscle insulin resistance in vivo. The potential 
role of BCAA derived acylcarnitines in insulin resistance and their role as 
biomarkers of progression to T2D requires further investigation.  




Robert Jones, Pardeep Pabla, Joanne Mallinson, Aline Nixon, Tariq Taylor, 
Andrew Bennett, and Kostas Tsintzas. 2020. “Two Weeks of Early Time-
Restricted Feeding (ETRF) Improves Skeletal Muscle Insulin and Anabolic 
Sensitivity in Healthy Men.” The American Journal of Clinical Nutrition 112 (4): 
1015–28.  
Kostas Tsintzas, Robert Jones, Pardeep Pabla, Joanne Mallinson, David A. 
Barrett, Dong Hyun Kim, Scott Cooper, et al. 2020. “Effect of Acute and Short-
Term Dietary Fat Ingestion on Postprandial Skeletal Muscle Protein Synthesis 
Rates in Middle-Aged, Overweight, and Obese Men.” American Journal of 
Physiology - Endocrinology and Metabolism 318 (3): E417–29.  
Abstracts 
Pardeep Pabla, Dong-Hyun Kim, David Barrett, Francis Stephens, and 
Kostas Tsintzas. Targeted metabolomics in human skeletal muscle and 
plasma reveals distinct differences in key biomarkers of Type 2 diabetes. 
Presented at Physiology 2019. Aberdeen, UK. 
Pardeep Pabla, Dong-Hyun Kim, David Barrett, and Kostas Tsintzas. A novel 
targeted LC-MS/MS method for absolute quantification of acylcarnitines in 
human skeletal muscle: Implications for insulin resistance. Presented at 




All of the development and validation of the analytical method in chapter 3 was 
performed by myself. The method was applied to biological samples obtained 
from various human in vivo studies conducted within our research group. All 
the sample processing, metabolite extraction, metabolite data acquisition and 
data processing was performed by myself. I assisted with sample collection in 
all the studies, with the exception of samples used in chapter 5. Where others 
contributed to the data presented in this thesis is declared below. 
In chapter 3, Dr Robert Jones and I recruited participants and conducted all 
in vivo testing, Aline Nixon performed cannulations and Drs Tariq Taylor and 
Natalie Shur performed skeletal muscle biopsy procedures to obtain samples 
used for confirmation of method suitability of the analytical method. 
In chapter 4 some of participants in the control group were recruited by 
Professor Kostas Tsintzas and I assisted with sample collection and analysis. 
In chapter 5 all participant recruitment, assessment of body composition, 
blood and muscle biopsy collection, and the hyperinsulinaemic- euglycaemic 
clamp was performed by Dr Carolyn Chee. 
In chapters 4 and 6, all patients with Type 2 diabetes were recruited by Dr 
Christopher Gaffney who also performed assessments of body composition, 
dietary intake. Professor Francis Stephens analysed meal derived fatty acid 
oxidation data. 
Analysis of serum insulin in chapters 4 and 6 and plasma free fatty acids in 
chapter 6 was performed by Sally Cordon. Skeletal muscle biopsy and 
 VII 
cannulation procedures in those chapters were performed by Drs Tariq Taylor 
and Ciaran Doherty  
All studies and in vivo procedures were performed in the David Greenfield 
Human Physiology Unit, Queen’s Medical Centre, University of Nottingham. 
 
I declare that the thesis is the result of my own work which has been 
undertaken during my period of registration for this degree at The University 
of Nottingham.  
 
 
Signed:   
 











I would like to express my sincerest gratitude to my primary supervisor, 
Professor Kostas Tsintzas for his continual support, guidance and friendship 
from the beginning of my MSc and throughout my PhD. Through his wealth of 
knowledge on all matters scientific (and otherwise, especially BMWs), 
meticulous nature and attention to detail, he has taught me so many important 
life lessons. I hope we can continue to work together for many years to come. 
Secondly, to Dr Dong-Hyun Kim who introduced me to world of metabolomics. 
His patient supervision and encouragement were vital in helping me find my 
feet in a new area of science and enabled me to grow as a researcher. Thirdly, 
I would like to thank Professor David Barrett for his invaluable advice and input 
even after his retirement. I feel privileged to have profited so generously from 
his vast analytical experience which gave me the confidence to overcome the 
many challenges of quantitative metabolomics. Finally, I owe a huge thank you 
to Professor Francis Stephens who was always there to point me in the right 
direction. His mentorship and scientific rigour inspire to me to pursue a career 
in research.  
I am indebted to Drs Catharine Ortori and Salah Abdelrazig for introducing me 
to world of liquid chromatography coupled to mass spectrometry and their 
technical support throughout my PhD. Cath, for her thorough training and 
seemingly never-ending analytical knowledge and patience. Salah, for his 
countless and creative analogies that made some of the most complex 
analytical aspects understandable to a relative novice like me. I will remember 
those stressful days (and nights) spent panicking by Q Exactive for a long time. 
 IX 
I am incredibly lucky to have made so many new friends along the way with 
whom I was able to share the journey with. To everyone in the offices of D83, 
C15 and the extended members of the CAB and metabolic and molecular 
physiology research groups over the years, thank you for your help and warm 
welcome, it made the process so much more enjoyable. In particular, Robbie, 
Simon and Andy for all the discussions, laughs, lab days and beers. Tariq, 
thanks for being a big brother and for constantly challenging me but most 
importantly for always being there, especially when times got really hard. 
I also greatly appreciate the assistance of the staff of the David Greenfield 
Human Physiology Unit for their support in completing the studies that 
contributed to this thesis. I also acknowledge Dr Scott Cooper for this patience 
and training in several laboratory techniques. 
Finally, a huge heartfelt thank you to my family, for their enduring love, support 
and sacrifice not just during my studies but always, and to my friends who 
accept and believe in me. 
To those no longer with us, I hope I can make you proud. The work in this 








Table of Contents 
Abstract................................................................................................................ I 
Publications ......................................................................................................... V 
Declarations ....................................................................................................... VI 
Acknowledgements .......................................................................................... VIII 
Table of Contents ................................................................................................. X 
List of Abbreviations ........................................................................................ XVII 
Chapter 1 General introduction ............................................................................ 1 
1.1 Obesity and Type 2 diabetes ................................................................................. 2 
1.1.1 Obesity ................................................................................................................................. 2 
1.1.2 Type 2 diabetes .................................................................................................................... 3 
1.1.3 Insulin signalling in muscle .................................................................................................. 7 
1.1.4 Basis of ectopic fat accumulation ...................................................................................... 10 
1.2 Skeletal muscle metabolism ................................................................................ 13 
1.2.1 Skeletal muscle fat metabolism ......................................................................................... 13 
1.2.2 Skeletal muscle glucose metabolism ................................................................................. 17 
1.2.3 Interaction of fat and glucose in muscle ............................................................................ 18 
1.2.4 Skeletal muscle protein metabolism ................................................................................. 21 
1.3 Lipid induced insulin resistance in muscle ............................................................ 24 
1.3.1 Accumulation of lipids in muscle ....................................................................................... 25 
1.3.2 Mitochondrial overload hypothesis ................................................................................... 30 
1.3.3 Metabolic inflexibility of insulin resistant muscle ............................................................. 35 
1.3.4 Mitochondrial dysfunction ................................................................................................ 36 
1.3.5 Inactivity induced insulin resistance .................................................................................. 37 
 XI 
1.3.6 Summary ............................................................................................................................ 38 
1.4 Branched chain amino acids ................................................................................ 40 
1.4.1 Overview and synthesis ..................................................................................................... 40 
1.4.2 BCAA catabolism ................................................................................................................ 43 
1.4.3 BCAAs Obesity and Insulin resistance ................................................................................ 48 
1.4.4 Evidence from animal studies ............................................................................................ 49 
1.4.5 Evidence from humans studies .......................................................................................... 53 
1.5 Metabolomics .................................................................................................... 57 
1.5.1 Metabolomics and the metabolome ................................................................................. 57 
1.5.2 Use of metabolomics for chronic diseases. ....................................................................... 57 
1.5.3 Qualitative and Quantitative metabolomics...................................................................... 59 
1.5.4 Overview of metabolomics work flow ............................................................................... 59 
1.5.5 Challenges associated with metabolite quantification in biological samples .................... 65 
1.6 Aims and objectives ............................................................................................ 67 
2 Chapter 2 General methods ............................................................................. 68 
2.1 Human volunteers .............................................................................................. 69 
2.1.1 Ethical approval ................................................................................................................. 69 
2.1.2 General screening for healthy volunteers ......................................................................... 70 
2.1.3 Patient recruitment ........................................................................................................... 70 
2.2 Assessment of insulin sensitivity and body composition ...................................... 71 
2.2.1 Hyperinsulineamic- euglycaemic clamp ............................................................................ 71 
2.2.2 Oral glucose tolerance test ................................................................................................ 73 
2.2.3 Homeostasis model assessment of insulin resistance ....................................................... 73 
2.2.4 Dual Energy X-ray Absorptiometry .................................................................................... 74 
2.3 Blood sampling and analysis ............................................................................... 75 
2.3.1 Blood collection and arterialisation ................................................................................... 75 
 XII 
2.3.2 Blood glucose concentration ............................................................................................. 76 
2.3.3 Isolation of plasma ............................................................................................................. 76 
2.3.4 Plasma free fatty acids ....................................................................................................... 76 
2.3.5 Isolation of serum .............................................................................................................. 77 
2.3.6 Serum insulin ..................................................................................................................... 77 
2.4 Muscle analysis .................................................................................................. 78 
2.4.1 Muscle biopsy procedure .................................................................................................. 78 
2.4.2 Muscle protein expression ................................................................................................ 78 
2.4.3 Protein extraction .............................................................................................................. 79 
2.4.4 Protein quantification ........................................................................................................ 80 
2.4.5 Electrophoresis/SDS-PAGE and Western blotting ............................................................. 81 
2.5 BCAAs, BCKAs, free carnitine and acylcarnitines in muscle and plasma ................. 82 
3 Chapter 3 Development and Validation of a liquid chromatography coupled to 
high resolution mass spectrometry method for quantification of acylcarnitines, 
branched chain amino and keto acids in human skeletal muscle and plasma. ..... 83 
3.1 Introduction ....................................................................................................... 84 
3.1.1 Overview of acylcarnitine metabolism .............................................................................. 84 
3.1.2 Branched chain amino acids and acylcarnitines ................................................................ 86 
3.1.3 Previous methods for the quantitative analysis of acylcarnitines, BCAAs and BCKAs ....... 87 
3.1.4 Justification of method development ................................................................................ 90 
3.1.5 Aims ................................................................................................................................... 91 
3.2 Methods............................................................................................................. 92 
3.2.1 Materials and chemicals .................................................................................................... 92 
3.2.2 Sample preparation and metabolite extraction ................................................................ 92 
3.2.3 Liquid chromatography coupled to high resolution mass spectrometry conditions ......... 94 
3.2.4 Preparation of standards ................................................................................................... 95 
 XIII 
3.2.5 Method validation in the biological matrix ........................................................................ 95 
3.2.6 Validation of the proxy matrix as a substitute for human plasma .................................... 97 
3.2.7 Method validation experiments and parameters .............................................................. 98 
3.2.8 Extraction efficiency experiment ....................................................................................... 99 
3.2.9 Application of method to human samples for confirmation of method suitability ......... 100 
3.2.10 Peak extraction, analyte confirmation and quantification ............................................ 100 
3.3 Results and discussion ...................................................................................... 104 
3.3.1 Optimisation of analyte separation and mass spectrometry detection .......................... 104 
3.3.2 Biological matrix validation with isotopically labelled standards .................................... 112 
3.3.3 Use of the proxy BSA in PBS matrix as a valid substitute for analyte quantification in 
powdered skeletal muscle and plasma ..................................................................................... 118 
3.3.4 Method validation for analytes with high endogenous concentrations .......................... 123 
3.3.5 Sample stability and extraction repeatability .................................................................. 126 
3.3.6 Effect of sample weight on extraction efficiency ............................................................ 128 
3.3.7 Application of method to human samples for confirmation of method suitability ......... 131 
3.3.8 General discussion ........................................................................................................... 133 
3.3.9 Limitations ....................................................................................................................... 135 
3.4 Conclusions ...................................................................................................... 136 
4 Chapter 4 Quantitative metabolomics in human skeletal muscle and plasma 
reveals distinct differences in key biomarkers of Type 2 diabetes ...................... 137 
4.1 Introduction ..................................................................................................... 138 
4.1.1 Aims ................................................................................................................................. 141 
4.2 Methods........................................................................................................... 142 
4.2.1 Participant characteristics ............................................................................................... 142 
4.2.2 Sample collection ............................................................................................................. 143 
4.2.3 Preparation of samples, calibrants and QCs for LC-MS analysis ...................................... 143 
4.2.4 LC-MS setup and analysis ................................................................................................ 144 
 XIV 
4.2.5 Peak extraction and statistical analysis ........................................................................... 145 
4.3 Results ............................................................................................................. 147 
4.3.1 Assessment of method performance and QCs ................................................................ 147 
4.3.2 Plasma metabolites ......................................................................................................... 149 
4.3.3 Muscle metabolites ......................................................................................................... 150 
4.3.4 Correlations between muscle, plasma and fasting blood glucose................................... 156 
4.4 Discussion ........................................................................................................ 158 
4.5 Conclusions ...................................................................................................... 166 
5 Chapter 5 The effect of insulin on skeletal muscle branched chain amino acid and 
acylcarnitine profiles. A comparison of age and obesity. .................................. 168 
5.1 Introduction ..................................................................................................... 169 
5.1.1 Aims ................................................................................................................................. 171 
5.2 Methods........................................................................................................... 172 
5.2.1 Participant characteristics ............................................................................................... 172 
5.2.2 Experimental protocol ..................................................................................................... 174 
5.2.3 Sample collection ............................................................................................................. 174 
5.2.4 BCAA, BCKA and acylcarnitine quantification .................................................................. 174 
5.2.5 Western blotting .............................................................................................................. 175 
5.2.6 Statistical analysis ............................................................................................................ 175 
5.3 Results ............................................................................................................. 177 
5.3.1 Participants ...................................................................................................................... 177 
5.3.2 Analytical method parameters ....................................................................................... 177 
5.3.3 Effect of age and insulin (YL vs OL groups) ...................................................................... 177 
5.3.4 Effect of increased adiposity (OL vs OO groups) ............................................................ 179 
5.3.5 Muscle BCKDH phosphorylation status ........................................................................... 184 
5.4 Discussion ........................................................................................................ 185 
 XV 
5.5 Conclusion ........................................................................................................ 194 
6 Chapter 6. The effect of Type 2 diabetes and age on whole body fat oxidation 
and BCAA metabolism. .................................................................................... 195 
6.1 Introduction ..................................................................................................... 196 
6.1.1 Aims ................................................................................................................................. 198 
6.2 Methods........................................................................................................... 199 
6.2.1 Participants ...................................................................................................................... 199 
6.2.2 Experimental protocol ..................................................................................................... 201 
6.2.3 Sample collection and analysis ........................................................................................ 204 
6.2.4 Statistical analysis ............................................................................................................ 205 
6.3 Results ............................................................................................................. 206 
6.3.1 Participant characteristics and free-living measurements .............................................. 206 
6.3.2 Dietary fat oxidation ........................................................................................................ 207 
6.3.3 Response to OGTT ........................................................................................................... 208 
6.3.4 Muscle metabolites ......................................................................................................... 213 
6.3.5 Plasma metabolites ......................................................................................................... 218 
6.3.6 BCKDH protein expression ............................................................................................... 225 
6.4 Discussion ........................................................................................................ 226 
6.5 Conclusion ........................................................................................................ 236 
7 Chapter 7 General Discussion ........................................................................ 237 
7.1 Overview of findings ......................................................................................... 238 
7.2 Development of a targeted method .................................................................. 239 
7.3 The effect of T2D per se on BCAA metabolism ................................................... 240 
7.4 The effect of age on BCAA metabolism .............................................................. 241 
 XVI 
7.5 Acylcarnitines and insulin resistance ................................................................. 244 
7.6 Potential impact of fat oxidation on BCAA metabolism ...................................... 245 
7.7 Limitations of the current work ......................................................................... 246 
7.8 Future directions .............................................................................................. 248 
7.9 Conclusions ...................................................................................................... 250 
References ....................................................................................................... 252 
Appendices ...................................................................................................... 298 
Appendix A MS inclusion list ................................................................................... 299 
Appendix B Free carnitine concentration ................................................................ 301 
Appendix C Muscle acylcarnitine profiles ................................................................ 302 
Muscle short chain acylcarnitines............................................................................................. 302 
Muscle medium chain acylcarnitines ........................................................................................ 303 
Muscle long chain acylcarnitines .............................................................................................. 304 
Appendix D Muscle acylcarnitine profiles ................................................................ 305 
Muscle short chain acylcarnitines............................................................................................. 305 
Muscle medium chain acylcarnitines ........................................................................................ 306 
Muscle Long chain acylcarnitines ............................................................................................. 307 
Appendix E Plasma acylcarnitine profiles ................................................................ 308 
Plasma medium chain acylcarnitines ........................................................................................ 308 
Plasma long chain acylcarnitines .............................................................................................. 309 




List of Abbreviations 
ACC Acetyl coenzyme A carboxylase  
Akt Protein Kinase B 
ANOVA Analysis of Variance 
BCAA Branched chain amino acid 
BCAT Branched chain amino transferase 
BCKA  Branched chain keto acid 
BCKDH Branched chain keto dehydrogenase  
BCKDK Branched chain keto dehydrogenase kinase 
BMI Body mass index 
BSA Bovine serum albumin 
CACT Carnitine acylcarnitine translocase  
CD36 Cluster of differentiation 36  
CoA Coenzyme A 
CoASH Free coenzyme A 
CPT1 Carnitine palmitoyltransferase 1  
CPT2 Carnitine palmitoyltransferase 2 
CV coefficient of variance  
DAG Diacylglycerols 
DEXA  Dual Energy X-ray Absorptiometry  
DM/  dm Dry mass 
DNA Deoxyribonucleic acid  
EI Electron impact  
EMCL Extramyocellular lipid  
ESI Electrospray ionization 
FABPpm Fatty acid binding protein  
FAT Fatty acid translocase  
FATP Fatty acid transport protein  
FDA Food and Drug Administration  
FFA Free-Fatty Acid 
G6P Glucose 6 phosphate 
GC Gas chromatography  
GDR Glucose disposal  rate  
GFR Glomerular filtration rate  
GIR Glucose infusion rate  
GLUT4 Glucose Transporter 4 
GSK3 Glycogen synthase kinase 3  
HFD High fat diet  
HGP Hepatic glucose production 




Homeostatic Model Assessment of Insulin 
Resistance 
 XVIII 
HPLC High-performance liquid chromatography 
IMCL Intramyocellular Lipid 
IMTG Intramuscular triglyceride  
INSR Insulin receptor  
IRS-1 Insulin receptor substrate  
KH2PO4 Potassium phosphate  
LC Liquid chromatography  
LCFA Long chain fatty acids  
LLE Liquid-liquid extraction  
LOD Limit of detection 
LOQ Limit of quantification 
m/z Mass/charge ratio  
MCD Malonyl CoA decarboxylase  
MCFA Medium chain fatty acids  
MPB Muscle protein breakdown 
MPS Muscle protein synthesis 
mRNA Messenger Ribonucleic Acid 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
mTOR Mammalian target of rapamycin  
NAD Nicotinamide Adenine Dinucleotide (Oxidised) 
NADH Nicotinamide Adenine Dinucleotide (Reduced) 
NAFLD Non alcoholic fatty liver disease 
NFkB Nuclear factor kappa β  
OGTT Oral Glucose Tolerance Test 
PBS Phosphate buffered saline 
PDC Pyruvate Dehydrogenase Complex 
PDCa Pyruvate Dehydrogenase Complex (active) 
PDK Pyruvate Dehydrogenase Kinase 
PFK Phosphofructokinase  
PFP Pentafluorophenyl 
PI3K Phosphatidylinositol (PI)-3 kinase 
PKC Protein Kinase C 
PP2A Protein Phosphatase 2A 
PP2Cm Protein Phosphatase 2 
QC Quality control 
RP Reversed phase 
RQ Respiratory Quotient  
SD Standard Deviation 
SEM Standard Error of the Mean 
SPE Solid phase extraction 
SSD System suitability standard 
T2D Type 2 diabetes 
TAG Triacylglycerol/Triglyceride 
 XIX 
TCA Tricarboxylic acid cycle 
TST-T Tris-Buffered Saline with 0.1% Tween 20 
UHPLC Ultra-high-performance liquid chromatography 
v:v Volume:Volume 
VLDL Very low-density lipoprotein  
w:v Weight:Volume 
WHO World Health Organisation 
 
For a full list of abbreviations for all analytes quantified with the method 
developed in this thesis see Table 3.2 
 
 1 
1 Chapter 1 General introduction 
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1.1 Obesity and Type 2 diabetes  
1.1.1 Obesity  
Obesity can be defined as an abnormal or excessive body fat accumulation in 
the adipose tissue and other organs, with multiple organ specific 
pathophysiological consequences (González-Muniesa et al. 2017). Implicit 
with this definition is the link between body fat and ill health. The World Health 
Organization (WHO) defines overweight as a body mass index (BMI) 
calculated as weight (kg) divided by height squared (m2) equal to or greater 
than 25 kg/m2 and obese as a BMI equal to or greater than 30 kg/m2. 
Considered by some as a 21st century epidemic, primarily due to lifestyle 
trends and excessive energy intake, the prevalence of obesity is increasing at 
an alarming rate worldwide (Di Cesare et al. 2016). The projected global 
number of people who will be overweight or obese is estimated at 1.4 billion 
and 570 million, respectively, by 2030 (Kelly et al. 2008). 
Although it is generally accepted that increased fat deposition is primarily 
driven by an imbalance between energy intake and energy expenditure, with 
some arguing a particular role of physical inactivity i.e., reduced energy 
expenditure (Prentice and Jebb 1995), it is likely that multiple environmental 
and genetic factors also contribute to an individual’s propensity for weight gain 
(Ravussin 1995). Indeed, circumstances such as socioeconomic status, 
environment and personal behaviours, and genotype–phenotype interactions 
must be considered to understand the development of obesity, as all these 
factors affect food intake, nutrient turnover, thermogenesis, lipid utilization of 
fatty acids away from storage and towards oxidation, and differential fat 
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storage in regional adipose depots versus non-adipose tissues. Regardless of 
the cause, obesity is associated with increased risk of mortality (Manson et al. 
1995) and the development of several cardiometabolic diseases, such as type 
2 diabetes mellitus (discussed below), cardiovascular diseases, some types 
of cancer and other adverse pathological conditions (Williams et al. 2015). 
Thus, obesity is associated with a significant increase in morbidity and 
mortality and is a major public health problem.  
Another difficulty encountered in studying obesity is the marked heterogeneity 
of individuals with obesity. Examples of obesity types at both ends of the 
continuum are subcutaneous obesity, in which excess subcutaneous fat is 
found around the hip and thigh areas (pear-like body shape or gynoid obesity, 
which is more common in women), and visceral obesity, in which fat (mainly 
mesenteric adipose tissue) is mainly concentrated in the abdominal region 
(apple-like body shape or android obesity). Visceral obesity is more common 
in men and tends to be more pernicious in health terms, particularly affecting 
cardiovascular disease risk factors (González-Muniesa et al. 2017). 
Furthermore, others have suggested that visceral adipose tissue may be an 
innocent bystander and simply reflects inappropriate fat storage within organs 
such as liver and muscle, also known as ectopic fat (Frayn et al.1997; Fabbrini 
et al. 2009). Therefore, both fat distribution as well as overall level of fat 
accumulation, is key in mediating the adverse health consequences of obesity.  
1.1.2 Type 2 diabetes  
Type 2 diabetes (T2D) mellitus is a disease characterized by dysregulation of 
carbohydrate, lipid and protein metabolism, and results from impaired insulin 
secretion by pancreatic islet β-cells, resistance to the metabolic effects of the 
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hormone insulin on peripheral tissues (termed insulin resistance) or a 
combination of both. As a result, a state of chronically elevated blood glucose 
concentrations (hyperglycaemia) ensues. Although only a subset of obese 
people develops T2D, obesity is a major risk factor for T2D, and rates of T2D 
prevalence have paralleled those of obesity (Kahn, Hull, and Utzschneider 
2006). Skeletal muscle insulin resistance is considered to be an important 
initiating or primary defect that is evident year or even decades before β-cell 
failure and overt hyperglycaemia develops (DeFronzo and Tripathy 2009). 
However, the importance of muscle insulin resistance in the development of 
T2D is debated by others. For example in the proposed twin cycle hypothesis 
of the etiology of T2D (Taylor 2013), pre-existing muscle insulin resistance and 
raised circulating insulin levels, results in hepatic (liver) and pancreatic fat 
accumulation. Indeed, elevated circulating insulin leads to hepatic de novo 
lipogenesis (Schwarz et al. 2003), that is the conversion of non-fat precursors 
to fatty acids and subsequent accumulation of fat in the liver leading to hepatic 
insulin resistance, and this may be more important for the progression from 
insulin resistance to clinically overt T2D (this is discussed further below).  
For some obese individuals, the pancreatic islet β-cells increase insulin 
release sufficiently to overcome the reduced efficiency of insulin action, 
thereby maintaining normal glucose tolerance. Clinically overt T2D manifests 
only when β-cells are unable to secrete sufficient amounts of insulin to offset 
the insulin resistance (Ferrannini and Mari 2014). Interestingly, β-cell 
dysfunction exists in individuals who are at high risk of developing the disease 
even when their glucose levels are still normal (Kahn, 2001). Several 
mechanisms have been speculated to explain β-cell decline, these include 
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ageing, β-cell exhaustion due to the increased secretory demand arising from 
insulin resistance, desensitization of the β-cell due to the elevations in glucose, 
lipid accumulation (also referred to as lipotoxicity) and a reduction in β-cell 
mass (Kahn, 2001). 
1.1.2.1 Reversal of T2D  
Although it was previously believed that T2D was inexorably progressive, 
recent work has clearly demonstrated reversibility of T2D (especially within the 
first 6 years of diagnosis). This was demonstrated in a study in which eleven 
patients with T2D with an average BMI ~ 33 kg/m2 were subject to a very low 
calorie diet comprising of only 600 Kcal per day, for eight weeks (Lim et al. 
2011). Remarkably, fasting plasma glucose, which is determine primarily by 
liver insulin sensitivity, declined after just one week. This was accompanied by 
a 30% reduction in liver fat which reached 70% by eight weeks. Furthermore, 
pancreatic fat was lowered by ~25% and normal insulin secretion was 
restored. Insulin sensitivity also increased, which was primarily attributed to an 
increased capability to supress hepatic glucose production and not increased 
peripheral glucose update (by muscle). These findings substantiated the twin 
cycle hypothesis suggested by Taylor and colleagues (Taylor 2013) (Figure 
1.1) Nevertheless, alterations in muscle insulin sensitivity contribute to the 
initial development of the pre-existing insulin resistance that exacerbates the 
accumulation of fat in other organs. Therefore, the understanding of how 




Figure 1.1 The twin cycle hypothesis proposed by R Taylor (2013). During 
long-term intake of more calories than are expended each day, any excess 
carbohydrate undergoes de novo lipogenesis, which particularly promotes fat 
accumulation in the liver. Because insulin stimulates de novo lipogenesis, 
individuals with a degree of insulin resistance (determined by family or lifestyle 
factors) will accumulate liver fat more readily than others because of higher 
plasma insulin levels. In turn, the increased liver fat will cause relative 
resistance to insulin suppression of hepatic glucose production Over many 
years, a modest increase in fasting plasma glucose level will stimulate 
increased basal insulin secretion rates to maintain euglycemia. The 
consequent hyperinsulinemia will further increase the conversion of excess 
calories to liver fat. A cycle of hyperinsulinemia and blunted suppression of 
hepatic glucose production becomes established. Fatty liver leads to 
increased export of VLDL triacylglycerol which will increase fat delivery to all 
tissues, including the islets. This process is further stimulated by elevated 
plasma glucose levels Excess fatty acid availability in the pancreatic islet 
would be expected to impair the acute insulin secretion in response to ingested 
food, and at a certain level of fatty acid exposure, postprandial hyperglycemia 
will supervene. The hyperglycemia will further increase insulin secretion rates, 
with consequent enhancement of hepatic lipogenesis, spinning the liver cycle 
faster and driving the pancreas cycle. Eventually, the fatty acid and glucose 
inhibitory effects on the islets reach a trigger level that leads to a relatively 




1.1.3 Insulin signalling in muscle 
Insulin exerts all its known physiological effects by binding to the insulin 
receptor (INSR) on the plasma membrane of target cells. In muscle, the 
primary action of insulin is to augment glucose uptake through increased 
translocation of GLUT4 stored in intracellular vesicles to the plasma 
membrane (Shepherd and Kahn 1999). INSR is a heterotetrameric receptor 
tyrosine kinase formed from two extracellular α subunits, which bind insulin 
and (intracellular) two membrane-spanning β subunits, each of which contains 
a tyrosine kinase domain. Upon insulin binding at the α site, there is 
conformational change in the β subunit leading to phosphorylation of three 
tyrosine molecules on the insulin receptor. Once the insulin receptor has been 
phosphorylated, insulin receptor substrate (IRS)-1 moves to the cell 
membrane and becomes phosphorylated. Tyrosine phosphorylation of IRS-1 
results in activation of the p85 regulatory subunit of phosphatidylinositol (PI)-
3 kinase and activates the p110 catalytic subunit, leading to an increase in 
phosphatidylinositol-3,4,5 triphosphate. The latter acts as a secondary 
messenger by travelling along the cell membrane to activate PDK1, which is 
crucial in the activation of downstream protein kinase B (also called Akt) and 
phosphorylation of Akt substrate 160 (AS160), which facilitates the 
translocation of GLUT4 to the sarcolemma and subsequent entry of glucose 
into the cell. (Figure 1.2). It also activates glycolytic enzymes including 
hexokinase and phosphorylates glycogen synthase kinase 3 (GSK3) (Cross 
et al. 1995). The latter action prevents this enzyme from deactivating glycogen 
synthase and hence promotes increased glycogen synthesis. Akt also plays a 
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key role in the regulation of cell growth, via its stimulatory effects on the 
mammalian target of rapamycin (mTOR) pathway (Haar et al. 2007) 
 
 
Figure 1.2 The insulin signalling pathway in skeletal muscle and its 
involvement in the regulation of glucose transport and glycogen synthesis. 
Taken from Yu and Chai (2015) 
 
1.1.3.1 Contraction mediated glucose uptake in muscle  
It is important to note that muscle contraction can also regulate glucose uptake 
into the muscle cell. The molecular signalling mechanisms that lead to GLUT4 
translocation during muscle contraction are not well understood. It is generally 
believed that contractions stimulate GLUT4 translocation via a molecular 
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mechanism distinct from that of insulin (Richter and Hargreaves 2013). 
However, it appears these two pathways at least partially converge in their 
distal parts, and there are now a number of signalling molecules involved in 
GLUT4 translocation that are activated both by insulin and muscle 
contractions. This is supported by the observation that the phosphatidylinositol 
3-kinase (PI3K) inhibitor wortmannin blocks insulin-induced PI3K activation in 
perfused rat skeletal muscle, also inhibits contraction induced glucose uptake 
(Wojtaszewski et al. 1996). The various signalling mechanisms by which 
contraction regulates glucose uptake through GLUT4 are unclear at present 
but may be related to contract induced calcium release from the sarcoplasmic 
reticulum, regulation of cytoskeletal components such as the actin 
cytoskeleton, nitric oxide production, reactive oxygen species and other 
downstream targets (Richter and Hargreaves 2013). Evidence for the 
importance of any one component over the other as of yet is unknown. The 
significance of contraction induced glucose uptake will be important to 
consider later when physical inactivity induce insulin resistance is discussed. 
Another insulin independent mechanism that can regulate GLUT4 
translocation (and independently of insulin) is through the AMP-activated 
protein kinase (AMPK). AMPK is an enzyme that is activated in situations 
where there are changes in the cellular energy status such as muscle 
contraction and hypoxia (Musi and Goodyear 2003). This pathway is activated 
by phosphorylation of AMPK by an upstream kinase. AMPK then acts on yet 
unidentified targets to initiate a singling cascade which results in GLUT4 
translocation (Musi and Goodyear 2003). 
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1.1.4  Basis of ectopic fat accumulation 
As stated, earlier distribution of fat in the body appears to be more important 
than overall fatness in the development of insulin resistance. Increased 
adiposity/obesity is a major risk factor of T2D. Indeed, 80-90 % of T2D patients 
are overweight or obese (Smyth and Heron 2006).  However, many individuals 
with high levels of obesity maintain normal glucose tolerance and do not 
develop insulin resistance and T2D. One study measured 314 individuals and 
quantified total body, skeletal muscle and liver fat with magnetic spectroscopy 
and assessed insulin sensitivity with an oral glucose tolerance test. It was 
demonstrated that despite being matched for BMI and total body fat, the 
accumulation of fat in the muscle and liver differentiated insulin sensitive and 
insulin resistant obese individuals. In fact, the obese insulin sensitive group 
were more insulin sensitive than a group with lower BMI (25-29) and total body 
fat but more intramuscular fat (Stefan et al. 2009). Another compelling line of 
support for this comes from a study in which two groups of obese individuals 
matched for body composition, but different liver fat content (one obese group 
had < 4 % total fat in the liver and the other obese group had >15 %) were 
subject to overfeeding until both groups gained ~6 % total body mass. After 
weight gain, liver (hepatic), muscle and adipose tissue insulin sensitivity were 
assessed. Although both groups gained equal weight only the obese group 
with higher liver fat content had worsened insulin sensitivity and this was 
accompanied by the finding that adipose tissue genes involved in lipogenesis 
(fat storage) increased in the obese group with the lower, but not higher liver 
fat content (Fabbrini et al. 2015). The data clearly demonstrate body fat 
distribution is vital in the pathogenesis of insulin resistance and T2D. 
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One postulated reason for this could be explained by the adipose tissue 
expandability capacity (Figure 1.3), in which individuals have set capacity to 
expand and store excess energy and once the limit has been reached, fat spills 
over into the circulation and is inappropriately stored ectopically in tissues such 
as muscle, liver and pancreas (Gray and Vidal-Puig 2007; Brøns and Grunnet 
2017a). Indeed, it has been shown in a study that measured adipose tissue 
blood flow and arterial-venous blood sampling across the tissue together with 
isotopically labelled fat ingestion, that obese individuals had substantially 
depressed adipose tissue storage of meal derived fat (McQuaid et al. 2011b). 
As a result, more of meal derived fat appeared in the very low-density 
lipoprotein (VLDL) fraction which suggests that the meal derived fat was 




Figure 1.3 The proposed hypothesis for limited adipose tissue expandability. 
When the body is in a positive energy balance, the adipose tissue will expand 
to handle the excess energy. If the adipose tissue is not capable of expanding 
sufficiently, there will be a spillover of (free fatty acids) FFA to non-adipose 
tissue leading to harmful effects in liver, muscle and pancreas. Figure from 
Brøns and Grunnet (2017). 
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1.2 Skeletal muscle metabolism  
1.2.1 Skeletal muscle fat metabolism 
1.2.1.1 Fatty acid transport across the membrane  
The provision of fatty acids to muscle originates from several sources, 
including chylomicrons, carrying exogenously supplied dietary lipids and 
VLDLs carrying endogenously supplied lipids from the liver, and as fatty acids 
bound to albumin directly from the adipose tissue. On the surface of the 
capillaries, these blood-borne TAGs are hydrolysed by lipoprotein lipase, 
thereby providing the fatty acids for utilisation by muscle. In contrast to the 
original belief that fatty acid entry into muscle tissues was determined solely 
by their delivery to and the diffusion across the plasma membrane of muscle, 
it has been demonstrated that fatty acid uptake occurs via a highly regulated, 
protein mediated mechanism involving one or more fatty acid transporters 
(Holloway et al. 2017). This system is acutely and chronically regulated by 
physiologic and metabolic stimuli and appears to be dysregulated in insulin-
resistant muscle. With selected metabolic stimuli (i.e., muscle contraction and 
insulin), these fatty acid transporters can be induced to translocate within 
minutes from its intracellular depot to the plasma membrane, thereby 
increasing fatty acid influx into muscle cells. Three main types of tissue specific 
transport/binding proteins have been identified, the plasma membrane fatty 
acid binding protein (FABPpm), cluster of differentiation 36 (CD36) transporting 
protein which are ubiquitously expressed and fatty acid transport protein 
(FATP) which has some tissue specificity (Bonen et al. 2007). Evidence has 
revealed that obesity (Fabbrini et al. 2009) and T2D (Bonen et al. 2004) is 
associated with increased expression of CD36. In T2D it would appear that 
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more of muscle CD36 pool may be relocated to the membrane rather than just 
increased expression (Bonen et al. 2004; C. Aguer et al. 2010). 
After fatty acids enter the muscle cell cytosol, they are converted to a fatty 
acyl-CoA derivative by the action of ATP linked fatty acyl-CoA synthetase in 
preparation for β-oxidation, the major pathway by which fatty acids are 
oxidised. Alternatively, they can be stored in the intramuscular triglyceride 
(TAG) store. To take part in the β-oxidation pathway, cytosolic long-chain acyl-
CoA must be transported across the otherwise impermeable inner 
mitochondrial membrane. Therefore, carrier mediated transport is required in 
the form of free carnitine. 
1.2.1.2 Carnitine  
Carnitine (3-hydroxy-4-N-trimethylaminobutyric acid) is a naturally occurring 
quaternary amine compound, synthesised from the amino acids lysine and 
methionine. Being a zwitterionic molecule, carnitine contains a positively 
charged amine and a negatively charged carboxyl group, as well as a centrally 
positioned hydroxyl group. The hydroxyl group functions as a binding site for 
acyl residues and is fundamental to the two primary biochemical roles of 
carnitine in skeletal muscle which are the translocation of fatty acids across 
the mitochondrial membrane and the buffering of excess acetyl groups from 
high glycolytic flux (such as during exercise) (Stephens, Constantin-Teodosiu, 
and Greenhaff 2007). Around 95% of whole-body carnitine stores are 
sequestered within skeletal muscle  (Brass 1995).  
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1.2.1.3 Translocation into mitochondria and β-oxidation with carnitine 
Once activated to their respective CoA esters via acyl-CoA synthetase, long 
chain fatty acyl-CoAs must be converted to acylcarnitine esters before they 
are able to permeate the mitochondrial membranes and access the matrix 
enzymes of the β-oxidation pathway (Fritz and Yue 1963). Carnitine 
palmitoyltransferase 1 (CPT1), situated within the outer mitochondrial 
membrane (Murthy and Pande 1987)), catalyses the reversible esterification 
of carnitine with long-chain acyl-CoA to form long-chain acylcarnitine. CPT1 is 
considered to be the rate-limiting enzyme for long-chain fatty acid entry into 
the mitochondria and oxidation (McGarry and Brown, 1997). Cytosolic 
acylcarnitine is then transported into the mitochondrial matrix in a 
simultaneous 1:1 exchange with intramitochondrial free carnitine via the 
carnitine acylcarnitine translocase (CACT), which is situated within the 
mitochondrial inner membrane. Some evidence from isolated mitochondria 
from human skeletal muscle has suggested that the fatty acid translocase 
FAT/CD36, which is located in the outer mitochondrial membrane, 
translocates acylcarnitine from CPT1 to CACT (Bezaire et al. 2006). Once 
inside the mitochondrial matrix, acylcarnitine is transesterified back to free 
carnitine and long-chain acyl-CoA in a reaction catalysed by carnitine 
palmitoyltransferase 2 (CPT2), which is situated on the matrix side of the inner 
mitochondrial membrane (Woeltje et al. 1987)). The intramitochondrial long-
chain acyl-CoA is then oxidized and cleaved by the β-oxidation pathway to 
form the ultimate product, acetyl-CoA, which enters tricarboxylic cycle to be 
oxidized (Figure 1.4). Evidence from inherited diseases affecting fatty acid 
oxidation, revealed that the process is bidirectional; acylcarnitines can be 
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formed in the mitochondrial matrix from acyl-CoA and carnitine and are 
exported into the cytosol and released into plasma. Almost all acyl-CoA can 
be found as its respective carnitine ester in the circulation with a pronounced 
increase in physiological and pathophysiological conditions (Rinaldo, Cowan, 
and Matern, 2008).  
 
 
Figure 1.4 An overview of muscle fat (red) and glucose (blue) metabolism in 
skeletal muscle prior to the entry into the tricarboxylic (TCA) cycle (purple). 
PDC, pyruvate dehydrogenase complex; TCA, tricarboxylic acid cycle; CAT, 
carnitine acetyltransferase; CACT, carnitine acylcarnitine translocase; CPT, 
carnitine palmitoyltransferase; CD36, fatty acid translocase. Taken from 




1.2.2 Skeletal muscle glucose metabolism  
As stated earlier, glucose transport into the cell is mediated via the GLUT4 
transporter. Upon entry into the cell, glucose is rapidly phosphorylated to form 
glucose-6-phosphate (G-6-P), a reaction catalysed by hexokinase which is an 
irrreversible step. Phosphorylation effectively traps glucose in the cell and 
commits the G-6-P molecule to its intracellular fate of either storage in the form 
of glycogen or oxidation through glycolysis to form cytosolic pyruvate that can 
enter the TCA cycle. Under different experimental conditions the fate of G-6-
P may change. Under physiological hyperinsulinaemia both oxidation and 
glycogen storage contribute to glucose disposal, but ‘under conditions of 
sustained hyperinsulinaemia (such as those observed during a 
hyperinsulaemic clamp) glycogen storage predominates as the site of glucose 
disposal (Thiebaud et al. 1982).  
1.2.2.1 The pyruvate dehydrogenase complex (PDC)  
Depending on the redox state of the cell, pyruvate can either be reduced to 
lactate via the lactate dehydrogenase reaction or converted to acetyl-CoA by 
the PDC. The PDC is a mitochondrial membrane-bound multi-enzyme 
complex that catalyses the irreversible decarboxylation of pyruvate to acetyl-
CoA and is considered one of the rate-controlling reactions in carbohydrate 
oxidation. The catalytic activity of the PDC is regulated by covalent 
transformation between its active and inactive forms (Linn et al., 1969), as well 
as by end-product inhibition. Transformation of the PDC to its active form 
(PDCa) is determined by the competing activities of the PDC phosphatase 
(activator) and kinase (deactivator), whilst in-vitro observations suggest end-
product inhibition to be principally regulated by the ratios of acetyl-CoA to 
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CoASH (free co-enzyme A) and NADH to NAD (Pettit et al, 1975). Flux through 
the PDC reaction ultimately determines the fate of pyruvate and is thus 
considered a branch-point between mitochondrial and non-mitochondrial 
substrate utilisation. Therefore, an intracellular accumulation of products that 
result in the inhibition of PDCa could subsequently create a ‘back-log’ leading 
to a mismatch between cytosolic reactions and mitochondrial oxidation. 
1.2.3 Interaction of fat and glucose in muscle  
Some of earliest work investigating the relationship between fat and 
carbohydrate metabolism was performed by Randle and colleagues when they 
proposed the glucose-fatty acid cycle (Randle et al. 1963). In isolated heart 
and skeletal muscle preparations, Randle and colleagues demonstrated that 
the utilization of one nutrient inhibited the use of the other directly and without 
hormonal mediation (Figure 1.5). It appears that increased concentrations of 
intercellular accumulation of products from fatty acid oxidation inhibit key 
enzymes in the glucose metabolism pathway such phosphofructokinase 
(PFK), and the PDC, the rate-limiting enzyme in the conversion of pyruvate to 
acetyl-CoA. The extent of inhibition is graded and increases along the 
glycolytic pathway, being most severe at the level of PDC and less severe at 
the level of PFK. This sequence occurs because the initial event, triggered by 
fatty acid oxidation, is an increase in the mitochondrial ratios of acetyl-CoA/ 
CoA and NADH/ NAD, both of which inhibit PDC activity. It was proposed that 
these changes lead to an accumulation of cytosolic citrate, which in turn 
inhibits PFK, followed by an increase in glucose 6-phosphate, which 
eventually inhibits hexokinase. Consequently, there would be an accumulation 
of intracellular glucose and inhibition of its cellular uptake due to impaired 
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phosphorylation at the hexokinase step. Whilst this mechanism regulates 
muscle fuel usage actually, whether this mechanism operates in human 
skeletal muscle chronically (specifically in pathological states) remains 
uncertain (Samuel, Petersen, and Shulman 2010) 
 
 
Figure 1.5  The glucose‐FA or Randle cycle describes potential mechanisms 
involved in the interaction between fat and carbohydrate metabolism. In this 
model, FA availability seems to be the dominant factor. Briefly, increased FA 
availability would increase acetyl‐CoA concentrations; accumulation of acetyl‐
CoA would result in inhibition of pyruvate dehydrogenase (PDH); accumulation 
of citrate would inhibit phosphofructokinase (PFK); and accumulation of 
glucose‐6‐phosphate (G6P) would reduce hexokinase (HK) activity. 
Ultimately, this would inhibit carbohydrate metabolism with increasing 
availability and oxidation of FA. Taken from Jeukendrup (2002)  
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1.2.3.1 Glucose can also regulate fat oxidation  
Since the early work of Randle and colleagues it has now known that high 
glucose availability can regulate fat oxidation, most likely through the actions 
of Malonyl coenzyme A (malonyl-CoA) (Mcgarry, Mannaerts, and Foster, 
1977). Malonyl-CoA is the product of the acetyl coenzyme A carboxylase 
(ACC) reaction. ACC is activated by high levels of citrate and high levels of its 
precursor substrate cytosolic acetyl-CoA. Malonyl-CoA is found in a variety of 
tissues including heart, liver, adipose, and skeletal muscle (Mcgarry, 
Mannaerts, and Foster, 1977). in the liver, malonyl-CoA is both an 
intermediate in the de novo synthesis of fatty acids and an allosteric inhibitor 
of (CPT 1), the enzyme that regulates the rate at which long-chain fatty acyl 
(LCFA)-CoAs enter the mitochondria where they are oxidized. However, in 
tissues such as skeletal and cardiac muscle, in which the de novo synthesis 
of fatty acids is minimal, the regulation of CPT 1 is its dominant role. Evidence 
for this mechanism comes from studies which have measured the oxidation of 
isotopically labelled medium chain (octanoate) fatty acids (MCFA) which enter 
the mitochondria independent of CPT 1 and LCFAs (oleate) whilst maintaining 
physiological hyperglycaemia and hyperinsulinemia (Sidossis et al. 1996, 
1999; Rasmussen et al. 2002). Through this elegant design, it has been 
demonstrated that skeletal muscle malonyl-CoA is increased during 
physiological hyperglycaemia with hyperinsulinemia and that this increase is 
associated with the inhibition of functional CPT-1 activity and reduced muscle 
LCFA oxidation but not MCFA oxidation (Rasmussen et al. 2002). 
Interestingly, muscle uptake of LCFA was unchanged between the fasting and 
hyperglycaemia with hyperinsulinemia states, suggesting that increase in 
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malonyl-CoA shunted LCFA away from oxidation and toward storage inside 
the muscle cell. It has since been demonstrated that skeletal muscle of obese 
individuals and patients with T2D has elevated malonyl-CoA compared to lean 
controls (Bandyopadhyay et al. 2006). This was accompanied by reduced 
palmitate (a LCFA) oxidation and increased lipogenesis in tissue 
homogenates. However, it is important to note that it would appear that muscle 
malonyl-CoA concentration may not regulate long-chain fatty acid oxidation 
during exercise, despite high PDC flux during exercise, and therefore the 
marked accumulation of acetyl groups (constantin‐teodosiu et al. 1991). It is 
possible that the sensitivity of CPT1 to malonyl-CoA paradoxically decreases 
in response to exercise (Stephens, Constantin-Teodosiu, and Greenhaff 
2007).Thus, under different physiological circumstances and availability, both 
fatty acids and glucose can regulate the oxidation of the other substrate.  
1.2.4 Skeletal muscle protein metabolism 
Human skeletal muscle is in a constant state of turnover. This involves the 
opposing anabolic process of muscle protein synthesis (MPS) and catabolic 
process of muscle protein breakdown (MPB). The dynamic equilibrium 
between these ultimately determines net muscle protein balance. Thus, a 
significant rise in MPS (anabolism) and/or a reduction in MPB (catabolism), 
such that net protein balance remains positive can result in the accretion of 
skeletal muscle proteins. Conversely, a negative net protein balance, arising 
from a reduction in MPS and/or increase in MPB, will result in a loss of skeletal 
muscle protein.Net protein balance is maintained by ingestion of protein-
containing meals which results in systemic hyperaminoacidemia that is 
stimulatory for the synthesis of new proteins (Breen and Phillips 2011). 
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1.2.4.1 Insulin and muscle protein metabolism  
The main in vivo effect of insulin with regards to protein metabolism is the 
inhibition of protein breakdown and oxidation (Tessari et al. 1986; Abdulla et 
al. 2016) but there is contention over its ability to stimulate protein synthesis, 
especially independent of maintained amino acid availability. In a specific 
experimental conditions , insulin may stimulate muscle protein synthesis when 
concentrations are raised to supraphysiological concentrations or when insulin 
is infused locally across a limb where local hypoaminoacidaemia may not 
occur (Fujita et al. 2006; Trommelen et al. 2015). However, it is unlikely that 
this experimental condition would occur in vivo. Ageing appears to be 
associated with a blunted MPB response to insulin (Wilkes et al. 2009) and 
this response appears to be independent of body of composition.  
1.2.4.2 Interactions of lipid and protein metabolism  
Work from this group has shown a direct impact of increasing lipid availability 
and muscle protein metabolism. It has been shown that inducing insulin 
resistance through lipid infusion during a hyperinsulineamic- euglycaemic 
clamp resulted in a completely attenuated muscle protein synthetic response 
to a 21g bolus of amino acids (Stephens et al. 2015). This blunted anabolic 
response was attributed to reduced activation of the mTOR pathway which is 
they key pathway involved in the regulation of protein synthesis. The induction 
of insulin resistance appears to be key in mediating this blunted response as 
the consumption of an oral lipid emulsion prior to the coingestion of milk protein 
and dextrose (a more physiological representation of the former report) 
resulted in an increase amino acid incorporation into skeletal muscle. (Tsintzas 
et al. 2020). Interestingly, inducing insulin resistance through lipid infusion 
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during a hyperinsulineamic- euglycaemic clamp has also been shown to be 
accompanied,  by the accumulation of branched chain amino acid derived 
catabolites in muscle biopsies obtained at the end of the clamp (Stephens et 
al. 2014). Thus, models of acute lipid induced insulin resistance appears to be 
associated with both a reduced synthetic response and perturbations in 
branched chain amino acid metabolism. Indeed, it has been shown that obese 
middle-aged men have a reduced protein synthetic response under 
hyperinsulineamic hyperaminoacideamic-euglycemic clamp (representing the 
post-prandial state) conditions. However this blunting was offset by a decline 
in MPB, despite lower postprandial leg glucose disposal (Murton et al. 2015). 
Therefore, obese non -frail middle-aged men do not appear to be an increased 
risk of muscle mass loss but clearly have a diminished muscle synthetic 
capacity.  
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1.3 Lipid induced insulin resistance in muscle 
The early work of Randle and colleagues clearly provided the framework of 
our understanding of the reciprocal relationship between fat and glucose, 
certainly as basis to acutely regulate substrate usage. However, whether this 
mechanism is responsible for the impairments in glucose utilisation seen in 
chronic progressive conditions such as T2D remains uncertain. Despite 
several decades of work in this specific area the specific mechanism by which 
lipids or specific lipid species impair glucose uptake is still largely unknown. 
An overview of the (often conflicting) opinions in this area is provided below. 
It has long been demonstrated that elevated circulating fatty acids are present 
in obesity and T2D and plasma fatty acids are negatively correlated with insulin 
resistance (Perseghin et al. 1997). However, a stronger predictor of insulin 
resistance appears to be the amount of triglyceride stored in the muscle (Pan 
et al. 1997; Perseghin et al. 1999). These findings clearly implicate increased 
fatty acid availability and storage with the development of insulin resistance. 
Lipid infusions combined with heparin to activate lipoprotein lipase and raise 
plasma concentrations of free fatty acids during a euglycaemic-
hyperinsulinaemic clamp is an experimental model for studying the direct 
impact of increased fatty acid availability on muscle metabolism (Boden 1996). 
Under these circumstances some studies have shown that the intramuscular 
concentrations of G-6-P and glucose were lower compared to infusions where 
fatty acids were absent (Roden et al. 1996; Dresner et al. 1999). Furthermore, 
in patients with T2D, intramyocellular concentrations of glucose were much 
lower than healthy controls during a euglycaemic-hyperinsulinaemic clamp 
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(Cline et al. 1999). These findings were also accompanied by reduced activity 
of key signalling molecules in the insulin signalling cascade, namely IRS-1–
associated PI 3-kinase activity (Dresner et al. 1999). Taken together these 
findings suggest impairments in insulin mediated glucose transport across the 
cell are primarily responsible for reduced glucose uptake and are in contrast 
with the mechanisms described by the original hypothesis put forward in the 
glucose-fatty acid cycle hypothesis (Randle et al. 1963). A strength of these 
studies is that they used a non-invasive magnetic resonance imaging method 
to sequentially measure the accumulation of these metabolites over time. 
Whilst these findings implicate impairments in insulin mediated glucose 
transport as the main factor underlying lipid induced insulin resistance, those 
studies did not measure other elements of the glucose-fatty acid cycle 
including PDC activity directly. In combination with the findings that obesity 
and T2D is characterised by reduced oxidative capacity got fatty acid oxidation 
(Kelley and Simoneau 1994; Petersen et al. 2003) led to the consensus that 
lipid oversupply (likely mediated by increased delivery from the adipose tissue) 
is not matched by skeletal muscle oxidative capacity. Thus, lipid is diverted 
away from oxidation to storage as TAG within muscle. 
1.3.1 Accumulation of lipids in muscle  
Intramuscular lipid can be found in several distinct metabolic depots within 
muscle tissue, in particular in the interstitium as extramyocellular lipid (EMCL) 
or within muscle fibres as intramyocellular lipid (IMCL). EMCL is quantitatively 
the largest lipid pool within muscle and, together with the intermuscular lipid 
depot found under the facia between individual muscles, has consistently been 
correlated with insulin resistance in large cross‐sectional studies. The much 
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smaller IMCL pool is predominantly composed of intramuscular triglyceride 
(IMTG) droplets and phospholipids, but also includes diacylglycerols (DAG) 
and ceramides, which are mechanistically linked to insulin resistance since 
accumulation can interfere with intracellular insulin signalling (Bosma et al. 
2012). 
It is now well known that IMTG nor IMCLs per se do not cause insulin 
resistance, this is evidenced by the finding that highly trained endurance 
athletes have similar IMTG content to individuals with T2D yet are very insulin 
sensitive (Goodpaster et al. 2001). Well trained athletes also exhibit 
mitochondrial adaptations that increase capacity for fat oxidation and likely 
have much higher turnover rates, since IMCLs are a key fuel source during 
light to moderate intensity PA (Schrauwen-Hinderling et al. 2003). There is a 
need to distinguish between subcellular fractions of lipid, with obese T2D 
individuals having three times higher subsarcolemmal lipid content but similar 
levels of intermyofibrillar lipids compared to normoglyceamic obese controls.  
Exercise training studies have reported increased IMCL content, including the 
number of droplets residing close to mitochondria (Tarnopolsky et al. 2007) 
which likely function as a local energy store. Interestingly, the training-induced 
improvements of insulin sensitivity in overweight/obese insulin resistant 
individuals have been associated with increased IMCL content but reduced 
lipid intermediates (Dubé et al. 2008). When considered together, these 
findings suggest that the accumulation of IMCL per se does not cause insulin 
resistance and may simply act as a biomarker of dysfunctional glucose 
metabolism in individuals with obesity and T2D. Instead, the focus has largely 
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shifted to the accumulation of lipid intermediates including long-chain fatty 
acyl-CoAs, acylcarnitines, ceramides and DAGs. 
1.3.1.1 DAGs 
DAG can be formed from the hydrolysis of TAG or synthesised from glycerol 
combining with long-chain fatty acyl CoA. Lipid infusion induces a transient 
increase in muscle DAG content that precedes the activation of protein kinase 
C (PKC) theta (θ). This was associated with impaired insulin-stimulated 
activation of IRS-1 and supressed downstream activity of PI3K/Akt 
(Szendroedi et al. 2014). Accumulation of DAGs and subsequent activation of 
PKCθ were augmented in individuals with obesity or T2D. This could reflect 
differential lipid partitioning caused by an increased ratio of TAG hydrolase to 
DAG hydrolase (Moro et al., 2009) or reduced levels of hormone sensitive 
lipase (Blaak, 2004). The proposed role of PKCθ is supported in rodent 
knockout models which are protected from lipid-induced insulin resistance 
(Kim et al., 2004).  
Rodents overexpressing DAG acetyl transferase, which increases the 
conversion of DAG into TAG, are protected from lipid-induced IR (Liu et al., 
2007). A similar overexpression model observed a paradoxical increase in 
DAG content, accompanied by an improvement in insulin sensitivity (Timmers 
et al., 2011). This suggests a more complex role for DAGs and the importance 
of considering the turnover rate (balance between supply and oxidation). This 
may explain the increased DAG content in highly trained and obese individuals 
(Amati et al., 2011). Exercise has been shown to increase DAG acetyl 
transferase (Liu et al., 2007), which suggests the increased DAG content in 
highly trained individuals may be from increased supply, whereas it may reflect 
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reduced oxidation of fatty acids in the obese population. This could explain 
why the DAG composition varies considerably between these groups.  
1.3.1.2 Ceramides  
Ceramides are sphingolipids that can be derived from palmitate and are 
strongly associated with insulin resistance. Previous research has shown 
inverse correlations between ceramide content and insulin sensitivity (Adams 
et al., 2004; Straczkowski et al., 2004). Elevated levels of ceramides (both 
saturated and unsaturated) are found in obese, but not well-trained individuals 
and this is likely due to higher skeletal muscle turnover and therefore less 
accumulation (Amati et al., 2011). This suggests ceramide synthesis is linked 
to lipid oversupply, but it has also been shown that inflammatory agonists 
augment ceramide production (Holland et al., 2011). This is important to 
consider as obesity and insulin resistance are widely considered as pro-
inflammatory states. Although in a group of females with obesity, elevated 
ceramide levels were only found in those with insulin resistance (Coen et al., 
2010), which could suggest a more specific role for ceramides mediating 
insulin signalling. Interestingly, exercise-induced improvements in insulin 
sensitivity of obese adults were correlated with the reduction in ceramide but 
not DAG content (Dubé et al., 2008).  
Supplying long-chain saturated fatty acids such as palmitate (C16:0) or 
stearate (C18:0) increases ceramide synthesis both in vitro (Chavez et al., 
2003) and in vivo (Blachnio-Zabielska et al., 2010). Both chemically inhibiting 
(Holland et al., 2007) and reducing the expression of serine palmitoyl 
transferase (Watson et al., 2009), a key enzyme in the synthesis of ceramide 
from palmitate, ameliorates lipid-induced insulin resistance. The relatively low 
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abundance of saturated fatty acids (SFA) in intralipid infusions may therefore 
explain why some studies do not see an acute increase in ceramide content 
despite inducing IR (Itani et al., 2002). Recent findings using genetic ablation 
to block the synthesis of specific chain lengths of ceramides, implicate C18:0 
as most abundant in skeletal muscle and disruptive to glucose homeostasis 
(Turpin-Nolan et al., 2019). Mechanistically, ceramides are thought to exert 
their effect by impaired insulin-stimulated activation of Akt through activation 
of PKC (Fox et al., 2007) and hyperactivation of protein phosphatase 2A 
(PP2A) (Dobrowsky et al., 1993). 
1.3.1.3 PDC and PDKs 
Studies from this group and others have shown that the intravenous infusion 
of lipid emulsion combined with heparin in healthy individuals during 
euglycaemic hyperinsulinaemia results in impaired insulin-stimulated oxidative 
and nonoxidative glucose disposal, with both inhibition of the PDC by 
increased fatty acid β-oxidation and/or lipid intermediate accumulation as a 
primary event (Tsintzas et al. 2007; Stephens et al. 2014). Lipid infusion during 
a glucose clamp was accompanied by increased fat oxidation, decreased 
skeletal muscle PDC activity, accumulation of long chain-Acyl CoAs and 
acetylcarnitine as well as increased expression of muscle PD kinase (PDK) 
(which phosphorylates and inactivates PDC and thus inhibits glucose 
oxidation). The increased muscle acetylcarnitine under these circumstances, 
is a reflection of excessive Acetyl-CoA production (from increased fatty acid 
availably and oxidation), which itself is an allosteric inhibitor of PDC (Klyuyeva, 
Tuganova, and Popov 2008). Furthermore, these conditions are not 
necessarily accompanied by decreased proximal insulin signalling (Tsintzas 
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et al. 2007; Høeg et al. 2011; Storgaard et al. 2004). These findings suggest 
that both impairments in oxidative disposal and insulin mediated glucose 
transport contribute to lipid induced insulin resistance.  
1.3.2 Mitochondrial overload hypothesis 
In contrast to the work linking the diversion of fat away from the mitochondrial 
oxidation and into the accumulation of lipid intermediates that may impair 
insulin signalling and glucose uptake, other work has suggested the excessive 
mitochondrial entry of fatty acids as the primary driver of the development of 
insulin resistance (An et al. 2004; Koves et al. 2008). The mechanistic basis 
of this work originates from a study which subjected Wistar rats to a high fat 
diet (HFD) for 12 weeks and observed an accumulation of fatty acids and 
acylcarnitines in the fed state in both the circulating pool and within skeletal 
muscle (Koves et al. 2008). Whereas lean control rats showed a reduction in 
a fatty acid derived acylcarnitines in response to feeding, this response was 
absent in the HFD group suggesting continual mitochondrial fatty acid entry 
and an inability to switch substrate usage to carbohydrate in response to 
feeding. These findings were also observed in diabetic fatty rats and this was 
accompanied by a reduction in TCA intermediates. These findings suggest 
that excessive fatty acid availability leads to an increased entry of long chain 
Acyl-CoAs into the mitochondria and elevated β-oxidation which is not 
matched by a similar increase in TCA intermediates and TCA flux and thus an 
accumulation of acylcarnitines in muscle due to ‘incomplete’ fatty acid 
oxidation (i.e fatty acids are not completely oxidised to CO2 and accumulate 
and may be exported into the plasma). Moreover, in a subsequent experiment, 
knockout mice lacking malonyl CoA decarboxylase (MCD), which degrades 
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the natural inhibiter (malonyl-CoA) of CPT1 activity and β‐oxidation, had 
markedly lower acylcarnitine levels in muscle and were protected against diet-
induced insulin resistance, despite high levels of long chain Acyl-CoA. 
However, the longer-term consequences of such a genetic manoeuvre were 
not investigated. The authors proposed that strategies that reduced rather 
than enhanced muscle fatty acid oxidation be considered a therapeutic 
treatment of insulin resistance. Although these findings did not implicate 
acylcarnitines as directly causative of insulin resistance, they show that 
reduced accumulation of acylcarnitines in the mitochondria can improve 
insulin sensitivity. This work led to the hypothesis that with obesity, 
mitochondria become congested by elevated carbon supply and cannot 
adequately switch their fuel preference in different physiological states (Muoio 
2014). A schematic overview of some of the mechanisms pertaining to lipid 
induced insulin resistance is shown in Figure 1.7 
1.3.2.1 Acylcarnitines and insulin resistance  
Since the work implicating acylcarnitines in the development of insulin 
resistance, studies have also observed elevated concentrations of even chain 
length acylcarnitines in the plasma of obese subjects and T2D patients 
(Adams et al. 2009; Mihalik et al. 2010). These findings appear to substantiate 
the notion that obesity and T2D is a state of incomplete fatty acid oxidation. 
Acylcarnitines have also been shown to cause insulin resistance in vitro. 
Murine C2C12 myotubes were treated for 18 h with C4:0, C14:0, or C16:0 
acylcarnitine at 3 different concentrations (5, 10, and 25 µmol/L). Treatment 
with C4:0 acylcarnitine at all concentrations resulted in a significant decreased 
Akt (Ser473) phosphorylation in response to insulin. Treatment with 5–10 
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mmol/L C14:0 or C16:0 acylcarnitines significantly decreased Akt (Ser473) 
phosphorylation in response to insulin stimulation (Aguer et al. 2015). In 
addition, C12 and C14 acylcarnitine treatment (20 µmol for 15 hours) of murine 
monocyte cells has been shown to activate nuclear factor kappa β (NFkB) 
which is a protein transcription factor that can promote pathways that lead to 
serine phosphorylation of insulin receptor substrate-1 and a proinflammatory 
state leading reactive oxygen species production and further promote insulin 
resistance (Adams et al. 2009).These findings gave rise to yet another lipid 
intermediate that could cause insulin resistance.  
Whilst acylcarnitines per se have been shown to induce insulin resistance in 
vitro (Aguer et al. 2015), little is known about their intramuscular profiles in 
human skeletal muscle from diabetic patients. This is important as numerous 
studies have reported on elevated plasma acylcarnitines in human studies with 
the assumption that they reflect skeletal muscle metabolism (Mihalik et al. 
2010). However, more recent studies measuring transorgan fluxes in pigs 
(Schooneman et al. 2015) and humans ( Xu et al. 2016) have demonstrated 
that liver is a major contributor to the plasma pool under fasting conditions and 
inadequately reflect skeletal muscle metabolism (Schooneman et al. 2014). 
Furthermore, in response to an OGTT the only tissue that appeared to reflect 
plasma acylcarnitine profiles was the heart (Makrecka-Kuka et al. 2017) 
providing further evidence that plasma acylcarnitines may not be an 
appropriate biomarker for skeletal muscle insulin resistance. Little is known 
about the skeletal muscle acylcarnitine profiles in obese and T2D humans nor 
if they reflect ‘incomplete or excessive’ fat oxidation. 
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1.3.2.2 Increasing or decreasing muscle fatty acid oxidation? 
It should be noted that the strategy to divert fatty acids away from oxidation 
and particularly in the muscle may appear an attractive option, but it is 
important to consider the potential longer-term consequences of such a 
strategy. Indeed, carnitine depletion with meldonium in rodents increased 
carbohydrate and reduced fat oxidation at the whole body level (Porter et al. 
2017). Conversely, carnitine feeding in humans for 12 weeks led to 20% 
increase in muscle total carnitine and 6% increase in energy expenditure 
compared to a carbohydrate consuming control group. Furthermore, the 
increase in energy expenditure was able to offset an increase in fat mass seen 
in the carbohydrate control group (Stephens et al. 2013). Therefore, whilst 
excessive fatty acid flux through β-oxidation can be detrimental to insulin 
action, whether strategies to reduce fatty acid oxidation in the face of 
increased fat availability are appropriate is questionable. A recent study 
investigated the long-term effects of reduced fatty acid oxidation in mice by 
using the drug etomoxir, an inhibitor of CPT-1 (Lundsgaard et al. 2019). Similar 
to previous findings, acute increases in glucose oxidation and peripheral 
glucose disposal were observed. However, circulating fatty acid and lipid 
accumulation in the liver and heart increased within hours, and after several 
days the mice developed hepatic steatosis and glucose intolerance and 
exhibited lower whole body insulin sensitivity (Lundsgaard et al. 2019). These 
findings demonstrate inhibiting fatty acid oxidation by diverting fatty acids away 
from CPT-1 may not be a viable long-term strategy to treat insulin resistance, 




Figure 1.6  An overview of potential pathways in muscle by which perturbed lipid metabolism leads to insulin resistance, see text 
above for details.
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1.3.3 Metabolic inflexibility of insulin resistant muscle 
Work by Kelley and colleagues, characterised muscle fuel metabolism in 
healthy, obese and insulin resistant individuals. One of the key characteristics 
of skeletal muscle is its ability to switch fuel utilisation in response to the 
availability of different substrates. One measure of muscle fuel usage is 
respiratory quotient (RQ) which is a measure of carbon dioxide production as 
a ratio to oxygen consumption. At a RQ of 1 glucose is the sole fuel (6 carbons 
from glucose oxidised to 6 molecules of oxygen) and an RQ of 0.7 is marker 
of fat oxidation. As RQ increased from 0.7 to 1, the contribution of glucose to 
the fuel mixture is increasing. Measuring RQ in arterial and venous blood 
across a limb, permits the calculation of muscle specific fuel usage, assuming 
the contribution of adipose tissue, skin and bone do not contribute significantly. 
Lean, healthy subjects shifted from a low RQ (0.83) in the fasted state to a 
high RQ (0.99) during a hyperinsulinaemic-euglycaemic clamp demonstrating 
a clear shift from fat to carbohydrate use with increased glucose availability. 
In contrast, in obese subjects, despite rates of fatty acid uptake that were 
equivalent to those of lean subjects, fasting rates of fatty acid oxidation by leg 
tissues were significantly lower. Fasting RQ was 0.9 (suggesting higher 
glucose use) and in response to insulin did not change and therefore there 
was an impaired ability to switch to glucose usage (Kelley et al. 1999; Kelley 
and Mandarino 1990). These observations led the authors to ask the question 
whether impairments in muscle mitochondria oxidative capacity could precede 
insulin resistance and possibly inherent impairments of mitochondria 
predispose individuals to accumulate lipid and lipid species in muscle which 
then cause insulin resistance. Indeed, reduced mitochondrial enzyme content 
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was observed in cross sectional comparisons between lean and insulin 
resistant individuals (Colberg et al. 1995; Kelley et al. 1999). It should be noted 
that later investigations have shown that metabolic inflexibility with regards to 
mitochondria does not explain the difference in fuel use and that the 
impairments lay at the level of glucose transport into the cell. When adjusting 
the difference in RQ between healthy lean and T2D groups for glucose 
disposal rate, the differences in RQ between groups were abolished (i.e. the 
reason RQ does not change in response to insulin is because T2D are insulin 
resistant and do not transport the glucose into the cell for subsequent 
oxidation) (Galgani et al. 2008). This suggests that the metabolic inflexibility to 
glucose observed in T2D cannot not be solely explained by a primary 
impairment in glucose oxidation but may also be the consequence of impaired 
glucose transport. 
1.3.4 Mitochondrial dysfunction 
Inherent defects in mitochondrial activity and function could in part explain why 
some individuals develop insulin resistance. However, when directly 
measuring mitochondrial respiration in muscle samples, the lower oxygen flux 
capacity in T2D patients is normalised to that of age-matched non-diabetic 
controls, when expressed relative to mitochondrial deoxyribonucleic acid 
(DNA) levels (Boushel et al. 2007). Thus, whilst it appears that mitochondrial 
content is lower, perhaps due to increased physical inactivity/sedentary 
lifestyle, muscle mitochondrial function at rest remains largely 
uncompromised. Additionally, direct assessment of hepatic mitochondrial 
oxidation by magnetic resonance spectroscopy revealed no difference in 
mitochondrial flux between healthy BMI matched control subjects and non-
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alcohol fatty liver disease (NAFLD) patients (Petersen et al. 2016), a disease 
characterised by excessive hepatic fat accumulation. These data suggest that 
tissue accumulation of lipids and lipid related species is most cases is a result 
of an imbalance between supply and oxidative capacity of tissues, the latter is 
most likely a reflection of physical activity levels. Work from this group has 
shown that old inactive obese subjects with low aerobic capacity had an 
equivalent rate of fatty acid disappearance from plasma into muscle but a 
reduced oxidation of plasma derived fatty acids and increased accumulation 
of IMCL compared to age-matched lean subjects following a single bout of 
exercise at 50 % of VO2 max (Chee et al. 2016). These findings clearly show 
the implications of a reduced oxidative capacity relative to fatty acid supply, 
which subsequently causes an accumulation of IMCL. 
1.3.5 Inactivity induced insulin resistance  
It should be noted that are physiological states in which the induction of muscle 
insulin resistance can be induced without parallel increases in IMCL. During 
periods of physical inactivity it would appear that muscle insulin resistance can 
precede accumulation of IMCL and the lack of muscle contraction explains the 
reduction in glucose uptake (Dirks, Wall, and Stephens 2020). For example, 
one week of bed rest can reduce whole body glucose disposal by 30-40 % 
(Stuart et al. 1988; Dirks et al. 2016). Importantly, this was assessed by 
hyperinsulinaemic–euglycaemic conditions, which considered the gold 
standard assessment of muscle insulin sensitivity (DeFronzo, Tobin, and 
Andres 1979). Remarkably, reduction in glucose tolerance can be observed 
within only a few days of the induction of physical inactivity (Dirks et al. 2018) 
The rapid development of insulin resistance suggests that the removal of 
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muscle contraction per se disuse‐induced insulin resistance, likely due to a 
lack of stimulus for translocation of the facilitative glucose transporter, GLUT4, 
to the plasma membrane via various signalling pathways, which is the most 
adjacent physiological mechanism preceding muscle glucose uptake (as 
stated in Section 1.1.3.1). Indeed, the aforementioned reports displayed 
reductions in gene expression of GLUT4 following bed rest (Dirks et al. 2018). 
Moreover, in this experimental model the reduction in insulin sensitivity was 
not accompanied by an accumulation in IMTG content nor lipid intermediate 
species such as ceramides (Dirks et al. 2016). However a trend for increased 
DAG has been observed following a week of bed rest induced inactivity (Dirks 
et al. 2018). Taken together, these data suggest that IMCL accumulation 
follows (rather than precedes) the development of insulin resistance, perhaps 
suggesting that insulin resistance may be a cause, not a consequence, of 
IMCL accumulation. Collectively these findings give rise to question as to 
whether IMCL are causative of insulin resistance or are in innocent bystander 
of reduced muscle energy expenditure with physical inactivity. 
1.3.6 Summary  
To summarise, there are clearly several (and sometimes conflicting) opinions 
on specific mechanisms underpinning the pathophysiology of lipid induced 
insulin resistance. This could in part be explained by the range of mechanistic 
models used to investigate this area and a lack of control of confounding 
factors such as physical activity. Given that models of acute but extreme 
physical inactivity such as bedrest or limb immobilisation clearly show the 
induction of insulin resistance may even precede lipid accumulation in the 
muscle (Dirks, Wall, and Stephens 2020), further questions which factor is 
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primarily responsible for the reduced glucose uptake. Furthermore, although 
several studies implicate the tissue accumulation of lipid and lipid species with 
aberrant insulin action, there appears to be no consensus on which lipid 
specie(s) constitute the primary cause of lipid induced insulin resistance. 
Moreover, previous aspects not previously investigated such as sub cellular 
localisation of lipid may also be a key factor (Kahn et al. 2021). One way to 
reconcile all these contrasting views would be to measure each aspect 
(physical activity and the subcellular accumulation of each lipid intermediated 
implicated in the development of insulin resistance) using time course studies. 
Of course, availability of methods is likely to preclude this type of analysis. 
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1.4 Branched chain amino acids 
1.4.1 Overview and synthesis 
The branched-chain amino acids (BCAAs), valine, leucine, and isoleucine are 
essential amino acids that cannot be synthesised in the human body and 
therefore must be obtained from the diet. BCAAs are synthesized in bacteria, 
plants, and fungi. The synthesis of valine and isoleucine is carried out by the 
same enzymes, and leucine is created from α-ketoisovalerate, a 
transamination precursor of valine (Figure 1.7a). The carbons in valine (and 
leucine) are derived from the readily available and abundant pyruvate, but 
isoleucine carbons are derived from the relatively rare threonine. Despite the 
absence of synthesis in animals, BCAAs are abundant in the human body, 
constituting approximately 35 % of all essential amino acids in most mammals 
and greater than 30 % of muscle proteins (Harper, Miller, and Block 1984). 
The functional R groups of all three BCAAs are branched (hence their name), 
small, and hydrophobic, rendering them critical components of most proteins 





Figure 1.7 BCAA synthesis and catabolism. Synthesis (a) occurs in plants, 
bacteria, and fungi. Oxidation (b) occurs in plants, bacteria, fungi, and animals. 
All three BCAAs share the BCAT and BCKDH steps, after which catabolism of 
each BCAA is unique. The BCKDH complex is composed of a core of 24 E2 
subunits, which are docked by E1 heterotetamers and E3 dimers. BCKDK 
inhibits E1 via phosphorylation, which is reversed by PP2Cm. Abbreviations: 
ACAD8, acyl-CoA dehydrogenase family member 8; ACADSB, 
short/branched chain acyl-CoA dehydrogenase; ACAT1, acetyl-CoA 
acetyltransferase 1; AHAS, acetohydroxyacid synthase; α-KIC, α-
ketoisocaproic acid; α-KIV, α-ketoisovaleric acid; α-KMV, α-ketomethylvaleric 
acid; ALDH6A1, aldehyde dehydrogenase 6 family member A1; AUH, AU 
RNA-binding protein/enoyl-coenzyme A hydratase; BAIBA, beta-amino-
isobutyric acid; BCAA, branched chain amino acid; BCAT, branched chain 
amino transferase; BCFA, branched chain fatty acid; BCKDH, branched chain 
amino acid dehydrogenase; BCKDK, BCKDH kinase; CoA, coenzyme A; 
DHAD, dihydroxyacid dehydratase; HADHA, hydroxyacyl-CoA 
dehydrogenase subunit alpha; HIBADH, 3-hydroxyisobutyrate 
dehydrogenase; HIBCH, 3-hydroxyisobutyryl-CoA hydrolase; HMGCL, 3-
hydroxymethyl-3-methylglutaryl-CoA lyase; HSD17B0, 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase; IPMDH, isopropylmalate 
dehydrogenase; IPMI, isopropylmalate isomerase; IPMS, isopropylmalate 
synthase; IVD, isovaleryl-CoA dehydrogenase; MCCC, methylcrotonoyl-CoA 
carboxylase; MUT, methylmalonyl-CoA mutase; OCFA, odd-chain fatty acid; 
OXCT1, 3-oxoacid CoA transferase; P, phosphorylation; PCCB, propionyl-
CoA carboxylase subunit beta. Taken from Neinast et al. (2018) 
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1.4.2 BCAA catabolism 
The clinical importance of BCAA catabolism is demonstrated in patients with 
in-born errors of metabolism such as maple syrup urine disease, a rare 
autosomal recessive disorder caused by mutations in the branched chain α-
ketoacid dehydrogenase (BCKDH) enzyme complex. The body is not able to 
catabolise BCAAs leading to supraphysiological levels of BCAAs and BCKAs 
in the blood. As a result, these individuals experience hypotonia and 
ketoacidosis as well as serious neurological issues such as developmental 
delay, hallucinations, seizures, and coma (Siddik and Shin 2019). 
1.4.2.1 Transamination 
The catabolic pathways of the BCAA have several features in common. All 
three BCAAs are initially transaminated by branched chain amino transferase 
(BCAT) to form branched chain ketoacids (BCKAs). The products of this 
reaction are α-ketoisocaproate (KIC), α-keto-b-methylvalerate (KMV), and α-
ketoisovalerate (KIV) and are formed from leucine, isoleucine and valine 
transamination, respectively. In this readily reversible reaction, α-ketoglutarate 
(αKG) acts as the nitrogen acceptor to yield glutamate (Ichihara 1975) (Figure 
1.8). Glutamate then acts as an amino group source to form alanine from 
pyruvate or as a substrate for ammonia detoxification to glutamine. Glutamine, 
alanine, and a significant portion of the BCKA can be released from muscles 




Figure 1.8 The reversible transamination reaction catalysed by branched 
chain amino transferases (BCATs). 
 
1.4.2.2 Branched chain α-ketoacid dehydrogenase complex 
The next steps of BCAA catabolism involve the irreversible oxidation of BCKAs 
and is catalysed by the branched chain α-ketoacid dehydrogenase (BCKDH) 
complex. This enzyme is located on the inner surface of the inner membrane 
of the mitochondria and shares many attributes with the pyruvate 
dehydrogenase (PDH) complex. Like the PDH complex, BCKDH catalyses an 
oxidative decarboxylation, releasing CO2 and NADH and covalently adding a 
coenzyme A (CoA) group to the oxidized BCKA product (Johnson and 
Connelly 1972). This step commits the BCAA carbon skeleton to the 
degradative pathway (Figure 1.8b).  
The BCKDH complex consists of 3 catalytic components: a heterotetrameric 
BCKA decarboxylase (E1), a homo‐24‐meric dihydrolipoyltransacylase (E2), 
and homodimeric dihydrolipoamide dehydrogenase (E3). BCKDH activity is 
also regulated by post‐translational covalent modification involving 
phosphorylation and dephosphorylation of its E1‐α subunit. The inhibitory 
regulation of the BCKDH complex occurs via the inactivating phosphorylation 
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at Ser293 on the E1‐α subunit by the BCKDH kinase (BCKDK), resulting in 
decreased BCKDH complex activity. The complementary activating 
dephosphorylation is carried out by protein phosphatase, PP2Cm (also known 
as PPM1K) (Harris et al. 2005). BCKDK is allosterically suppressed by BCKAs 
(its greatest for (α-KIC) thus allowing elevations in BCKAs to promote their 
own oxidation (Randle 1983). Efficient product inhibition of BCKDH also 
occurs by NADH and acyl-CoAs.  
Oxidation of branched-chain amino acids in muscle serves two functions. The 
first is the generation of ATP and therefore can be used for energy provision, 
and the second is the synthesis of glutamine, which effluxes from the muscle. 
Work investigating the fate of BCAA derived carbon within muscle using 
radioactive isotopes revealed that only a small proportion (5%) ultimately 
enters the TCA cycle for oxidation and the majority are converted to glutamate 
(Goldberg 1978; Wagenmakers, Salden, and Veerkamp 1985).  
After BCKDH decarboxylation, subsequent catabolism of BCAAs resembles 
fatty acid oxidation, and indeed, these two processes share a number of 
enzymatic subunits. Each set of reactions is mostly unique to each BCAA, and 
all occur inside the mitochondrial matrix. Ultimately, BCAA carbons are either 
lost as CO2 or enter the tricarboxylic acid (TCA) cycle. Specifically, valine (5C) 
loses 2 carbons to CO2 and contributes 3 carbons to the TCA as succinyl-CoA; 
leucine (6C) loses 1 carbon to CO2 and contributes 5 carbons to the TCA in 
acetyl-CoAs; and isoleucine (6C) loses 1 carbon to CO2 and contributes 5 
carbons to the TCA as acetyl-CoA and succinyl-CoA. Short chain acylcarnitine 
can be formed in the catabolism of BCAAs, in the same manor described for 
fatty acids. Chain lengths of 3,4 and 5 carbons (some steps are shown in figure 
 46 
1.7b but for a detailed schematic see (Figure 4.4). Valine is considered 
glucogenic (i.e., succinyl-CoA is anaplerotic), whereas leucine is considered 
ketogenic, and isoleucine is both keto and glucogenic. As of yet, little is known 
about the relative activities and kinetics of enzymes involved in the catabolic 
pathways for BCAAs in human tissues. This is important as, short chain acyl 
CoA products and associated short chain acylcarnitines could theoretically 
increase with both increased tissue flux through BCKDH or reduced enzyme 
activity of catabolic enzymes or both and no studies have addressed this 
directly to date nor quantitatively assessed BCAA and catabolites in muscle to 
give an indication of flux. 
1.4.2.3 Distribution of BCAA catabolism  
One unique aspect of BCAAs is that several organs contribute to their 
catabolism and there appears to be significant interorgan exchange. 
Consequently, assessment of whole body BCAA catabolism, especially in 
humans has been extremely challenging. Furthermore, the characterisation of 
activities of the BCAT and BCKDH enzymes has largely been performed in ex 
vivo preparations (Harper, Miller, and Block 1984; Sitryawan et al. 1998b). 
what has been established is that BCAT and the BCKDH complex are broadly 
expressed in human tissues, indicating wide tissue ability for BCAAs 
transamination and oxidation.  
BCAT activity in human tissues is highest for kidney, followed by brain, 
stomach, and heart. A lesser and similar grade of activity is present in liver, 
small intestine, and colon while the lowest activity is showed by muscle and 
adipose tissue. The highest enzymatic activity of the human BCKDH complex 
has been found in kidney, followed by liver, brain, and heart. Muscle, stomach, 
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and colon had similar and lesser activity of the enzyme. Adipose tissue and 
small intestine had the lowest BCKD complex activity. The highest 
concentration of human BCKDH kinase (responsible for the inactivation of the 
complex) has been found in skeletal muscle while kidney possesses the lowest 
activity state (Sitryawan et al. 1998) When taking into account the organ weight 
as a proportion of body weight, the skeletal muscle has the highest quantitative 
capacity for both BCAAs transamination and oxidation. However, the BCKD 
kinase concentration is highest in muscle tissue, denoting the capacity of 
skeletal muscle to restrain the oxidation of BCKAs as well (Sitryawan et al. 
1998; Brosnan and Brosnan, 2006). These results are only suggestive 
because other factors such as rates of blood flow, and transport into cells, are 
also important to consider. The muscle capacity for transamination appears to 
be far greater than oxidation. Assessment of leucine kinetics in humans has 
shown that the rate of transamination is much greater than KIC oxidation 
(Matthews et al. 1981), fitting with the model of high BCAT activity but highly 
constrained BCKDH activity in human muscle. However, the situation is 
reversed in the liver (at least in rodents) and the general consensus is that 
muscle transaminates BCAAs and releases significant quantities of BCKAs 
which are taken up by the liver. There is generally a lack of data on the fate of 
BCAAs in humans most likely due to the challenges of obtaining tissue 
samples and cannulation across the liver. 
In perhaps in the most comprehensive integrative study to date, which 
investigated the whole body fate of BCAAs in rodents using a stable isotopes 
and tissue level flux analysis in rodents has shown that indeed muscle, liver 
and adipose tissue house the largest capacity to oxidise BCAAs but also that 
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tissue oxidative flux correlates very poorly with phosphorylation status of the 
BCKDH (Neinast et al. 2018). 
1.4.3 BCAAs Obesity and Insulin resistance  
Elevated BCAAs were first associated with obesity almost 50 years ago when 
Felig and colleagues made the observation that obesity was associated with 
elevated circulating BCAAs and infusion of insulin did not fully suppress their 
efflux from the forearm in obese individuals (Felig, Marliss, and Cahill 1969; 
Felig 1975). Despite these early observation, little regard was paid to 
perturbed BCAA metabolism and its potential contribution to insulin resistance. 
Interest in BCAA being implicated in the progression of insulin resistance was 
renewed in the last decade by a study that performed comprehensive 
metabolic profiling of plasma from lean and obese subjects (Newgard, An, 
Bain, Muehlbauer, Stevens, Lien, Haqq, Shah, Arlotto, Slentz, Rochon, et al. 
2009). An unbiased metabolomic and principal component analysis revealed 
the three BCAAs, the aromatic acids phenylalanine and tyrosine and C3 and 
C5 BCAA-derived acylcarnitine species were the components that most 
strongly dissociated between lean and obese individuals. Furthermore, 
evaluation of the association between this BCAA-related metabolite 
component and HOMA-IR revealed a significant linear relationship (r = 0.58, 
p<0.0001), even after adjusting for obese vs. lean status using a partial 
Spearman correlation coefficient (r=0.33, p<0.0001). This independent 
relationship persisted even after adjustment for age, race, and gender. 
Surprisingly, even though elevations in free fatty acids were also observed in 
obese plasma, these were not identified as a component that differentiated 
obese from lean subjects. Furthermore, although adjustments were made for 
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age, race, and gender, the obese subjects were also less physical active (as 
assessed using the international physical activity questionnaire) and an 
adjustment for physical activity was not considered. Thus, it is unknown to 
what extent physical inactivity could be accountable for the associations seen. 
The association between BCAA and insulin resistance was strengthened 
when it was later demonstrated that plasma baseline BCAA concentrations 
could predict the onset of T2D many years before clinical diagnosis in a 
longitudinal study (Wang et al. 2011). These findings validated BCAAs as new 
biomarkers for T2D development and interest in BCAA as a causative rather 
simply a reflective component of T2D was renewed. Moreover, Mendelian 
genetics studies revealed that polymorphisms near the PPM2 gene (encoding 
for the BCKDH phosphatase) that affect BCAA levels also increase the risk of 
insulin resistance (Lotta et al. 2016) However, these studies still provided no 
mechanistic link between BCAAs, obesity and insulin resistance.  
1.4.4 Evidence from animal studies  
Work in animals has focused primarily on the manipulation of dietary BCAA 
intake. Rodents fed a high fat diet supplemented with BCAAs had an 
overaccumulation of even chained acylcarnitines species (arising from fatty 
acid oxidation) as well as specific accumulation of C3 and C5 acylcarnitine 
species (arising from BCAA catabolism) in skeletal muscle. In contrast, BCAA 
supplementation of a standard diet caused no accumulation of acylcarnitine 
species and the animals did not become insulin resistant (Newgard et al. 
2009). The authors suggested that against a background of a high fat diet, 
excess BCAAs may compete with fatty acid for oxidation and saturate the 
capacity for mitochondrial fuel oxidation in muscle leading to incomplete fatty 
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acid oxidation and development of insulin resistance, which corroborates with 
previous findings in humans from the same group (Koves et al. 2008) This 
suggestion is difficult to reconcile with the data outlined above suggesting only  
a small fraction of BCAA carbon enters the TCA cycle (Goldberg 1978; 
Wagenmakers, Salden, and Veerkamp 1985). Whilst these studies did not 
demonstrate a causal role of amino acids and their catabolites in inducing 
skeletal muscle insulin resistance, their results did suggest for the first time 
that aberrant BCAA metabolism may either contribute to or result from the 
development of insulin resistance. 
1.4.4.1 Impaired BCAA catabolism in animal models of obesity  
One consistent finding from rodent models of obesity is that, through a yet 
unidentified mechanism, obesity results in down regulated transcription of 
BCAA catabolic genes in adipose tissue and the liver (She et al. 2007; Zhou 
et al. 2019) as well as increased phosphorylation of the BCKDH enzyme in 
these tissues (She et al. 2007; Lackey et al. 2013) and this was associated 
with elevated plasma BCAA concentrations (She, Horn, et al. 2007). Indeed, 
the modulation of adipose tissue through adipose tissue transplantation of 
healthy adipose tissue into mice lacking the enzyme BCAT, reduced 
circulating BCAA concentrations (Herman et al. 2010). However, when 
assessing BCAA flux across the subcutaneous adipose tissue in lean, obese 
insulin sensitive and obese insulin resistance humans, there were no 
differences in uptake or release (Lackey et al. 2013). These findings 
questioned the significance of adipose tissue to human BCAA metabolism. 
The metabolic consequences of reduced BCAA catabolism in those tissues 
seems unclear but some have suggested that it results in shift in BCAA 
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catabolism to the muscle where they compete with fatty acids for oxidation 
(White et al. 2016).  
More recently another study has demonstrated a relationship between skeletal 
muscle BCAA and fat oxidation. Using a transcriptomics approach, it was 
shown that skeletal muscle of insulin resistant and T2D individuals had lower 
mRNA expression (activity was not measured) of BCAA catabolic enzymes 
(mut and ALDH6A1, see figure 1.7b) (Lerin et al. 2016). Interestingly high fat 
feeding of rodents for 4 months or rendering mice inactive through denervation 
also resulted in similar reductions in BCAA catabolic gene expression (Lerin 
et al. 2016). Untargeted metabolomics analysis revealed reduced muscle 
BCKA content despite similar BCAA levels in insulin resistant individuals 
compared to insulin sensitive controls. This could in part be explained by 
reduced levels of the nitrogen accepter (αKG) possibly reflecting reduced 
transamination. However, there was also increased relative expression of C5 
acylcarnitine which would suggest increased catabolic flux. Given that these 
data were relative expression of metabolites with no quantification it is difficult 
to assess what scenario this represents (i.e increased or decreased catabolic 
flux). Heterogenous gene deletion of the enzyme mutase (mut), which 
converts methylmalonyl-CoA to succinyl-CoA (that can be incorporated into 
the TCA cycle or enter complex II of the electron transport chain), in mice 
resulted in weight gain and impaired glucose tolerance. The authors attributed 
this effect to reduced fatty acid oxidation, which was based on increased 
relative expression of acylcarnitines in muscle and elevated TAG content in 
muscle. Thus, reduced BCAA flux resulted in ‘incomplete’ fatty acid oxidation, 
resulting in the accumulation of lipid in muscle and probably caused insulin 
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resistance. There are several limitations to this work, firstly the heterogenous 
knock out model could have had several offsite effects on whole body 
metabolism and no quantitative assessment of fatty acid oxidation was made. 
Other reports have also shown a reduced mRNA expression of BCAA 
catabolic enzymes in muscle of patients with T2D together with increased 
plasma BCAA and BCKA concentrations (Hernández-Alvarez et al. 2017). 
These findings were reproduced in a mouse model of T2D (using the db/db 
mouse) suggesting that T2D is state of reduced muscle BCAA catabolism and 
oxidation although no assessment of BCAA complete oxidation were made. 
However it has subsequently been shown with the use of stable isotope tracers 
and direct measures of tissue oxidative flux that the db/db mouse does in fact 
have increased muscle BCAA oxidation (Neinast et al. 2018). Furthermore, 
this same report has shown that post translation modifications (i.e the 
phosphorylation status) of the BCKDH enzyme, considered the rate limiting 
step in BCAA oxidation, does not correlate with tissue oxidation. These 
findings question the extent at which mRNA expression reflects tissue 
oxidation given that post translation modification does not appear to. These 
are serious limitations of the work outlined in the former reports that have not 
been considered. 
Collectively, the data from animal and untargeted metabolomics, and 
assumptions from mRNA expression data from human works appears to 
suggest that obesity and insulin resistance are a state of impaired BCAA 
catabolism. Thus, it has been suggested that strategies to increase BCAA 
catabolism are warranted to as a treatment for obesity (Zhou et al. 2019). 
Furthermore, animal studies have shown that both excessive and impaired 
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BCAA oxidation in muscle can lead to reduced fatty acid oxidation. The 
differences appear to be a result of different analytical methods used for 
assessment and static measures with untargeted analysis (and hence no 
information on actual concentration) and gene expression data. Furthermore, 
these studies have failed to address the question, if BCAA catabolism is 
impaired in muscle then what is the reason for the increased BCAA catabolites 
in muscle of insulin resistant individuals. Therefore, a more likely explanation 
for those findings is that there may be a mismatch within the mitochondria 
between catabolism and complete oxidation which may be in a feedback 
mechanism be inhibiting further flux in the BCAA catabolism pathway. To 
address this, quantitative assessments of this pathway to give an indication of 
concentrations are required. 
1.4.5 Evidence from human studies  
Direct evidence from human studies appears to contradict the animal work. 
Reports that have investigated human BCAA metabolism appear to confirm 
the earliest observations that pre-existing insulin resistance leads to perturbed 
BCAA metabolism (Piro et al. 2020; Tan et al. 2020). In fact, since the earlier 
associative reports linking BCAA to the development of T2D (Wang et al. 
2011), more recent mendelian genome wide association reports have 
demonstrated that higher BCAA levels do not have a causal effect on insulin 
resistance, rather insulin resistance likely drives higher fasting BCAAs (Wang 
et al. 2017; Mahendran et al. 2017). 
Targeted profiling of visceral adipose tissue in humans has shown a down 
regulation of the three BCAA levels in the visceral adipose tissue of patients 
with the metabolic syndrome and otherwise healthy obese subjects compared 
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to healthy lean controls together with an up regulation of their metabolic 
derivatives, the short chain acyl-carnitines (C3-C5) (Piro et al. 2020). In 
addition, elevated levels of kynurenine, a catabolic product of tryptophan was 
also seen to be elevated, adding further support for increased not impaired 
catabolism in human adipose tissue. These findings appear to be in 
contradiction with previous studies where a lower expression of BCAA 
catabolic enzymes has been observed (She, Horn, et al. 2007).  
Another recent study investigated whole body leucine flux, using stable 
isotope tracers (U-13C6) leucine and concentrations of circulating BCAAs, 
BCKAs and short chain acylcarnitines in morbidly obese humans before and 
after gastric bypass surgery and directly tested the hypothesis from animal 
work that BCAA catabolism is impaired with obesity and insulin resistance 
(Tan et al. 2020). In contrast to animal reports, an elevation in whole body 
leucine flux (a measure of leucine transamination to KIC), leucine oxidation (a 
measure of 13CO2 production) and non-oxidative disposal of leucine (a 
measure of protein synthesis) were all elevated in insulin resistance morbidly 
obese subjects. Furthermore, these observations were also accompanied by 
increased plasma BCAA, BCKA and short chain acylcarnitines, demonstrating 
that elevations of the metabolites can reflect accelerated BCAA catabolism 
and not just impaired BCAA catabolism as previous studies which have only 
measured relative expression of enzymes and non-quantitative concentrations 
of BCAA related metabolites have suggested (Lerin et al. 2016; Zhou et al. 
2019). Following gastric bypass surgery and an increase in insulin sensitivity, 
the elevations in leucine flux and plasma BCAA profiles all significantly 
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reduced providing further evidence that impaired BCAA metabolism is a 
consequence of the insulin resistant state. 
Another question that remains to be addressed is what are the consequences 
of elevated short chain acylcarnitines in humans? Although a number of 
studies have assumed that skeletal muscle insulin resistance may be a 
consequence of reduced BCAA catabolism in other tissues, which effectively 
burdens skeletal muscle with excess BCAAs, there are very few studies that 
have investigated human skeletal muscle BCAA metabolism in this context. 
One study from this group did show that in response to lipid infusion during a 
hyperinsulinaemic clamp, short chain BCAA derived acylcarnitines (C3-C5) 
were elevated in muscle when compared to saline control (Stephens et al. 
2014). These acylcarnitine species were negatively correlated with glucose 
disposal and muscle glycogen accumulation during the clamp. Given that high 
levels of insulin (during the clamp) are expected to supress protein catabolism 
(Tessari et al. 1986), these findings provided a novel scenario in which lipid 
induced insulin resistance (through high lipid oxidation under clamp 
conditions) may directly impact upon BCAA catabolism, increasing oxidation 
which could exacerbate insulin resistance. In support of this, it has been shown 
the valine catabolite 3-HIB is elevated in muscle of patients with T2D (Jang et 
al. 2016). Furthermore, in cultured myotubes it was shown that this metabolite 
can leave the muscle cell and drive endothelial transport of fatty acids into the 
muscle in a paracrine fashion (Jang et al. 2016). Therefore one proposed 
model from these studies is that lipid overspill into muscle resulting in insulin 
resistance, increases BCAA catabolism (Stephens et al. 2014). Indeed 
postprandial lipid supply to muscle is increased in insulin resistant individuals 
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(van Hees et al. 2011). In turn, excessive BCAA catabolism in muscle may in 
turn lead to further influx of fatty acid into the muscle (Jang et al. 2016), 
potentially leading to a vicious cycle whereby insulin resistance promotes 
BCAA catabolism in muscle which in turn worsens insulin resistance. 
However, mechanistic data to support this concept is lacking and there has 
been a lack of experimental evidence on alterations in muscle per se as 
primary cite of perturbed BCAA metabolism.  
The lack of quantitative assessment of BCAAs, related catabolites and fatty 
acid oxidation in human muscle and plasma has precluded the assessment of 
how these pathways are interacting. Furthermore, there appears to be direct 
contradictions between rodent and human work. Given that the more robust 
integrative physiology reports suggest that insulin resistance drives excessive 
BCAA catabolism. This is an important area of research that has been under 
investigated thus far. One way to address the issues outline above is to 
develop targeted metabolomic methods to assess tissue concentrations of 
metabolites. The premise of metabolomics is discussed in the next section 
below. Moreover, much of the work in this area has been limited to the fasting 
state, if BCAAs or any related catabolite was truly causative of insulin 
resistance and not simply just a biomarker then the well documented 
elevations in these metabolites should persist in the insulin stimulated state as 
opposed to being suppressed. However, how the muscle profiles of these 
metabolites change in the face of insulin (across varying degrees of insulin 
sensitivity) has not been assessed thus far.  
 57 
1.5 Metabolomics 
1.5.1 Metabolomics and the metabolome 
Metabolomics, which is the profiling of metabolites in biofluids, cells and 
tissues, is routinely applied as a tool for biomarker discovery (Nicholson, 
Lindon, and Holmes 1999). Perhaps more importantly, the inherent sensitivity 
of metabolomics enables subtle alterations in biological pathways to be 
detected to provide insight into the mechanisms that underlie various 
physiological conditions and aberrant processes, including diseases. 
Metabolites can be defined as small molecular weight chemicals involved in 
metabolism (such as glucose and ethanol). Metabolites are the substrates and 
products of metabolism that drive essential cellular functions, such as energy 
production and storage, signal transduction and apoptosis. Collectively, the 
total number of metabolites in a sample is referred to as the metabolome. 
1.5.2 Use of metabolomics for chronic diseases. 
In the case of many chronic metabolic diseases, the condition may well be 
present or in progression for years before they become clinically apparent. For 
example, by the time relative insulin deficiency manifests as hyperglycaemia 
and a diagnosis of type 2 diabetes is made, considerable pancreatic beta cell 
insufficiency has already occurred (Tabák et al. 2009). Whilst clinical and 
laboratory-based predictors such as glucose tolerance tests may aid in 
identifying disease risk, they must often be performed in close proximity to the 
onset of overt disease and may provide little insight regarding the underlying 
mechanisms. For diseases such as chronic kidney disease (CKD), which is 
defined as the presence of kidney damage for at least 3 months, independent 
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of the underlying chronic renal disease, current diagnostic methods have 
numerous limitations (Hocher and Adamski 2017). In CKD current diagnostic 
methods such as urinary albumin excretion and/or estimated glomerular 
filtration rate (GFR) are also used to determine the clinical stage of CKD and 
inform decisions on subsequent treatment. However, estimates of GFR that 
are based on creatinine are influenced by biological confounders such as age, 
sex and in particular muscle mass. As creatinine is produced by muscle 
metabolism, changes in muscle mass can result in false estimates of GFR 
(Ferguson et al. 2015). 
The identification of novel biomarkers may negate the requirement for invasive 
procedures such as tissue biopsy, which may have many associated 
complications. Furthermore, metabolites may have unanticipated roles as 
regulatory signals with hormone-like functions or effectors of the disease 
process itself. Therefore, metabolite concentrations could presage the onset 
of overt disease and therefore aid in the identification of at-risk individuals by 
adding information over standard clinical markers, which in the case of some 
diseases may not be reliable. Once biomarkers have been identified, the next 
steps involve validation of the biomarkers using targeted approaches to 
provide absolute quantification of metabolites in samples. Metabolomics 
analysis works very well with many types of sample of human or animal origin, 
including body fluids (urine, serum, plasma, dried blood spots, saliva, 
cerebrospinal, lung lavage or seminal fluid), tissue (including biopsy samples), 
stool, cell culture or exhaled breath. 
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1.5.3 Qualitative and Quantitative metabolomics  
The two orthogonal approaches used in metabolomics are targeted and non-
targeted metabolomics. 
Untargeted metabolomics  
Untargeted metabolomic methods are global in scope and have the aim to 
simultaneously measure as many metabolites as possible from biological 
samples without bias. Untargeted analyses are most effective when 
implemented in a high-resolution mass spectrometer, to facilitate structural 
characterization of the metabolites (i.e. which metabolite family they belong to 
and any biochemical isomers) Its unbiased nature allows it to examine the 
relationship between interconnected metabolites from multiple pathways. 
Targeted metabolomics  
Targeted metabolomic analyses measure the concentrations of a predefined 
set of metabolites. A standard curve for a concentration range of the 
metabolite of interest is prepared, so that accurate quantification can be 
gained. This type of analysis can be used to obtain exact concentrations of 
metabolites identified by untargeted metabolomics, providing analytical 
validation (Roberts et al. 2012). 
1.5.4 Overview of metabolomics work flow 
The main methodologies that are used for untargeted and targeted metabolite 
recovery and identification are mass spectrometry-based metabolomics. Mass 
spectrometry (MS) can be defined as an analytical method by which ionised 
molecules are detected according to their mass-to-charge (m/z). MS can be 
combined with a chromatography method, as thousands of ions can be 
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present in metabolomic experiments. Chromatographic separation before 
entering the mass spectrometer minimizes signal suppression and allows for 
greater sensitivity.  
1.5.4.1 Sample extraction 
The first step in any metabolomics involves metabolite extraction from the 
sample. In general, metabolites of interest are extracted by liquid extraction 
with one solvent, aqueous or organic, or with a combination of solvents (Lees, 
and Sloane 1953) Sample preparation and sample introduction methods for 
the analysis of biological samples can include, but are not limited to, direct 
injection, liquid-liquid extraction (LLE), solid-phase extraction (SPE), 
supercritical fluid extraction, accelerated solvent extraction, microwave-
assisted extraction, protein precipitation, and membrane methods, such as 
dialysis or ultracentrifugation. Each method has its own relative merits and is 
appropriate for certain metabolites (Dettmer, Aronov, and Hammock 2007)  
1.5.4.2 Sample injection & chromatography  
As stated above, MS systems are often coupled with a chromatography 
approach to enable the separation of metabolites in the sample matrix. 
Chromatography is based on the principle where molecules in mixture applied 
onto the surface or into the solid, and fluid stationary phase (stable phase) is 
separating from each other while moving with the aid of a mobile phase (which 
can be either gas or liquid). The factors effective on this separation process 
include molecular characteristics related to adsorption (liquid-solid), partition 
(liquid-solid), and affinity or differences among their molecular weights. 
Because of these differences, some components of the mixture stay longer in 
the stationary phase, and they move slowly in the chromatography system, 
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while others pass rapidly into mobile phase, and leave the system faster 
(Coskun 2016) 
The main chromatography approaches utilise either liquid chromatography 
(LC) or gas chromatography (GC). Liquid chromatography followed by MS 
(LC/MS) enables the detection of the most metabolites and has therefore been 
the technique of choice for global metabolite profiling work. Analysis of a wide 
range of metabolites, ranging from high to low molecular weight, and from 
hydrophilic to hydrophobic, can be performed by selecting the appropriate 
column and mobile phases (Putri et al. 2013) 
During chromatography, aliquots of separated metabolites are applied to 
ionization chambers; only ionized metabolites will be analysed. The MS 
provides information on mass/charge ratio (m/z), which is used to calculate the 
mass of individual metabolites. Reversed phase chromatography is a standard 
tool for the separation of medium polar and nonpolar analytes, whereas 
hydrophilic interaction chromatography (HILIC) is used for the analysis of 
highly polar compounds.  
1.5.4.3 Analyte ionisation  
After chromatographic separation, analytes are ionised before MS analysis but 
the efficacy of this process differs between metabolites and some might not 
be suitable for analysis in the mass spectrometer (Baldwin 2005) The most 
often used ionization methods in the field of metabolomics are electrospray 
ionization (ESI) and electron impact (EI) ionization. ESI is the favourite 
ionization technique for HPLC-MS for multiple reasons. It adequately ionizes 
molecules in the liquid phase and can universally be used for small molecules 
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(<1,000 amu) as well as for large molecules such as peptides and proteins. 
Moreover, ESI is a soft ionization technique, so it does not induce a significant 
fragmentation of the molecular ions. A drawback in using ESI is that its 
ionization efficiency is negatively affected by the presence of salts, so the 
chromatography methods are limited to the use of only volatile buffers such as 
ammonium acetate or ammonium formate. In addition, ion suppression can 
occur when co-eluting metabolites compete for a limited number of molecular 
ions with low electron or when proton affinity metabolites are obscured, or not 
detected at all. EI is the ionization method of choice for GC-MS based analysis. 
EI is a hard ionization method as it causes fragmentation of metabolites and it 
enables detection with minimal matrix effects due to co-eluting metabolites 
(Nagana Gowda and Djukovic 2014). In order to obtain a broad coverage of 
the metabolome, ionization must be performed in positive and negative mode. 
Depending on the mass analyser used, detection in positive and negative 
mode can be performed simultaneously in a single run (Idborg-Björkman et al. 
2003) thus, reducing the time needed for analysis and eliminating possible 
variability due to injection errors. 
1.5.4.4 Mass spectrometry 
Metabolite detection with high resolution and sensitivity is generally desired. 
However, achieving both goals in a single MS detection mode is challenging 
because as a general rule higher sensitivity leads to lower resolution and vice 
versa. There are various options including single (MS) or tandem (MS/MS) 
mass analyzers to choose from, each of which has different sensitivity and 
resolution performance. The single-configuration mass analyzers include the 
quadrupole (Q), linear ion trap (LIT), quadrupole ion trap (QIT), time of flight 
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(TOF), Fourier transform ion cyclotron resonance (FTICR), and Orbitrap. 
Quadrupole and ion trap analyzers offer high sensitivity, but limited resolution 
whereas TOF, FTICR, and Orbitrap offer high mass resolution. Mass 
analyzers arranged in a tandem configuration include triple-quadrupole ion 
trap (QTrap), triple quadrupole (TQ), quadrupole-TOF (Q-TOF), and linear-
quadrupole ion trap-Orbitrap (LTQ-Orbitrap). Because of their high sensitivity 
and selectivity, TQ and QTrap analyzers are the most common MS 
spectrometers hyphenated to LC and employed in targeted metabolic studies, 
while Q-TOF, LTQ-Orbitrap, and FTICR analyzers are more suitable for global 
profiling and metabolite identification (including isotopomer analysis) due to 
their higher mass-resolving power. An overview of the metabolomics workflow 




Figure 1.9 Metabolites have to be extracted from the sample (for example using 
organic solvents) to facilitate further analytics. Some metabolites such as amino acids 
require derivatization steps to increase the mobility of their ions before MS. To 
increase resolution and minimize matrix effects, metabolites are separated using high 
performance liquid or gas chromatography. The individual peaks observed during 
chromatography may contain several metabolites. During chromatography, aliquots 
of separated metabolites are applied to ionization chambers; only ionized metabolites 
will be analysed later in the process. The MS provides information on mass/charge 
ratio (m/z), which is used to calculate the mass of individual metabolites. The mass 
spectrometer can be constructed in various ways; the schematic depicts a tandem 
mass spectrometer run in targeted mode. All parts of the mass spectrometer operate 
under a vacuum (depicted by the green line). Ionized molecules are pre-selected by 
m/z ratio in the first quadrupole (Q1), which consists of four metal rods (black bars, 
for clarity only two rods are shown) arranged in parallel around one axis. In the second 
quadrupole (Q2) molecules released sequentially from Q1 are fragmented by collision 
with neutral gas. Each molecule fragments into a characteristic pattern, which can be 
used to unequivocally identify the molecule. To quantify the molecule of interest its 
fragment is selected in quadrupole 3 (Q3) and quantified in a detector. This procedure 
is repeated for every molecule of interest. Metabolite annotation is based on 
molecular mass, validation by fragmentation spectra and retention time during 
chromatography. Figure taken from (Hocher and Adamski 2017). 
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1.5.5 Challenges associated with metabolite quantification in 
biological samples 
A commonly cited challenge of quantifying tissue metabolites is the lack of an 
appropriate ‘blank’ which can mirror the complexity of the matrix. This is 
important as the potential of ‘matrix effects’ to enhance or suppress analyte 
signal can lead to inaccurate quantification. Two analytical approaches are 
generally used to produce standard curves for metabolite quantification, the 
method of standard addition or using a metabolite free representative proxy 
(or surrogate) matrix in the traditional standard addition approach, a known 
quantity of analyte is added directly to aliquots of the matrix of interest and the 
signal response to increasing amounts of analyte is measured. This approach 
is important as coeluting compounds in the biological matrix, which may not 
be present in the proxy matrix, may be a source of signal suppression or 
enhancement and thus may lead to erroneous calculations of analyte 
concentrations in biological samples (Andersen 2017). Whilst it is important to 
determine these matrix effects, the use of the method of standard addition 
approach has certain limitations and may be problematic for calibration 
purposes. For example, the BCAAs have endogenous concentrations in the 
µM range and free carnitine has an endogenous intramuscular concentration 
in the mmol/kg (dry mass). Therefore, the calibration standards at the lowest 
points on the calibration curve may not result in detectable responses above 
the high endogenous baseline such as when spiking nM calibrants upon a high 
µM background. In addition, the higher points on the calibration curve may 
lead to detector saturation and therefore the calibration is no longer in the 
linear range. These disadvantages can be overcome by using a proxy matrix 
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and isotopically labelled standards which a structurally the same as the 
analytes of interest (Stokvis, Rosing, and Beijnen 2005). Aqueous solutions of 
bovine serum albumin (BSA) have previously been used as substitutes for 
biological matrices such as plasma (Minkler et al. 2015) and liver (Xu et al. 
2020). Access to tissues of interest, lack of internal standards and analytical 
instruments is likely to be the reason there is dearth in quantitative assessment 
of metabolites relating to BCAA catabolism in human muscle. 
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1.6 Aims and objectives 
The first aim of this thesis was to develop an LC-MS/MS method for the 
quantitative assessment of acylcarnitines, BCAAs and related metabolites in 
human skeletal muscle and plasma samples. The commonly cited challenges 
with targeted metabolomics in biological samples were addressed using both 
the method of standard addition within the biological matrix and a substitute 
matrix using isotopically labelled internal standards.  
The second aim of this thesis was to provide quantitative assessments of 
muscle and plasma BCAA and acylcarnitine concentrations in patients with 
T2D. Simultaneously profiling muscle and plasma enabled the determination 
of the extent plasma profiles are reflective of tissue profiles 
The third aim of this thesis was to extend upon much of the current data which 
is limited to the fasted state by determining how the fasting muscle 
concentration of acylcarnitines, BCAAs and related metabolites change with 
age and insulin resistance in response to insulin infusion.  
To date, no studies have quantitively assessed BCAA catabolites together with 
markers of fatty acid oxidation in both plasma and muscle of obese subjects 
and patients with T2D. In chapter 6, the potential interactions of fatty acid and 
BCAA metabolism were explored with the use of an isotopically labelled fatty 
acid drink and the application of the analytical method. The impact of age with 
T2D was also investigated.  
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2 Chapter 2 General methods 
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2.1 Human volunteers  
2.1.1 Ethical approval  
All studies and sample collection protocols were approved by the University of 
Nottingham Faculty of Medicine & Health Sciences Research Ethics and the 
NHS Research Ethics Committees and met the regulations outlined in the 
Declaration of Helsinki. All studies were performed at the David Greenfield 
Human Physiology Unit, University of Nottingham. 
In Chapter 3, muscle and plasma samples used for method development and 
assessment of method suitability in biological samples were obtained from a 
study assessing the effects of time restricted feeding in young healthy males 
(Ethics approval Ref. Number. 19–1705). The study was also registered at 
clinicaltrials.gov as NCT03969745.  
In Chapter 4, samples used were from two separate studies, the first 
investigating the acute effect of feeding on muscle protein synthesis (Ethics 
approval Ref. Number 14/EM/0136) and the second was a clinical trial 
involving patients with Type 2 diabetes (Ethics Ref. No 14/EM/0136 and 
ClinicalTrials.gov Identifier: NCT02197299). Diabetics patients recruited as a 
part of the same clinical trial study were also studied in Chapter 6. 
In Chapter 5, samples were from a larger study investigating the skeletal 
muscle lipid metabolism and insulin sensitivity in young and elderly subject 
(Ethics approval Ref. Number E13102011BMS). 
 70 
2.1.2 General screening for healthy volunteers 
Volunteers were medically screened and completed a health questionnaire, 
blood screen of full blood count, urea and electrolytes, liver function tests 
coagulation, lipid profile, thyroid function test and electrocardiograph (ECG). 
Subjects were excluded if they had a history of diabetes, cardiovascular, 
metabolic or respiratory disease. Those who did not meet inclusion criteria 
were excluded from further participation. 
2.1.3 Patient recruitment  
To achieve the recruitment targets 25 GP surgeries in Nottingham City, 
Nottinghamshire County, and Derbyshire Count were contacted, who provided 
a patient list. Subjects were contacted (by mail) if they were male patients aged 
18-65 years old, with type 2 diabetes that were not taking insulin or 
sulfonylureas. Those who met the initial criteria were invited for a general 
health screening as described above and excluded based on the following 
exclusion criteria. 
• Malignancy (excluding localised basal and squamous cell skin 
cancer) 
• Metabolic diseases (stable treated hypothyroidism allowed) 
• Active cardiovascular disease (current angina, myocardial infarct, 
or coronary artery surgery/angioplasty within 12 months)  
• Primary muscle disorders 
• Cerebrovascular disease 
• Neurological disease e.g. epilepsy, Parkinsons disease 
• Active respiratory disease 
• Active gastrointestinal or liver disease 
• Renal impairment (eGFR <60 ml/min) 
• Clotting dysfunction 
• Anti-diabetes medication other than metformin 
• Other medications that may affect glucose tolerance (e.g. 
corticosteroids), muscle metabolism, or safety (e.g. anticoagulants) 
• Any other conditions in addition to the above that the investigators 
consider may affect study measurements or safety 
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• Abnormalities on screening blood tests that in the view of the 
investigators are clinically significant 
 
All participants provided written informed consent. The Informed Consent 
Form was signed and dated by the participant before they entered the trial.  
2.2 Assessment of insulin sensitivity and body 
composition  
2.2.1 Hyperinsulineamic- euglycaemic clamp 
The hyperinsulineamic-euglycaemic glucose clamp technique, originally 
developed by DeFronzo and colleagues (R. A. DeFronzo, Tobin, and Andres 
1979b), is widely accepted as the gold standard method of directly determining 
metabolic insulin sensitivity in vivo, particularly when the assessment of insulin 
sensitivity per se is of primary interest and feasibility is not an issue. After an 
overnight fast, insulin is infused intravenously at a constant rate (dose per 
body surface area per minute). As a result of the constant infusion, a new 
steady-state insulin level that is above the fasting level (hyperinsulinaemia) is 
achieved. Consequently, glucose disposal in insulin sensitive tissues such as 
skeletal muscle and adipose tissue is increased, whereas hepatic glucose 
production (HGP) is suppressed. A bedside glucose analyser is used to 
frequently monitor blood glucose levels at 5 min intervals while 20% glucose 
is given intravenously at a variable rate to “clamp” blood glucose 
concentrations in the normal range (euglycaemia). This concentration is a 
predetermined level of glycaemia within normal range of glycaemia; a fasting 
level of 4.5mmol/L was chosen for chapter 5. Because 80–90% of the infused 
glucose is taken up by skeletal muscle under conditions of euglycaemic 
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hyperinsulinaemia, insulin sensitivity measured with the insulin clamp 
technique primarily reflects skeletal muscle (Eleuterio Ferrannini et al. 1988). 
After ~2 hours of constant insulin infusion, steady-state conditions can typically 
be achieved for plasma insulin, blood glucose, and the glucose infusion rate 
(GIR). Assuming that the hyperinsulinaemic state is sufficient to completely 
suppress HGP, and since there is no net change in blood glucose 
concentrations under steady-state clamp conditions, the GIR must be equal to 
the glucose disposal rate (M). Thus, whole body glucose disposal at a given 
level of hyperinsulinaemia can be determined directly. M is typically 
normalized to body weight or fat-free mass to generate an estimate of insulin 
sensitivity. The validity of insulin sensitivity utilising the glucose clamp 
technique depends on steady state conditions being achieved. Therefore, the 
values for glucose disposal rates were taken during a period of at least 30 
minutes to more than 1-hour post insulin start during which the coefficient of 
variation for blood glucose, plasma insulin and GIR is < 5%. The contribution 
of HGP can also be directly assessed (allowing appropriate adjustments to M) 
with the use of labelled glucose tracers. 
There are some limitations of the hyperinsulineamic-euglycaemic clamp 
technique that should be considered. The main limitations of this approach are 
that it is time consuming, labour intensive, expensive and requires an 
experienced operator to manage the technical difficulties. Thus, for 
epidemiological studies, large clinical investigations, or routine clinical 
applications the glucose clamp is not appropriate. In addition, if measuring 
insulin sensitivity/resistance is not a primary study outcome, then the 
cost/benefit ratio for the clamp may not be favourable. Another limitation is that 
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the clamp utilizes steady-state insulin levels that may be supraphysiological. 
This results in a reversal of the normal portal to peripheral insulin gradient. 
Thus, the glucose clamp may not accurately reflect insulin action and glucose 
kinetics sunder physiological conditions that a dynamic test such as an oral 
meal or oral glucose load may determine (Muniyappa et al. 2008) 
2.2.2 Oral glucose tolerance test  
The oral glucose tolerance test (OGTT) used in chapter 6 is a simple test 
widely used in clinical practice to diagnose glucose intolerance and T2D. In 
the overnight fasted state, a standard oral glucose load (75g) is consumed and 
blood sampling for blood glucose and insulin are measure at (15-30 min) 
intervals for 120 mins (Man et al. 2005). The OGTT reflects the efficiency of 
the body to dispose of glucose after an oral glucose load or meal. During an 
OGTT, significant (∼30–40%) amounts of glucose are taken up by the 
splanchnic bed (liver), and HGP is less completely suppressed than during the 
hyperinsulinaemic- euglycaaemic clamp technique. As a result, the plasma 
glucose concentration during OGTT is affected by both hepatic and peripheral 
(primarily muscle) insulin resistance. Although the OGTT reflects glucose 
tolerance rather than insulin resistance per se, it has the advantage of being 
representative of the normal physiological response to a glucose load. 
2.2.3 Homeostasis model assessment of insulin resistance 
The homeostasis model assessment of insulin resistance (HOMA-IR) is a 
simplistic model of the interaction between glucose and insulin dynamics 
which is underpinned by the assumption that an increase in fasting blood 
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glucose will result in a corresponding increase in insulin (Muniyappa et al. 
2008). The HOMA-IR is calculated as follows: 




Where 𝐼0  is equal to fasting insulin concentration (µU/ml), 𝐺0 is equal to fasting 
glucose (mmoll/L). The denominator of 22.5 is a normalising factor, the product 
of normal fasting plasma insulin of 5 µU/ml and normal fasting plasma glucose 
of 4.5 mmol/L typical of a “normal” healthy individua = 22.5. Therefore, for an 
individual with “normal” insulin sensitivity, HOMA-IR = 1. 
2.2.4 Dual Energy X-ray Absorptiometry  
In Chapters 5 and 6, whole-body and regional body composition was assessed 
by Dual Energy X-ray Absorptiometry (DEXA) scans (Lunar Prodigy DEXA; 
GE Medical Systems, Bedford, UK). All participants filled out a questionnaire 
prior to each scan to assess suitability and wore light clothing free from any 
metallic items. Scans were undertaken with the participant motionless in a 
supine position with arms placed by their side and hands pronated. All regional 
analysis was performed using specialised software (enCORE; GE Medical 
Systems, Chicago, IL, USA). The scanner passes two low-dose X-ray beams 
through the body (40 and 70 keV). Due to the different elemental composition 
of fat, muscle tissue and bones, the X-rays pass through regions of the body 
at different rates. Regional determination of fat, lean mass and bone mineral 
density can then be calculated by linear decomposition of the measured X-ray 
beam attenuation (Pietrobelli et al. 1996). DEXA offers an accurate and 
convenient, non-invasive estimation of body composition. Limitations stem 
from the assumptions that there is a constant fractional composition of lean 
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tissue (water, protein and mineral content), which can vary with hydration 
states. To limit the influence of nutrition and hydration status, all scans were 
undertaken in the morning at approximately 08:00 after an overnight fast and 
voiding of the bladder.  
2.3 Blood sampling and analysis 
2.3.1 Blood collection and arterialisation  
In all Chapters, volunteers were cannulated to enable regular arterialised-
venous blood sampling. A sterile 12G cannula was placed retrograde into a 
dorsal vein on the back of the hand. Lidocaine (1%) was injected 
(approximately 1 ml) subcutaneously prior to cannula insertion to minimise 
discomfort. The cannula was kept patent by a slow running 0.9% saline 
infusion. To arterialise the blood, this hand was then placed in an air-warming 
unit set to heat the hand to 55°C and kept there for the remainder of the visit. 
This technique has minimal effects on core temperature and blood flow 
distribution to the contralateral forearm (Gallen and Macdonald 1990). 
Due to the inherent risks associated with direct cannulation of an artery, the 
heated hand technique was used. As the skin temperature of the hand is 
warmed to above 37℃ there is an increased blood flow from vasodilation of 
the forearm muscle and opening of the arteriovenous anastomoses. Capillary 
beds open to increase blood flow to the skin and disperse heat, the heat-
induced vasodilatation reduces blood transit time and results in arterialised-
venous blood that is similar in concentrations of metabolites to arterial blood. 
(McGuire et al. 1976) 
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Arterial metabolite concentrations do not differ substantially across the body 
(i.e., in different arteries) whereas venous samples can differ depending on 
the sampling site (i.e the organ that drains into that venous compartment). 
2.3.2 Blood glucose concentration  
Immediately after collection, whole blood glucose concentrations were 
determined using the glucose oxidase method (YSI 2300 STAT PLUS Glucose 
and Lactate Analyser, Yellow Springs Instruments, Ohio, USA). Glucose 
oxidase catalyses the conversion of glucose to hydrogen peroxide (H2O2), 
which is subsequently oxidised and releases electrons. When the reaction is 
in dynamic equilibrium, the electron flow is linearly proportional to H2O2 
concentration, which is determined by the initial blood glucose concentration. 
The YSI analyser was calibrated on the morning of each study visit using an 
external glucose standard of 10 mM. 
2.3.3 Isolation of plasma 
Blood was dispensed into a sodium heparin coated vacutainer containing 
egtazic acid (EGTA)-glutathione (7.5 μl∙ml
-1
 of whole blood). Vacutainers were 
gently mixed prior to being spun at 4400 g for 10 min at 4℃ in a centrifuge. 
Plasma from the sodium heparin tube was transferred to tubes containing 
tetrahydralipostatin to inhibit lipolytic activity and stored at – 800C until 
analysis. 
2.3.4 Plasma free fatty acids 
In Chapter 6, plasma free fatty acids (FFA) were quantified using an enzymatic 
colorimetric assay (NEFA-HR (2), Wako, Osaka, JP) on a benchtop clinical 
chemistry analyser (ABX Pentra 400, Horiba Ltd., Kyoto, JP). In brief, FFA 
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present in the samples was converted to acyl-CoA which was subsequently 
oxidised to form hydrogen peroxide. The latter undergoes an oxidation 
condensation reaction catalysed by peroxidase to form a blue-purple pigment, 
which was quantified for absorbance at 546/660 nm. An internal standard of 
oleic acid was used to obtain a calibration curve, from which FFA 
concentrations could be derived from. 
2.3.5 Isolation of serum 
Blood was dispensed into a vacutainer containing clotting activation factors 
and left to clot at room temperature for ≥ 20 min. Vacutainers were spun at 
4400 g for 10 min at 4℃, before the supernatant was transferred into an 
Eppendorf tube and stored at – 800C until analysis. 
2.3.6 Serum insulin  
In chapters 4 and 6, serum insulin concentrations were determined using a 
solid phase 125I radioimmunoassay kit (Human Insulin Assay HI-14K, Merck 
Millipore, Burlington, MI, USA). This assay utilises 125I-labelled human insulin, 
diluted with human insulin antiserum, to determine insulin concentrations 
using the double antibody technique. The unlabelled (endogenous) insulin in 
the sample competes with the 125I-labelled insulin antigen for the limited and 
fixed number of binding sites on the antibody lining the test tubes. After 20 to 
24 h, the test tubes were decanted, blotted, and left inverted for 30 min to dry, 
prior to measuring gamma radiation in a scintillation counter (COBRA II auto 
gamma, Canberra Packard, Melbourne, AU). Serum insulin values were 
determined using a standard curve of known insulin concentrations (0 to 200 
μU∙ml
-1
) normalised to the blank. All participants samples were measured on 
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the same assay and two quality control samples were included in each assay, 
to ensure they fit within the concentration range provided by the supplier.  
2.4 Muscle analysis 
2.4.1 Muscle biopsy procedure  
In Chapters 3, 4 ,5 and 6, skeletal muscle samples were obtained from the 
vastus lateralis in the fasted state using the Bergstrom needle biopsy 
technique (Bergström., 1975) and immediately frozen in liquid nitrogen-cooled 
2-methylbutane and subsequently stored in liquid nitrogen until analysis. In 
chapter 5 a vastus lateralis biopsy was also obtained immediately post a 3-
hour hyperinsulineamic-euglycaemic clamp and in chapter 6, following a 2-
hour OGTT. Initially, the area was cleaned with an antiseptic iodine solution 
prior to administering local anaesthetic (2% lidocaine) to the skin and 
surrounding fascia. After a short time, a small incision (<1 cm) was made with 
a sterile scalpel prior to insertion of a five-millimetre Bergström needle (Bignell 
Surgical Instruments Ltd, Sussex, UK); suction assistance was used to 
improve sample yield. 
2.4.2 Muscle protein expression 
In Chapters 5 and 6 western blotting was used to quantify target protein 
expression. Western blotting, also known as immunoblotting, is a well-
established and routinely used analytical technique used for the detection of 
specific proteins and phosphorylation status of proteins in a sample of tissue 
extract. The principles of Western blotting relay on forming a protein to 
antibody complex through specific binding of a primary antibody to a 
membrane-bound target protein separated by its molecular weight. Detection 
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of the primary antibody is generally achieved through a primary antibody 
specific secondary antibody. 
2.4.3 Protein extraction 
For samples in Chapter 6, one portion of frozen wet muscle (~30 mg) was 
extracted in HEPES buffer (50 mM HEPES, 10% glycerol, 1 mM EDTA, 10 
mM NaF, 1 mM Na3VO4, 150 mM NaCl, 1% Triton x-100, pH 7.5). Sodium 
orthovanadate and sodium fluoride were added as phosphatase inhibitors and 
a protease inhibitor cocktail (Cat# P8340, Sigma-Aldrich, St. Louis, MO, USA) 
was added on the day. Each sample was homogenised on ice for 30 sec and 
left on ice for 20 min prior to centrifugation at 12,000 x g for 15 min at 4℃. The 
supernatant was then transferred to a fresh tube, prior to quantifying total 
protein concentrations with the Pierce bicinchoninic acid assay 
In Chapter 5 proteins were extracted using the Trizol RNA extraction method. 
As a result, messenger RNA (mRNA) expression and protein content could be 
determined from the same part of each tissue sample. The mRNA data was 
not analysed for any results presented in this thesis.  
One 20 mg portion of wet muscle was transferred from liquid nitrogen into 800 
µl of TRI reagent (Thermo Fisher Scientific, Waltham, MA, USA) containing 
200 µg of glycogen, to extract ribonucleic acid (RNA). Samples were then 
homogenised for approximately 30 sec using a polytron. The homogenate was 
incubated at room temperature for a minimum of 5 min, prior to the addition of 
160 µl chloroform:isoamyl alcohol (49:1). Samples were mixed by repeated 
inversions for 30 sec before centrifugation at 12,000 x g for 15 min at 4℃. 
Subsequently, 400 µl of the aqueous phase was transferred to an Eppendorf 
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containing an equal volume of ice-cold isopropanol. These samples were 
incubated at −20℃ overnight. The mixture was then spun at 12,000 x g 4℃ for 
15 mins and resulting pellet washed in 75% ethanol. This was spun at 10,000 
x g for 10 mins, prior to removing the supernatant and drying the pellet using 
a water aspirator. Proteins were precipitated from the phenol-ethanol 
supernatant by adding 1.2 ml isopropanol and incubating for 10 min. Samples 
were then spun at 12,000 x g at 4℃ for 10 min to pellet the proteins, before 
washing 3 times with 0.3 M guanidine HCl in 95% ethanol. A final wash of 
100% ethanol was performed, prior to spinning samples at 7500 x g for 5 min. 
The supernatant was discarded and pellet air dried, before resuspending in 
400 µl of 8 M urea (deionised with amberlite ion exchange resin), 50 mM Tris 
and 4% SDS buffer. To aid with resuspension, samples were heated to 35℃ 
and pipetted up and down. Next, samples were sonicated on ice for 3 x 10 sec 
at 20 kHz, before a final spin at 10,000 x g for 10 min to isolate soluble proteins. 
The supernatant was transferred to a fresh tube prior to quantifying total 
protein concentrations with the Pierce bicinchoninic acid assay. 
2.4.4 Protein quantification  
The Pierce bicinchoninic acid assay (Thermo Fisher Scientific) was used to 
quantify total protein concentrations against a range (0 to 2000 μg∙ml
-1
) of 
albumin concentrations. Typically, samples were diluted 1 in 10 with water 
before loading and the standards were diluted in the same buffer used for the 
respective extraction. All samples were measured in duplicate and the plate 
was incubated for 30 min at 37℃ before quantifying absorbance on a 
spectrophotometer (Spectra Max 190, Molecular Devices) at 562 nm. From 
this a standard curve was derived and the diluted concentrations of the 
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samples were calculated. To ensure equal protein content, all samples were 
diluted to a uniform concentration with the appropriate extraction buffer and 
then mixed with 4 x SDS loading buffer (containing bromophenol blue). This 
mixture was heated for 5 min at 95℃ to fully denature proteins, before being 
left to cool at room temperature. Dilution and denaturing of proteins were 
performed on the day of the analysis. 
2.4.5 Electrophoresis/SDS-PAGE and Western blotting 
Gels were hand cast on the day at either a fixed % of acrylamide or a gradient 
(5 to 20%) depending on the molecular weight(s) of the proteins being probed 
for. A standard 4% stacking buffer was used, and plates were inserted into an 
electrophoresis cell (Atto, Tokyo, JP) filled with 1x Tris-Glycine-SDS running 
buffer. Ten µl of protein ladder (Precision Plus Protein, Bio-Rad, Hercules, CA, 
USA) was loaded on each gel. The gels were run at a constant amplitude of 
either 40 (one gel) or 80 (two gels) mA for approximately 2 h to separate 
proteins via electrophoresis. Proteins were then transferred onto a 
polyvinylidene difluoride membrane in an electrophoresis transfer cell (Bio-
Rad, Hercules, CA, USA) filled with Tris-Glycine-Methanol transfer buffer. 
Transfer of proteins was completed using an overnight transfer (≥ 16h) at a 
constant amplitude of 40 mA. 
Adequate transfer of proteins was visually inspected using a ponceau-S stain, 
this was extensively washed out in distilled water in tris-buffered saline 
containing 0.1% (w/v) tween 20 (TBS-T). Membranes were then blocked, 
typically in 5% (w/v) skimmed milk power or bovine serum albumin (BSA) 
diluted in TBS-T for 1 h at room temperature. After blocking, membranes were 
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washed 3 x 10 min in TBS-T, before incubation with the appropriate primary 
antibody on a rocking table overnight at 4℃ 
The next day, membranes were again washed 3 x 10 min in TBS-T prior to 
incubation with an anti-host (of animal primary antibody was raised in) 
horseradish peroxidase-linked secondary antibody (Dako, Glostrup, DK) for 1 
h at room temperature. A final wash step was performed prior to the addition 
of enhanced chemiluminescence (Amersham ECL Prime, GE Healthcare Life 
Sciences, Buckinghamshire, UK) solution for 5 min. Protein expression was 
then visualised in a dark room using X-ray film (Hyperfilm, Amersham 
Biosciences, Buckinghamshire, UK) for a variety of different exposure times. 
Films were then digitally scanned and intensity of band(s) quantified using 2D 
densitometry software (AIDA Image Analyser). Proteins of interest were 
normalised against an endogenous loading control of α-actin expression. The 
exact dilutions of primary and secondary antibodies and blocking solutions is 
provided in the appropriate method(s) section in the experimental chapters (5 
and 6). 
2.5 BCAAs, BCKAs, free carnitine and acylcarnitines 
in muscle and plasma 
Muscle and plasma samples were collected and stored as described above. 
All details including sample preparation, metabolite extraction and 
quantification using liquid chromatography coupled to high resolution mass 
spectrometry are described in full in Chapter 3 below.  
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3 Chapter 3 Development and validation of 
a liquid chromatography coupled to high 
resolution mass spectrometry method for 
quantification of acylcarnitines, branched 
chain amino and keto acids in human 
skeletal muscle and plasma.
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3.1 Introduction  
3.1.1 Overview of acylcarnitine metabolism 
Acylcarnitines are intermediary metabolites formed during fatty acid, 
carbohydrate and amino acid metabolism from the esterification of free 
carnitine to acyl-CoA species. Acylcarnitines species can vary in their chain 
length according to the different acyl groups attached, often characterised by 
short medium and long chain acylcarnitines.  
Long chain acylcarnitines are formed via the action of carnitine 
palmitoyltransferase 1 (CPT1) which facilitates the translocation of cytosolic 
long-chain fatty acyl-CoA groups into the mitochondrial matrix for β-oxidation 
(Fritz and Yue, 1963). Once inside the mitochondrial matrix, acylcarnitines are 
transesterified back to free carnitine and long-chain acyl-CoA in a reaction 
catalysed by carnitine palmitoyltransferase 2 (CPT2). The intramitochondrial 
long chain acyl CoA can then undergo β-oxidation; in a series of enzymatic 
steps, the long chain acyl-CoA is cleaved by 2 carbons to ultimately form the 
2-carbon compound Acetyl- CoA, which can enter the tricarboxylic acid (TCA) 
cycle for complete oxidation. The corresponding medium and short chain 
acylcarnitine esters can be formed during each step in the β-oxidation 
pathway.  
Acetylcarnitine, the shortest acylcarnitine species (formed directly from Acetyl-
CoA) can be formed from both carbohydrate and fatty acid metabolism. Under 
conditions of high glycolytic flux (such as high intensity exercise) Acetyl-CoA 
formation from pyruvate oxidation, catalysed by the pyruvate dehydrogenase 
complex (PDC), is in excess of its utilization by the TCA cycle (i.e., its rate of 
 85 
condensation with oxaloacetate is less than its rate of of formation) leading to 
its subsequent accumulation. Free carnitine thereby fulfils a key role as an 
Acetyl group buffer to maintain a viable free muscle CoA pool.(Stephens, 
Constantin-Teodosiu, and Greenhaff 2007) 
It is know well known that acylcarnitines are exported from the mitochondria 
into the cytosol (Lysiak-Szydlowska et al. 1986) and ultimately into the plasma. 
The efflux of acylcarnitine may be important to prevent the accumulation of 
toxic CoA products within the mitochondria in states of elevated or impaired 
fatty acid oxidation. Indeed, the profiling of plasma acylcarnitines has been 
routinely performed for the screening and diagnosis of genetic disorders of 
fatty acid oxidation, organic acid related diseases and renal failure (Rinaldo, 
Cowan and Matern, 2008). 
Acylcarnitines have also been identified as potential biomarkers in a number 
of chronic metabolic diseases involving derangement in energy metabolism, 
including type 2 diabetes (T2D) (Sun et al. 2016). It has been suggested that 
elevations in plasma acylcarnitines arise due to a mismatch between lipid 
supply and oxidative capacity in skeletal muscle resulting in their export and 
accumulation in plasma (Mihalik et al. 2010; Adams et al. 2009). It is thought 
that this oversupply of lipid leads to mitochondrial overload and stress which 
in turn leads to skeletal muscle insulin resistance, one of the pathological 
hallmarks of type 2 diabetes (Koves et al. 2008). Whilst elevated plasma 
acylcarnitines have been observed in obese and T2D subjects, plasma 
acylcarnitine profiles may not accurately reflect skeletal muscle metabolism 
(Schooneman et al. 2014). Direct and concurrent comparisons of muscle 
tissue and plasma in human subjects are therefore warranted. 
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3.1.2 Branched chain amino acids and acylcarnitines  
Several lines of emerging evidence have demonstrated a robust association 
between circulating branched chain amino acids (BCAAs) and the 
development of insulin resistance (Newgard 2012). Furthermore, plasma 
BCAA concentrations are a strong predictor of the future development of T2D 
(Wang et al. 2011). Interestingly, BCAAs and related metabolites of BCAA 
catabolism, short, odd chain acylcarnitines (C3 and C5 moieties) were shown 
to be more closely related to insulin resistance than any lipid related analyte 
as assessed by principal component analysis of over 100 metabolites in 
plasma of obese insulin resistant individuals compared to lean controls 
(Newgard et al,2009)  The fact that products of BCAA catabolism as well as 
BCAAs per se have been associated with insulin resistance suggests 
alterations in BCAA catabolic flux is likely to be implicated in the development 
of the condition. Despite these strong associations, the origin of these elevated 
metabolites in plasma is unknown. Recent evidence has demonstrated that 
BCAA catabolism is impaired in skeletal muscle of insulin resistant individuals 
(Lerin et al. 2016) and that skeletal muscle may contribute to the circulating 
BCAA pool following the induction of insulin resistance in rats (David et al. 
2019). These data point to an important and under investigated role of skeletal 
muscle BCAA metabolism and the need for further investigation in humans 
using quantitative assessments of metabolites involved in BCAA catabolism. 
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3.1.3 Previous methods for the quantitative analysis of 
acylcarnitines, BCAAs and BCKAs 
The detection and quantification of acylcarnitines is a useful tool to investigate 
alterations in energy metabolism in several diseases. Accordingly, a broad 
spectrum of methods for the analysis of carnitine and its acyl derivatives have 
been used, including radioenzymatic methods, spectrophotometry and high-
performance liquid chromatography (HPLC) linked to ultraviolet (UV) 
detectors. However, these methods have a number of draw backs including 
laborious and time consuming sample preparation as well as a lack of 
specificity and sensitivity to allow the coverage of a range of acylcarnitines 
(Möder, Kießling, and Löster 2005).  
There are several challenges encountered in the detection of acylcarnitines 
and BCAAs in biological samples, particularly if these are to be quantified 
simultaneously with a single extraction protocol. These include, complexity of 
the composition of different biological matrices resulting in matrix interference 
of the metabolites to be quantified, a range of polarities from the polar short 
chains to low polar long chains species, the presence of a number of isomers 
of metabolites found in biological samples and limited number of commercially 
available standards for accurate and confident determination of identities (S. 
Li, Gao, and Jiang 2019; Mansour, Wei, and Danielson 2013). 
The most common currently used method to overcome the challenges outlined 
above is liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS). Both reversed phase (RP) and hydrophilic interaction liquid 
chromatography (HILIC) methods have been developed (Minkler et al. 2008; 
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Peng et al. 2013). These methods allow for time dependant retention and 
separation of a range of metabolites, (including structural isomers of certain 
species) coupled to the highly selective and sensitive triple quadrupole mass 
spectrometer for detection (Giesbertz et al. 2015; Minkler et al. 2015) More 
recent work has also utilised high resolution mass spectrometry to quantify a 
range of acylcarnitines enabling accurate quantification without the need of 
any complex sample preparation nor the synthesis of authentic standards 
(Xiang et al. 2017). In addition, some very recent work has demonstrated that 
BCAAs and the products of the first step of their catabolism, branched chain 
keto acids (BCKAs) can also be quantified using reversed phase LC-MS with 
some methods enabling simultaneous quantification of both BCAA and BCKA 
in plasma (Zhang et al. 2018.; Li et al. 2016; Sargsyan and Trchounian 2020). 
A list of recent publications utilising these methodologies is shown in Table 
3.1. 
Table 3.1 Recent studies with validated LC-MS methods for the detection of 
acylcarnitines and/or BCAAs and BCKAs 
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The studies in Table 3.1 demonstrate that acylcarnitines, BCAA and BCKA 
can be successfully extracted and quantified in several biological matrices. 
Acylcarnitines have been successfully derivatised to butyl esters in previous 
work, but this process may result in partial hydrolysis of acylcarnitines leading 
to inaccurate quantification (D. W. Johnson 1999). Although these limitations 
have been largely overcome by the use of alternative derivatisation agents 
(Minkler et al. 2015) , any sample extraction procedure that involves complex 
protocols or steps to increase sample enrichment of chemically similar 
analytes (such as SPE) may result in the loss of other chemically dissimilar 
analytes because of its specificity. Therefore, the applicability of specific 
extraction methods is often limited to one type of metabolite (e.g. 
acylcarnitines) not allowing for simultaneous determination of upstream 
metabolites such as BCAAs and BCKAs. It is likely that with the correct 
combination of extraction solvents and LC-MS conditions that all metabolites 
of interest could be simultaneously quantified. The impact of matrix effects on 
analyte quantification can be accounted for with use of isotopically labelled 
internal standards with full method validation. 
3.1.4 Justification of method development  
Despite the comprehensive metabolite profiling and coverage with previously 
established methods (Giesbertz et al. 2015; Minkler et al. 2015; Xiang et al. 
2017), there currently is no available method for the simultaneous 
quantification of a range of carnitine and its acylated species, BCAAs and 
BCKAs with a single extraction method in multiple human tissues from the 
same donors. Furthermore, despite their increasing association with insulin 
resistance and type 2 diabetes (Koves et al. 2008; Céline Aguer et al. 2015a), 
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quantitative analysis of these metabolites in skeletal muscle samples of type 
2 diabetic patients have not been performed. Studies that have attempted to 
simultaneously investigate these metabolites have been limited to either 
untargeted metabolomic studies or have only been able to measure the 
relative concentration of these metabolites (Zhou et al. 2019).  
3.1.5 Aims  
Therefore, the aim of this chapter was to 
• To develop and optimise a liquid chromatography coupled to high 
resolution mass spectrometry method using a single extraction 
procedure to enable the simultaneous targeted quantification of a range 
of acylcarnitines, BCAAs and their BCKAs in both human skeletal 
muscle and plasma. 
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3.2 Methods  
3.2.1 Materials and chemicals 
A range of acylcarnitine standards (C2 - C16) were purchased from Tocris 
(Bristol, UK).C4 and C5 acylcarnitine, and all isotopically labelled (deuterated 
d9-C0, d3- C2, d3-C3, d3-C4, d9-C5, d3-C8, d9-C14 and d3-C16.) acylcarnitines, 
(uniformly labelled carbon -13, U- 13C) BCAA and BCKA internal standards 
were purchased from CK isotopes, (Newtown Unthank, UK.) Unlabelled free 
carnitine, BCAAs and their respective BCKA standards, bovine serum albumin 
(BSA), potassium phosphate (KH2PO4), LC-MS grade formic acid and 
ammonium carbonate were purchased from Sigma-Aldrich (Gillingham, 
U.K.).LC-MS grade methanol, acetonitrile (VWR, Leicestershire, UK ) and 
isopropanol (Fisher Scientific Ltd, Loughborough, UK), and were used 
throughout. All full list of standard names and details including retentions 
times, accurate masses and allocated analyte internal standards are given in 
Table 3.2. 
3.2.2 Sample preparation and metabolite extraction  
One portion of frozen muscle (~30mg) was freeze-dried, separated free of 
visible blood, fat and connective tissue. Wet muscle portions were placed into 
liquid nitrogen chilled Eppendorf tubes with pierced caps and placed upright in 
a carboard box containing liquid nitrogen. The box was then placed into the 
freeze dryer pre-set at -56o C and sealed under vacuum at low pressure for at 
least 24 hours. This enables the water in the biological sample to transition 
from the solid phase directly to the vapour phase without passing through the 
liquid phase. This allows the effect of any changes in water content on analyte 
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concentration and sample stability to be eliminated compared to wet tissue. 
Furthermore, connective tissue can account for up to 40-50 percent of the 
sample dry weight therefore it is necessary to freeze-dry the sample before 
powdering in order to remove the connective tissue and accurately collect 
muscle tissue (Harris, Hultman, and Nordesjö 1974). Indeed, the requirement 
of a fine powdered tissue sample for improved acylcarnitine extraction from 
muscle has been reported on previously (Sun et al. 2006). The dry sample 
was then powdered at room temperature using a pestle and mortar. All 
powdered samples were weighed out on a five decimal place balance. 
Analytes were extracted using modified versions of the methods described by 
Sun et al (Sun et al. 2006) and Stephens et al (Stephens et al. 2014). 
Powdered muscle samples were vigorously vortexed for 5 min following the 
addition of 500 µL of isopropanol/ 1 M KH2PO4 buffer (1:1 v: v). 50 µL of 
internal standard mixture (containing deuterated acylcarnitines and U- 13C 
BCAA and BCKA) was spiked into the extraction solvent prior to the addition 
to muscle powder. Then, samples were vigorously vortexed for a further 5 min 
following the addition of 500 µL of acetonitrile and centrifuged for 20 min at 
14,000 g at 4° C. The supernatant was removed and evaporated to dryness 
(~ 4 hours for tissue extractions and ~ 7 hours for standards) under vacuum 
centrifuge at room temperature. Dried samples were resuspended in 100 µL 
of methanol: water (1:1 v: v) and gently mixed for 5 min at 4° C. After 
centrifugation at 14,000 g, the supernatant was removed and stored at -80° C 
until analysis. Plasma samples were thawed on ice and a 100 µL aliquot was 
prepared and processed as described above for skeletal muscle samples. 
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3.2.3 Liquid chromatography coupled to high resolution mass 
spectrometry conditions 
The analysis was performed using an Dionex UHPLC system 
(FisherScientific,Waltham, MA) coupled to a high-resolution orbital-trap mass 
spectrometer (Q-Exactive, Thermo Fisher Scientific, Waltham, MA). Two 
separate injections of the same sample were used for reversed phase C18 
and HILIC analysis. The injection volume was 5 μL, and samples were 
maintained at 4 °C during the analysis.  
Acylcarnitines and BCKAs were separated using an ACE PFP - C18 column 
(100 x 2.1 mm, 2 µm pore size, Avantor, Theale, Reading, UK) maintained at 
40°C with a flow rate of 300 µL/min. The mobile phases were A: water with 0.1 
% formic acid and B: methanol with 0.1% formic acid. The gradient started at 
0.5% B and increased to 90% B over 13 min and followed by equilibration to 
give a total run time of 17 min.  
A ZIC-pHILIC column (4.6 × 150 mm, 5 μm particle size, Merck Sequant, 
Watford, U.K.), maintained at 45 °C with a flow rate of 300 μL/min, was used 
for the separation of BCAAs and free carnitine. Mobile phase A was composed 
of 20 mM ammonium carbonate in water (pH 9.1), and mobile phase B was 
composed of acetonitrile. The gradient started with 20% A and increased to 
95% A over 16 min. This was followed by equilibration to give a 24 min run 
time. 
MS was performed in simultaneous ESI+ and ESI− full-scan modes with spray 
voltages of 3.5 (ESI+) and 2.5 kV (ESI−) and capillary voltages of 40 (ESI+) 
and −30 V (ESI−). In both modes, the sheath-, auxiliary-, and sweep-gas flow 
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rates were 40,11,2 arbitrary units, respectively, and the capillary and heater 
temperatures were 300 and 400 °C, respectively. Automated gain control 
(AGC) was targeted at 1 × 104. The isolation width of the precursor ion was 
set at 0.7 (m/z). Mass resolution was set at 70,000 from m/z 100 to 600.  
3.2.4 Preparation of standards  
Free carnitine and acylcarnitine standards were prepared at concentrations of 
2 mmol/L in 100% methanol. BCAAs and BCKAs were prepared at 4 and 2 
mmol/L, respectively, in methanol/water 1:1 (v: v). The stock solutions were 
combined and diluted to create calibration standards across an appropriate 
concentration range for each analyte (see results sections for ranges) using 
methanol/water 1:1 (v: v). Stocks and calibration standards were stored at -
80o C until use. 1 mg of each BCAA and BCKA internal standard was weighed 
out at on 5 decimal place balance and diluted in 1 mL methanol/water 1:1 (v: 
v). The standards were combined and diluted to give a final concentration in 
each sample of ~ 1 µmol/L. The acylcarnitine internal standards (NSK-B, CK 
isotopes, Newtown Unthank, UK) were dissolved in 1 mL of LC-MS grade 
methanol and stored in accordance with the manufacturer’s guidance.  
3.2.5 Method validation in the biological matrix  
3.2.5.1 Use of isotopically labelled acylcarnitine standards for method 
validation 
To account for the issues involved with quantifying analytes in tissue samples 
(outlined in chapter 1, section 1.5.5), the method of addition approach was 
used in the current work. The isotopically labelled standards (deuterated and 
U- 13C) were used as a substitute for the authentic unlabelled standard and 
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spiked into equal amounts of powdered skeletal muscle to construct 10 point 
calibrations curves, with a triplicate at each point (as opposed to using internal 
standards). Several skeletal muscle biopsy samples from healthy control 
subjects were freeze dried and powdered (as described in section 3.2.2). 
Powdered muscle from each sample was subsequently mixed into one 
homogeneous pool using a pestle and mortar, the pool was collected, 
vigorously vortexed and decanted, and this process was repeated upon the 
addition of each powdered sample. Aliquots of this pool were used throughout 
the validation process. This approach was repeated for all analytes at the 
same concentrations in a proxy matrix (7.5 % BSA in PBS) to determine 
whether the assay could extract analytes equally from the two different 
biological matrices.  
3.2.5.2 Use of unlabelled standards and isotopically labelled internal 
standards for matrix comparison  
The use of the method of addition is essential to determine the effects of the 
matrix on sample processing factors such as analyte recovery, precision, 
accuracy and ion suppression. However, the routine use of this approach is 
not practical due to the large amount of muscle powder required each time for 
calibration and the inherent limitations described previously. Therefore, in a 
separate experiment both skeletal muscle and 7.5% BSA in PBS were spiked 
with each unlabelled standard expressed as a ratio a specific isotopically 
labelled standard to determine if their respective response was different 
between the two matrices and whether the more convenient proxy matrix of 
BSA was a valid substitution of human skeletal muscle as well as plasma for 
which it has been validated by others previously (Minkler et al. 2008, 2015). 
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This would determine if the internal standards could account for any ion 
suppression in skeletal muscle. In all cases calibration standards were 
analysed using the same procedure as was described for samples and the 
same calibrant range was spiked into each matrix. For example, a 100 µL 
calibrant at 1 µmol/L was spiked into BSA and extracted, dried and 
reconstituted into a final volume of 100 µL, representing a calibration 
concentration of 1 µmol/L. The equivalent calibrant spiked into ~ 1mg of 
muscle tissue and reconstituted in a final volume of 100 µL was then corrected 
by applying a dilution factor (to convert µmol/ 100 µL to µmol/L) and then 
divided by tissue mass in Kg to calculate the final concentration value 
expressed as 100 µmol/ kg dry mass (dm). 
3.2.6 Validation of the proxy matrix as a substitute for human 
plasma 
The anticipated biological range of acylcarnitines was initially established from 
previous publications investigating changes in human plasma concentrations 
in response to insulin infusion and weight loss (Mihalik et al. 2010; 
Schooneman et al. 2016). Based on this range of acylcarnitine concentrations, 
ten-point calibration standards (n=10) were analysed and compared between 
human control plasma and the BSA proxy matrix. Independent plasma 
samples from six separate healthy subjects were then analysed and the 
calculated concentrations from both approaches were compared. Free 
carnitine, BCAAs and BCKAs have a high endogenous plasma concentration 
in the µmol range and therefore these analytes were validated in the BSA 
solution using unlabelled and isotopically labelled standard peak area ratios.  
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3.2.7 Method validation experiments and parameters 
In both of the biological matrices studied, accuracy, precision and recovery 
were determined at three (low, middle and high) levels with six replicates at 
each point. The analyte concentration at each level was based on typical 
concentrations reported in previously published studies demonstrating that 
acylcarnitines may change between two and five fold following insulin infusion 
(Stephens et al. 2014; Mihalik et al. 2010). Accuracy and precision criteria 
were satisfied where the coefficient of variance (CV) of the 6 replicates were 
within 15 %. Recovery was assessed by comparing the analyte response 
between a sample spiked pre-extraction with the response of the analyte 
spiked post extraction at the sample reconstitution step.  
Stability of the samples during the analysis was determined by a repeat 
injection of a pooled QC sample stored in the autosampler at 4o C over a long 
acquisition time (24-60 hours) and measuring the CV of internal standard 
ratios of the injections (within run stability). Stability of the analytes was also 
determined by subjecting QC samples to a single freeze-thaw cycle following 
freezer storage at -800 C. Repeatability of the extraction assay was determined 
by extracting separate aliquots of a pooled powdered skeletal muscle and 
human plasma QC and measuring the CV of the quantified sample 
concentrations after correction for tissue volume. Matrix effects were 
determined by comparing the response of the analyte added at the post 
extraction point with the response of a standard directly injected without any 
sample extraction. A value greater than 100 % indicates that the analyte 
response is being enhanced by the matrix and conversely, a value below 100 
% indicates ion suppression in the matrix.  
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The limit of detection (LOD) and limit of quantification (LOQ) were determined 
by stable isotope dilution of the internal standards and extraction from the 
matrix. LOD and LOQ were measured at a signal to noise ratio of 3 and 10, 
respectively. Where possible, the Food and Drug Administration (FDA) 
analytical procedures and methods validation for drugs and biologics guidance 
for Industry was followed (FDA and CDER, 2018). 
3.2.8 Extraction efficiency experiment 
When determining tissue concentration, correcting for tissue mass can be a 
source of error. Due to the varying methods and tissue yield of human muscle 
biopsy techniques together with the requirement of large amounts of wet tissue 
for assays routinely performed in this laboratory it is not always possible to 
obtain equal amounts of dry powder for analysis from biopsy samples. Dried 
samples for metabolite quantification are advantageous as any changes in 
muscle water content and their effects on analyte concentrations are 
eliminated. In the current work, 1 fixed volume of extraction solvent was used 
for all samples. In the biological application (subsequent) chapter, the average 
skeletal muscle tissue mass was ~ 5 mg dry weight, which has been shown to 
be optimal previously (Stephens et al. 2014). To determine if lower tissue 
weights result in an overestimation of concentration or if doubling tissue 
weights saturates the extraction solvent, one biopsy was powdered and 
aliquoted at 3 different weights (1,5 and 9 mg) in triplicate. The calculated dry 
muscle concentration was compared to determine if the assay procedure was 
appropriate for a range of different tissue weights without the need to correct 
the extraction volume. 
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3.2.9 Application of method to human samples for 
confirmation of method suitability  
The method was applied to seven fasting skeletal muscle samples and six 
fasting plasma samples from healthy young male subjects [age, 23 ± 1 y, BMI 
(in kg·m2), 24.0 ± 0.6; mean ± SEM] that were recruited as a part of another 
study (University of Nottingham Faculty of Medicine and Health Sciences 
Research Ethics Committee, Ref. No. 19–1705). Samples were obtained prior 
to any intervention that would impact upon fasting skeletal muscle metabolism, 
full details of that study are available (Jones et al. 2020). The aim of this was 
to determine if the method resulted in analyte concentrations consistent with 
previously reported literature, either using mass spectrometry or other 
established methods for a particular analyte. Data are report as mean ± SEM 
3.2.10 Peak extraction, analyte confirmation and 
quantification 
Raw data collected from LC-MS were processed on Thermo Xcalibur 
Processing Quan Browser (version 4.1) software. The ratio of high-resolution 
LC–MS peak areas of the analyte/internal standard were calculated and were 
used to construct calibration curves of peak area ratio against analyte 
concentration. For acylcarnitines the identity of each species reported in the 
biological application was confirmed by screening for the accurate mass 
parent ion and the product ion common to all acylcarnitines (m/z 85).  
In the current approach tandem mass spectrometry (MS/MS) for the 
acquisition of product ion spectra was used for analyte confirmation. MS/MS 
was performed in data dependant mode in which a pre-selected inclusion list 
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of ions which were fragmented if a threshold frequency was exceeded. During 
MS acquisition, the top 5 eluting ions in terms of spectral peak intensity were 
selected for fragmentation and product ion analysis (MS/MS). A possible 
limitation of this approach could be low abundance, but relevant analytes may 
not be selected for MS/MS and consequently not identified and quantified. 
However, the analytes of interest in the current work have a relatively high 
endogenous abundance and the pathways they relate to are constantly in flux 
and the use of a targeted inclusion list largely overcome this limitation (See 
Appendix A) 
For species without a representative standard, analyte concentrations were 
determined using the closest structurally related and/or nearest eluting analyte 
standard curve. For skeletal muscle quantification a correction factor of tissue 
mass was applied which was then expressed as a concentration of µmol per 
kg dry weight. 
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Table 3.2 List of detected analyte names, accurate mass and retention times 
in the current method. The abbreviation STD refers to that analyte having an 
authentic unlabelled standard used for calibration 






Free carnitine STD C0 162.1124 d9- C0 9.66 
Acylcarnitines     
Acetylcarnitine STD C2 204.123 d3- C2 2.76 
Propionoylcarnitine STD C3 218.1387 d3-C3 3.72 
Malonylcarnitine C3-DC 248.1125 d3- C2 9.06 
Isobutyrylcarnitine ISO C4 232.1543 d3-C4 4.55 
Butryrylcarnitine STD C4 232.1543 d3-C4 4.64 
Hydroxybutyryl/ 
hydroxyisobutyryl carnitine 





d3- C2 8.90 
Isovalerylcarnitine STD C5 246.17 d9-C5 5.52 
2-methylbutyroylcarnitine Iso C5 246.17 d9-C5 5.36 
2-Methylcrotonoyl carnitine C5:1 244.1538 d9-C5 5.21 
3-Hydroxyisovaleryl carnitine C5-OH 262.1649 d9-C5 3.85 
Glutarylcarnitine C5-DC 276.1438 d9-C5 3.67 
Hexanoylcarnitine STD C6 260.1856 d9-C5 6.66 
Adipoyl/3-Methylglutaryl 
carnitine 
C6-DC  d9-C5 4.28/4.48 
3-Hydroxyhexanoylcarnitine C6-OH 276.1806 d9-C5 5.07 
Octanoyl-carnitine STD C8 288.2169 d3-C8 8.31 
3-Hydroxyoctanoyl carnitine C8-OH 304.211 d3-C8 6.90 
Octenoylcarnitine C8:1 286.2014 d3-C8 7.49 
Decanoylcarnitine STD C10 316.2482 d3-C8 9.46 
Decenoylcarnitine C10:1 314.2370 d3-C8 8.99 
Decadienoylcarnitine C10:2 312.2162 d3-C8 8.49 
Decatrienoylcarnitine C10:3 310.2011 d3-C8 8.42 
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3-hydroxydecanoylcarnitine C10-OH 332.2431 d3-C8 8.49 
Lauroylcarnitine STD C12 344.2795 d9-C14 10.27 
Dodecenoylcarnitine C12:1 342.2630 d9-C14 9.88 
Myristoylcarnitine STD C14 372.3108 d9-C14 10.87 
Tetradecenoylcarnitine C14:1 370.2952 d9-C14 10.53 
Tetradecandienoylcarnitine C14:2 368.2795 d9-C14 10.21 
3-hydroxytetradecenoyl- 
carnitine 
C14-OH 388.3057 d9-C14 10.40 
Palmitoylcarnitine STD C16 400.3421 d3-C16 11.49 
Hexadecenoylcarnitine C16:1 398.3262 d3-C16 11.02 
Hexadecadienylcarnitine C16:2 396.3108 d3-C16 10.72 
3-hyrdoxyhexadecanoyl-
carnitine 
C16-OH 416.3370 d3-C16 10.93 
Octadecanoylcarnnitine C18 428.3734 d3-C16 12.27 
Oleylcarnitine C18:1 426.3578 d3-C16 11.62 
Linoleoylcarnitine C18:2 424.3421 d3-C16 11.25 
3-hyrdoxystearoylcarnitine C18-OH 444.3677 d3-C16 11.55 
Arachidoylcarntine  C20 456.4047 d3-C16 13.27 
BCAAs     
Leucine STD  132.1019 U- 13C 
Leucine 
8.53 
Isoleucine STD  132.1019 U- 13C 
Isoleucine 
8.81 
Valine STD  118.0860 U- 13C Valine 9.47 
BCKAs     
α-ketoisocaproic acid STD KIC 129.0557 U- 13C KIC 5.04 
α-keto-β-methylvaleric acid 
STD 
KMV 129.0557 U- 13C KMV 4.61 
α-ketoisovaleric acid STD KIV 115.040 U- 13C KIV 2.84 
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3.3 Results and discussion  
3.3.1 Optimisation of analyte separation and mass 
spectrometry detection 
3.3.1.1 Reversed phase C18 chromatography. 
Chromatographic separation of acylcarnitines and BCKAs was achieved using 
a (PFP) C18 column. This resulted in good separation over a 17 min run time 
and good peak shape of short, medium, and long chain acylcarnitines 
including isomers of species related specifically to BCAA metabolism (Figure 
3.1 A). Analyte retention time increased with increasing carbon number. A 
coelution of analyte and IS was achieved, which is important to compensate 
for matrix effects and varying ionisation efficiencies during gradient elution 
(Figure 3.1 B). 
In the current method baseline separation of C4 and iso C4 (butryryl and 
isobutryryl- carnitine) was achieved in plasma samples allowing the distinction 
of the two isomers. However, within the skeletal muscle sample matrix the two 
isomers could not be distinguished. The reason for this lack of separation may, 
in part, be related to the much greater concentration of intramuscular butryryl-
carnitine relative to isobutryryl-carnitine, leading to the smaller peak being 
masked by the larger one. Therefore, a separate re-analysis of skeletal muscle 
samples would be required to confidently separate these two C4 carnitine 
isomers. As a result, all intramuscular C4 concentrations are presented as a 
total of this species whereas in plasma the two species are presented 
individually. 
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Similar to previous work also utilising a C18 column (Zhang et al. 2018) , the 
current method was able to separate all 3 BCKAs with excellent baseline 
separation for the isomers, KIC and KMV (Figure 3.3). This confirms the ability 
of the method to accurately determine the independent catabolic fate of 
leucine and isoleucine. The three BCKAs all eluted within 6 mins of the total 
17 min run time and if the aim of future work is focused solely on BCKA 
quantification this method could be optimised to enable a rapid, high 
throughput analysis approach. Recent publications have been able to 
successfully and simultaneously quantify the BCAAs and BCKAs in human 
plasma using ultra high performance liquid chromatography with reversed 
phased columns with run times < 10 mins (Li et al. 2016; Sargsyan and 
Trchounian 2020). However, the current method extends on the previous work 
by allowing the simultaneous quantification of BCKAs and acylcarnitines 
arising from further BCAA catabolism as well as acylcarnitines species arising 
from fatty acid and glucose metabolism.  
3.3.1.2 HILIC Chromatography 
BCAAs were separated using a HILIC column employing a mobile phase 
composition and gradient commonly used in our lab for the identification of a 
range of polar metabolites (Schatschneider et al. 2018)Whilst performance 
was excellent for valine, baseline separation was not achieved for leucine and 
isoleucine. However, their respective U- 13C resolved in an identical manner 
(Figure 3.4). Therefore, the midpoint of the peaks was selected as the cut-off 
point for manual peak integration and this criterion was applied to all samples 
across the validation procedure and for quantification of sample 
concentrations. Using this criterion satisfied all parameters of method 
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validation (see next sections for validation data). Furthermore, the reported 
sample concentrations are consistent with the established literature for 
quantification of plasma BCAAs using methods have derivatised amino acids 
to improve separation (Fuchs et al. 2019) 
In the current work free carnitine and short chain acylcarnitines were also well 
retained and separated with the HILIC column and mobile phase combination. 
In particular, the species C2, C3, C3-DC, C4-OH and C4-DC were retained and 
detected with HILIC method. Carnitine and acylcarnitines vary in their polarity 
with short chains being considerably more polar than the long chain species. 
HILIC columns permit excellent retention of small polar molecules and have 
been used with success by others for the retention of free and short chains 
(Xiang et al. 2017) and a full range of acylcarnitines (Peng et al. 2013).  
Free carnitine and the shortest acylcarnitine, C2, were both retained on the 
C18 column. However free carnitine eluted within 1 minute of the total run time 
and C2 peak showed peak fronting with an almost split peak (Figure 3.1) likely 
to due to the high concentration of this analyte relative to the other 
acylcarnitines. However, both free carnitine and C2 were retained with better, 
sharper peak shapes on the HILIC column despite their mmol concentration 
(Figure 3.4 B). The calibration curve gradients of C2 were identical between 
C18 and HILIC columns and peak area ratios from biological samples were 
also identical. This suggests that despite the poorer peak shape of C2 on the 
C18 column, retention of the analyte was not compromised. In accordance 
with this, C2 satisfied all analytical validation parameters with the C18 column.  
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3.3.1.3 MS/MS fragmentation  
Fragmentation of acylcarnitines yields a common fragment of m/z 85.0283 
which is considered the most abundant and diagnostic product ion (Chace et 
al. 1997; Cansu et al. 2011)Other common fragments include m/z 60.081 and 
144.101. Others fragments specific to certain species, as described by recent 
work that utilised parallel reaction monitoring (PRM) (Xiang et al. 2017) were 
also monitored and used to confirm the identity of different acylcarnitines. 
(Figure 3.2).  
3.3.1.4 Potential strategies to improve analyte detection  
A possible methodological approach to improve confidence in isomeric 
species quantification is to utilise the PRM capabilities of the Orbital trap mass 
spectrometer. Monitoring of all product ions produced by fragmenting an 
authentic standard of those analytes at different collision energies to 
determine if, for example, leucine or isoleucine produces a unique fragment 
which can in turn be used to quantify. Indeed, this approach was investigated 
but with no success using the current analytical conditions and was not 
investigated further (data not shown). A recent publication utilised a similar 
approach using a triple quadrupole instrument and monitoring separation 
mass transitions for leucine and isoleucine allowing detection and 
quantification without the need for chromatographic separation (Sargsyan and 
Trchounian 2020). This strategy could also be used for identification of the 
isomeric C4 acylcarnitines within skeletal muscle in the previous section. 
However, this approach would require the availability of an authentic standard 






Figure 3.1 Extracted total ion chromatograms for eight of the ten acylcarnitine 
standards at a concentration of 250 nmol (A) and deuterated acylcarnitine 
standards used for method validation and as internal standards in biological 
samples for quantification at a concentration of 80 nmol (B). Chromatograms 
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Figure 3.2 Product ion spectra of C2, acetylcarnitine with a precursor ion of 
m/z 204.123 (A) and its respective internal standard d3-C2, acetylcarnitine with 
a precursor ion of m/z  207.1417 (B). Spectra acquired using data dependant 
mass spectrometry with product ion of m/z 85.028 used for acylcarnitine 
species confirmation.  
  
DIABETESQC #105-493 RT: 1.01-3.95 AV: 33 NL: 7.28E6
T: Average spectrum MS2 204.12 (105-493)
































DIABETESQC #108-353 RT: 1.03-2.91 AV: 26 NL: 1.75E5
T: Average spectrum MS2 207.14 (108-353)














































Figure 3.3 Extracted total ion chromatograms of the three branched chain keto 
acids (BCKAs) at a concentration of 1 µmol and the two remaining unlabelled 
acylcarnitine standards at a concentration of 250 nmol (not displayed in Figure 
2.1) from a calibration standard spiked into 7.5% BSA in PBS. Analytes were 
separated using a reversed phase C18 column and detected in negative mode 
for BCKAs and in positive mode for acylcarnitines. 
  






Figure 3.4 Extracted total ion chromatograms (TICs) of the three branched 
chain amino acids (BCAAs) separated and quantified using hydrophilic 
interaction liquid chromatography (HILIC) coupled to high resolution mass 
spectrometry from a calibration standard spiked into 7.5 % BSA in PBS at 100 
µM and detected in positive mode (A). Free (C0), acetyl (C2) and propionoyl 
(C3) carntine TICs which were also detected using the HILIC method, 
extracted from a pooled skeletal muscle QC sample. 14 mins of the total 24 





C0 C2 C3 
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3.3.2 Biological matrix validation with isotopically labelled 
standards 
3.3.2.1 Validation using skeletal muscle with the standard addition 
method 
Validation data for this approach in skeletal muscle is shown in Table 3.3. All 
analytes showed excellent linearity (R2 > 0.99) across their respective 
calibration ranges. Precision ranged from 1.4 to 14.1 % for analytes and all 
were within the 15% FDA criteria for method validation. With the exception of 
C14 and C16 acylcarnitine at their lowest calibration level, all analytes satisfied 
the criteria for method accuracy and were within 15 % of the true calibration 
value. C14 acylcarnitine and the two BCKAs KMV and KIC were within 20 % of 
the true value at their lowest calibration point which is considered acceptable 
when analyte concentration is close to or at the LOQ. 
Long chain acylcarnitine recovery was lower than the shorter chains species. 
Therefore, a correction factor was applied to accuracy to account for the 
differing recovery levels for analytes. Only the highest concentration levels for 
long chain acylcarnitines were impacted by the lower recovery but these 
concentrations are higher than typical concentrations found in human muscle 
samples. It was noted that C14 and C16 analyte standards did not completely 
dissolve in methanol: water (1:1) above the nmol range and this is an important 
consideration when preparing the high concentration stock and calibration 
solutions as well as in the choice of reconstitution solvents for acylcarnitine 
analysis owing to the range of polarity of these analytes.  
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The BCKAs also had lower recovery at the low and mid-level but this recovery 
did not compromise the accuracy or precision of the measurements. Two 5-
point (rather than one 10 point) calibrations curves were constructed for these 
analytes to cover the low-mid range and the mid-high range to minimise the 
effects on quantification. The low recoveries observed for the BCKAs could be 
due an incompatibility of the organic solvents used for extraction (acetonitrile 
and isopropanol) and the highly polar BCKAs but this was not investigated 
further. However, the use of solvents in the current method satisfies all the 
parameters of validation across the biological range of the analytes. 
 114 
Table 3.3 Method validation data from the standard addition method using labelled isotopes as a substitute for the authentic 
unlabelled standards spiked into powdered human skeletal muscle. Calibration curves were prepared in triplicate and precision, 
accuracy and recovery were assessed with 6 replicates at each level. A matrix effect less than 100 % indicates ion suppression and 
















n = 6 
Accuracy 
(%) 






(d9) - C0 3 x 107 0.1-21.7 50 100 100 8.8 93.9 88.0 15.3 
 (0.999)    5.5 x 103 8.3 99.1 87.1 23.1 
     21.7 x 103 4.6 99.7 86.1 31.0 
(d3) - C2 
 
6 x 107 
(0.994) 
0.01-5.5 5 20 23.8 11.6 97.8 85.2 81.1 
1350 1.9 102 95.8 64.3 
5500 2.9 100 97.6 81.0 
(d3) - C3 
 
3 x 108 
(0.999) 
0.005-5 1 5 5 3.5 99.3 96.7 88.8 
250 14.1 104 97.3 109 
1000 1.4 96.6 92.8 96.9 
(d3) - C4 
 
5 x 108 
(0.998) 
0.005-5 1 5 5 6.3 92.0 95.5 86.9 
250 3.9 109 101 121 
1000 2.8 95.6 93.7 95.1 
(d9) - C5 
 
6 x 108 
(0.997) 
0.005-5 1 5 5 5.1 91.4 97.1 83.8 
250 3.0 104 100 120 
1000 2.6 91.4 92.1 91.0 
(d3) - C8 
 
7 x 108 
(0.999) 
0.005-5 0.5 1 5 3.5 95.2 102 62.0 
250 4.0 97.1 102 69.8 
1000 2.4 86.3 92.9 64.1 
(d9) - C14 
 
5 x 108 
(0.994) 
0.005-5 0.5 1 5 4.7 83.8 91.2 37.3 
250 13.8 102 83.5 38.0 
1000 7.2 104 70.0 38.9 
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(d3) - C16 
 
3 x 108 
(0.993) 
0.01-5 0.5 5 10 8.8 231 96.1 27.6 
500 10.1 109 63.1 28.1 
2000 12.6 119 48.6 24.9 
BCAA  (µmol/mg) (µmol/mg) (µmol/mg) (µmol/mg)     
(U-13C)  
Leucine 
4 x 107 
(0.998) 
1-350 0.3 0.6 0.75 6.5 94.3 94.3 80.1 
3.5 7.6 87.0 87.0 85.3 
300 9.5 97.8 97.8 86.7 
(U-13C) 
Isoleucine 
5 x 107 
(0.996) 
1-350 0.3 0.6 0.75 5.8 96.0 96.0 84.1 
3.5 7.9 88.3 88.3 83.8 
300 8.0 99.3 99.3 91.3 
(U-13C)  
Valine 
2 x 107 
(0.99) 
1-400 0.4 0.6 1 5.8 97.2 97.2 78.5 
4.5 3.7 85.2 85.2 81.5 
400 10.3 99.8 99.8 85.3 
BCKA          
(U-13C)  
KIC 
6 x 107 
(0.997) 
0.2-100 0.1 0.2 0.25 13.2 103 43.5 116 
1 13.5 86.0 31.6 97.1 
100 2.3 99.0 87.2 96.6 
(U-13C)  
KMV 
5 x 107 
(0.995) 
0.2-100 0.1 0.2 0.25 12.0 120 55.2 120 
1 10.5 93.0 42.2 100 
100 2.6 99.0 88.0 96.7 
(U-13C)  
KIV 
1 x 107 
(0.99) 
0.4-200 0.1 0.2 0.25 10.2 118 46.2 100 
1 13.6 60.0 35.5 120 
100 1.8 101 84.3 90.2 
Limit of detection (LOD), limit of quantification (LOQ), branched chain amino acids (BCAA), branched chain keto acids (BCKA). α-
ketoisocaproic (KIC), α-keto-β-methylvaleric acid (KMV) and α-ketoisovaleric acid (KIV). 
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3.3.2.2 Validation using proxy matrix method (7.5 % BSA in PBS) 
The isotope addition of carnitine and acylcarnitines was also performed in a 
proxy matrix (BSA) with the identical calibrants to assess the suitability of this 
matrix as a substitute for skeletal muscle. Data for this approach is shown in 
Table 3.4. The slopes of curves were similar between skeletal muscle and BSA 
with very similar linearity (R2 > 0.99), precision (2 – 9.3 %) and accuracy (72.5 
– 136 %). Analyte recovery was between 80.2 and 114 % for all acylcarnitines.  
There was a large range in the matrix effect on acylcarnitines in both matrices, 
with ion suppression increasing with longer chain lengths. These data highlight 
the importance of internal standards to account for these matrix effects to 
enable absolute quantification in biological samples 
.
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Table 3.4 Method validation data using isotopically labelled acylcarnitine standards spiked into the proxy matrix of 7.5 % BSA in PBS. 
Calibration curves were prepared in triplicate and precision, accuracy and recovery were assessed with 6 replicates at each level. A 
















n = 6 
Accuracy 
(%) 
n = 6 
Recovery 
(%) 
n = 6 
Matrix effect 
(%) 
(d9) - C0 8 x 107 0.1-21.7 10 20 100 4.7 105 89.3 42.5 
 (0.991)    5.5 x 103 1.1 112 91.7 80.0 
     21.7 x 103 4.1 108 91.1 83.0 
(d3) - C2 
 
8 x 107 
(0.995) 
0.01-5.5 1 20 23.8 2.9 142 94.4 77.5 
1350 2.2 114 93.3 89.6 
5500 3.9 89.2 95.3 89.3 
(d3) - C3 
 
3 x 108 
(0.998) 
0.005-5 0.5 1 5 3.3 102 96.5 67.1 
250 8.5 108 91.3 67.3 
1000 2.8 95.8 94.8 74.2 
(d3) - C4 
 
4 x 108 
(0.997) 
0.005-5 0.5 1 5 4.6 87.0 91.2 70.5 
250 2.2 111 96.0 72.1 
1000 2.8 96.4 93.1 71.9 
(d9) - C5 
 
5 x 108 
(0.996) 
0.005-5 0.5 1 5 4.6 95.6 96.4 67.7 
250 3.6 111 94.9 87.9 
1000 4.5 101 96.6 76.6 
(d3) - C8 
 
4 x 108 
(0.997) 
0.005-5 1 5 5 5.3 96.7 97.6 66.7 
250 3.6 102 96.2 77.7 
1000 5.0 99.1 96.8 81.2 
(d9) - C14 
 
3 x 108 
(0.994) 
0.005-5 0.5 1 5 2.0 72.5 99.4 48.9 
250 3.2 91.2 93.0 57.4 
1000 5.1 91.6 103 56.0 
(d3) - C16 
 
2 x 108 
(0.997) 
0.01-5 0.5 5 10 5.4 136 114 41.3 
500 6.8 94.5 85.0 27.9 
2000 9.3 95.6 80.2 38.2 
Limit of detection (LOD), limit of quantification (LOQ),
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3.3.3 Use of the proxy BSA in PBS matrix as a valid substitute 
for analyte quantification in powdered skeletal muscle and 
plasma  
3.3.3.1 Skeletal muscle 
The acylcarnitine peak area ratio response was almost identical between 
skeletal muscle and BSA with all analytes demonstrating excellent linearity 
(Table 3.5). These results indicate that the use of isotopically labelled internal 
standards is sufficient to account for the effect of the matrix on analyte 
detection and quantification. A representation of the likeness of the two 
matrices’ calibration is shown in Figure 3.5. Taken together with the method 
validation data from the isotope addition method outlined above, this method 
can extract acylcarnitines equally efficaciously from both skeletal muscle and 
BSA, meeting the validation parameters outlined in section 3.2.7. 
3.3.3.2 Plasma  
This approach was also carried out across the biological range in human 
plasma to compare the analyte response to the proxy matrix. Similar to skeletal 
muscle, the analyte response was very similar between human plasma and 
BSA (Figure 3.6). Six independent plasma samples were also analysed, and 
the concentration of each analyte was calculated and compared between the 
two matrices. Corrections for endogenous analyte concentrations in human 
plasma were made by subtracting the endogenous concentration from each 
calibration standard. With the exception of C16 acylcarnitine (8.6%), the CV of 
calculated concentrations between the two matrices was within 5% for all 
acylcarnitines. These data confirm that BSA is an appropriate substitute for 
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human plasma and can be used for calibration purposes. The data for these 
experiments are also displayed in Table 3.5. 
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y = 0.0416x + 0.0535
R2 = 0.999
y = 0.0416x + 0.0777
R2 = 0.998
 
Figure 3.5 Calibration curves for C4 butyrylcarnitine from a range of 1 nmol/ L 
to 1 µmol/L spiked into the proxy matrix of 7.5 % BSA in PBS (A) and same 
calibrants spiked into powdered human skeletal muscle (B) expressed as 
nmol/g  
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y = 0.0427x - 0.217
R2 = 0.998
y = 0.0422x - 0.027
R2 = 0.999
 
Figure 3.6 Calibration curves for C8 octanoylcarnitine from a range of 1 nmol/ 
L to 1 µmol/L spiked into the proxy matrix of 7.5 % BSA in PBS (A) and same 
calibrants spiked into 100 µL aliquots of human plasma (B) 
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Table 3.5 Comparisons of skeletal muscle and plasma to proxy matrix (7.5 % BSA in PBS) spiked with unlabelled standards. 
Responses are expressed as peak area ratios to isotopically labelled internal standards with calibration ranges specific to each 
matrix. CV of plasma samples relate to variation of 6 sample concentrations calculated with calibration in plasma and calibration in 
BSA. 























N = 6 



























































































3.3.4 Method validation for analytes with high endogenous 
concentrations 
The spiking of authentic unlabelled free carnitine (C0), BCAA and BCKA 
standards into skeletal muscle and/or plasma was not appropriate for 
calibration due to relatively high endogenous concentrations of these 
metabolites. However, the data from sections 3.3.2 – 3.3.4 demonstrated that 
the method can extract analytes from two matrices with equally efficiency and 
that BSA in PBS is an appropriate substitution of both skeletal muscle and 
plasma. The use of labelled internal standards can correct for any matrix 
effects that may impact upon method validation and calculation of analyte 
concentrations in biological samples. Therefore, a full validation of these 
analytes using unlabelled standard/ internal standard peak area ratios was 
performed in BSA in accordance with same criteria outlined in section 3.2.7 
and across the same calibration range outlined in Table 3.3. Data from these 
experiments is shown in Table 3.6. Free carnitine (C0), BCAAs and BCKAs 
showed excellent linearity, precision, accuracy. As seen with the isotopes, 
recovery of BCKA particularly at the low and mid-point was 50 % or less but 
this did not affect precision or accuracy. Previous work has shown high 
recoveries of BCKA albeit at higher concentration and using a more polar 
extraction solvent mixture of methanol/ water (Zhang et al., 2018).  
It should be noted that the current method covers a range of analytes with 
varying degrees of polarity using a single extraction procedure which is likely 
to have an impact on some validation parameters such as recovery and 
accuracy, particularly at extreme ends of polarity. These data highlight the 
importance of internal standards to correct for such challenges. One strength 
 124 
of the current method is the number of analyte specific internal standards used 
allowing for greater confidence in each analyte’s quantification. Of note, 
despite lower recoveries of some analytes, quantitative performance of the 
method was not impacted over the vast range of concentrations measured. 
This is of particular significance as if/when this method is applied to other 
tissues (e.g. adipose tissue) with varying levels of endogenous abundance, 
the method remains valid over the biological range of that tissue.  
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Table 3.6 Method validation data for free carnitine, branched chain amino and keto acids spiked into 7.5 % BSA in PBS using peak 
area ratio of unlabelled standards and isotopically internal standards. Calibration ranges were appropriate for both skeletal muscle 














n = 6 
Accuracy 
(%) 
N = 6 
Recovery 
(%) 




C0 d9-C0 1-1000 1.38 0.998 2.5 1.4 110 94.9 88.1 
     50 0.8 112 113 74.3 







0.999 0.75 2.3 86.9 90.3 148 
  3.5 1.0 106 95.6 128 







0.999 0.75 2.6 97.4 94.8 132 
  3.5 1.6 107 101 112 







0.998 1 5.2 103 84.7 86.7 
  4.5 1.6 109 93.6 73.3 







0.999 0.25 3.1 85.0 49.0 147 
  1 1.2 111 46.9 129 







0.999 0.25 3.4 96.1 53.3 118 
  1 1.2 114 52.3 113 







0.999 0.4 2.7 113 27.0 128 
  3 1.4 114 28.4 118 
  300 1.4 100 70.4 114 
α-ketoisocaproic (KIC), α-keto-β-methylvaleric acid (KMV) and α-ketoisovaleric acid (KIV)
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3.3.5 Sample stability and extraction repeatability 
With exception of C12 acylcarnitine, all analytes had an intra-day stability 
between 90 and 110% (referenced to time 0) For acylcarnitines and BCKAs 
this stability relates to an acquisition time of 48 hours and ~ 56 hours for BCAA 
and the samples was kept in the autosampler at 4o C throughout. Skeletal 
muscle QCs following a freeze thaw cycle in which the QCs were stored at -
80o C between analysis did not appear to have any effect on stability (free-
thaw stability ranged between 95 and 106 %). This is an important observation 
as the workflow of the current method requires two separate injections of the 
sample to cover all the analytes to be quantified (i.e. one injection for C18 and 
another for HILIC column). Sample stability and repeatability data are 
displayed in Table 3.7. 
Each analyte repeatability was below 12 % apart from KIV in skeletal muscle 
which had a CV of 17 %. C12 acylcarnitine had an RSD > 10 % in both plasma 
and muscle. This may be of importance if multiple batches of samples are to 
be extracted over a period before analysis. To reduce any impact of sample 
degradation over the acquisition a standard curve was run at the beginning 
and just prior to the conclusion of each quantitative analytical run. 
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Table 3.7 Method stability data from intra-day and following a freeze-thaw cycle in skeletal muscle presented as percentage with CV 
of the replicates. Freeze-thaw stability data not available for plasma. Analyte repeatability refers to the variation in calculated analyte 
concentration from 9 replicates of the same human skeletal muscle or plasma sample extracted on the same day. 












n = 6 
Repeatability 
CV (%) 






n = 11 
Repeatability 
CV (%) 
n = 9 
C0 101.5 4.7 100.8 2.0 5.6 98 1.1 1.5 
Acylcarnitines         
C2 99.3 1.4 99.7 1.7 5.8 103.4 1.8 0.7 
C3 102.5 1.4 99.2 2.1 4.7 99.2 2.5 2.9 
C4 104.0 2.5 101.6 1.0 5.5 104.9 5.1 4.0 
C5 93.9 4.4 97.6 4.8 6.2 95.1 3.2 4.9 
C6 90.7 5.6 106.2 6.3 6.5 91.0 6.2 4.2 
C8 100.9 1.4 99.8 0.6 4.0 98.3 1.3 2.3 
C10 93 6.0 103.2 2.2 5.3 91.2 6.1 11.1 
C12 89.2 7.3 100.2 2.6 11.4 85.6 11.6 10.0 
C14 98 1.5 97.3 1.9 6.1 91.1 3.2 5.3 
C16 100.2 0.5 98.0 2.4 5.5 94.2 3.2 3.5 
BCAA         
Leucine 94 2.7 100.7 1.8 3.5 97.5 2.1 2.9 
Isoleucine 109.1 5.7 101.5 6.6 5.7 95.4 4.8 3.3 
Valine 100.5 1.8 99.5 0.9 4.3 97.0 1.7 3.5 
BCKA         
KIC 100.9 1.7 99.6 1.1 7.7 98.0 1.7 2.6 
KMV 99.1 1.1 99 1.1 6.0 94.2 3.3 3.7 
KIV 109.6 6.3 95.9 2.9 17.7 98.5 1.6 2.3 
α-ketoisocaproic (KIC), α-keto-β-methylvaleric acid (KMV) and α-ketoisovaleric acid (KIV).
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3.3.6 Effect of sample weight on extraction efficiency 
C2 acylcarnitine and KIV were not detected in1 mg of tissue. KIC, KMV, C12 
and C5 had a CV of greater than 20 % with higher error in all cases attributable 
to a higher concentration being calculated at 1 mg vs 5 and 9 mg. Doubling 
the tissue volume had little effect on any metabolite with almost identical 
concentrations at 5 and 9 mg. Based on this data, it is recommended that low 
tissue volumes are avoided to minimise any errors in calculations. 
Alternatively, adjustments in extraction or reconstitution volumes could be 
made where appropriate but this was not investigated in the current work. Data 






































































































































































































































































































































































































































































































Figure 3.7 Comparison of calculated concentrations of each analyte extracted 
in triplicate from tissue weights of 1, 5 and 9 mg. Missing bars indicate that the 
analytes was undetected at a tissue weight of 1 mg. Data are mean ± SD. α-




3.3.7 Application of method to human samples for 
confirmation of method suitability 
3.3.7.1 Muscle metabolites 
Muscle free carnitine content has been extensively investigated, particularly in 
young male healthy as it pertains to its key role in the regulation of substrate 
metabolism during muscular contraction (Stephens, Constantin-Teodosiu, and 
Greenhaff 2007). The most common and established method used to measure 
muscle free carnitine is the radioisotopic method which can measure both free 
and acylated carnitine (Cederblad et al. 1990) but cannot discriminate acyl 
chain lengths. The reported muscle carnitine content across multiple 
previously published literature with a subject cohort that was very similar to 
these samples (i.e. young healthy males) is ~15-18 mmol/Kg (dry mass) with 
the sum of muscle free carnitine and the highest abundant acylated carnitine 
species, acetylcarnitine being ~20 mmol/Kg (dry mass) (Harris, Foster, and 
Hultman 1987; Sahlin 1990; Constantin-Teodosiu, Cederblad, and Hultman 
1992). The average reported muscle free carnitine content in this study was 
16.5 ± 1.7 mmol/kg which is consistent with the aforementioned studies using 
the established radioisotopic assay and a recent study that used LC-MS to 
determine intramuscular carnitine (Xu et al. 2016). In addition, muscle 
acetylcarnitine concentration was 2.1 ± 0.7 mmol/kg which is also consistent 
with concentrations determined by the radioisoptoic assay and LC-MS. 
Furthermore, the ratio of acetyl to free (0.13) carnitine was also in agreement 
with that reported previously (Constantin-Teodosiu, Cederblad, and Hultman 
1992). The calculated concentration of muscle free carnitine from the current  
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method also strongly correlated with concentration calculated using the 
radioisotopic assay (see Appendix B). 
Intramuscular BCAA concentrations have been reported on previously. Of the 
three BCAA, valine is of the highest abundance followed by leucine with 
isoleucine being of the lowest abundance (Bergström et al. 1974; Bergström, 
Fürst, and Hultman 1985). Indeed, the concentrations of BCAAs in the current 
showed the same pattern with values of 1133 ± 67, 591 ± 40 and 337 ± 27 
µmol/Kg for valine, leucine and isoleucine, respectively. Previous reports have 
expressed intramuscular BCAA concentrations in terms of wet muscle as 
opposed to dry mass (as in the current work). Due to the relatively large 
amount of water in skeletal muscle, wet muscle analyte concentrations are ~ 
four times lower than when expressed in dry tissue. In accordance, the BCAA 
concentrations measured are 3-5 times lower than the wet weight 
concentrations reported by others (Glover et al. 2008) but consistent with 
those measured in dry tissue by HPLC (Wilkinson et al. 2006). 
3.3.7.2 Plasma metabolites 
As with skeletal muscle, multiple reports have demonstrated that plasma 
BCAA concentrations follow the same pattern as skeletal muscle, with valine 
being the most abundant and isoleucine the lowest (Bergström, Fürst, and 
Hultman 1985; Fuchs et al. 2019). In healthy young males, BCAA plasma 
concentrations are in the µmol range. The average calculated concentrations 
in the six plasma samples were 253 ± 15. 124 ± 5 and 79 ± 4 valine, leucine 
and isoleucine, respectively. These concentrations are  in agreement with 
previously published work which can has measure plasma BCAA 
concentration using amino acid chromatography (Bergström et al. 1974), 
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HPLC (Sahlin, Katz, and Broberg 1990) and LC-MS/MS (Schmidt et al. 2016; 
Li et al. 2016) which have all reported very similar concentrations in subjects 
of similar age and body weight.  
Plasma free and acetylcarnitine have been reported to be in the µmol range 
as determined radioistopically (Stephens et al. 2006), direct infusion MS/MS 
(Schooneman et al. 2016) or LC-MS (G. Xu et al. 2016). Additionally, 
acylcarnitines from species lengths of three carbons and above have been 
reported to be in the nmol range. Concentrations in this study were 51.4 ± 3.3 
and 6.6 ± 1.4 µmol/L for free and acetyl carnitine, respectively. Acylcarnitine 
concentrations from species length 3 to 16 carbons ranged from 10 – 500 
nmol/L with C3 as the most abundant plasma acylcarnitine  
3.3.8 General discussion  
The aim of this chapter to develop and analytically validate a LC-MS method 
that could enable the simultaneous quantification of (acyl)carnitines, BCAA 
and BCKAs. These analytes have been individually and collectively associated 
with several chronic metabolic diseases (Newgard 2012; Gaggini et al. 2018). 
The retention of a range of acylcarnitine species lengths is important to make 
inferences about the metabolism of carbohydrate lipid and amino acids. An 
increasing area of active research in human physiology is the interaction of 
lipid and amino metabolism in skeletal muscle and the potential implications in 
the development of insulin resistance (Stephens et al. 2014, 2015) Whilst 
methods currently exist to quantify these analytes in range of matrices a 
validated method to quantify them from a single extraction procedure has not 
been developed previously. 
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A commonly cited challenge of quantifying tissue metabolites is the lack of an 
appropriate ‘blank’ which can mirror the complexity of the matrix. This is 
important as the potential of ‘matrix effects’ to enhance or suppress analyte 
signal can lead to inaccurate quantification. In addition, the method of standard 
addition approach within the biological matrix can also provide challenges to 
calibration when the endogenous concentration of an analyte is high (as is the 
case with the analytes of interest in this study) and thus spiking relatively small 
amount of the analyte does not result in a detector response above the 
baseline. These issues were addressed systematically in this chapter. First, 
isotopically labelled standards were used as substitutes of each analyte and 
spiked into powdered skeletal muscle and BSA and this approach satisfied the 
necessary validation parameters (Tables 3.4 and 3.5) However, this did reveal 
low recoveries of BCKAs and long chain acylcarnitines. These low recoveries 
did not impact on the analytical validation parameters and were easily 
accounted for by either adjusting calibration ranges and accuracy for analyte 
recovery. These results demonstrate that the single extraction procedure used 
in the current work is sufficient to extract a range of analytes with varying 
degrees of polarity and satisfy all the validation parameters required for 
confident quantification in biological samples. Following method validation 
within the biological matrix, isotopically labelled standards were used as 
internal standards to correct for differing matrix effects on analytes between 
skeletal muscle and BSA. For calibration and analyte quantification, increasing 
amounts of unlabelled standard expressed as a ratio to a fixed amount internal 
standard was spiked into skeletal muscle, plasma and BSA. This approach 
demonstrated an almost identical response within the between the matrices 
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(illustrated in Figures 3.4 and 3.5 and outlined in Table 3.5) confirming that the 
use of internal standards was appropriate to correct for matrix effects and 
result in accurate metabolite quantification. In support of this, when this 
method was applied to some biological samples (section 3.2.7), calculated 
concentrations of analytes such intramuscular free carnitine and plasma 
BCAAs were consistent with previous published studies which have used 
methodologies that were established and validated almost half a century ago 
(Bergström et al. 1974; Cederblad et al. 1990).  
The current work is a different approach to much of the previous work which 
has monitored pre-selected parent/product ion transitions using triple 
quadrupole instruments. This method is regarded as the gold standard for 
analyte quantification and has formed the basis for much of work in the area 
of acylcarnitine quantification (Minkler et al. 2008; Giesbertz et al. 2015). 
However, these methods also require authentic standards for metabolite 
identification and retention time alignment. The use of high-resolution MS 
allows the determination of analytes based on accurate mass of compounds, 
together with MS/MS fragmentation for confirmation. Indeed, a high-resolution 
approach has been used to successfully develop and validate a method for 
acylcarnitine quantification in animal plasma and urine (Xiang et al. 2017). The 
work in this chapter adds further support for the use of high-resolution mass 
spectrometry for quantitative metabolomics.  
3.3.9 Limitations 
Some limitations of the current work include the inability to separate certain 
isomers. For example, baseline separation was not achieved for leucine and 
isoleucine. However, the use of a consistent peak integration cut off point 
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resulted in satisfaction of all validation parameters with excellent repeatability 
and reproducibility of these analytes. In skeletal muscle, the separation of 
isomers of C4 acylcarnitnes was not possible with this method on either column 
and may require further optimisation of LC conditions or even longer C18 
columns. In addition, although laborious sample processing steps such as 
sample derivatisation and SPE were avoided with the current method, these 
steps may aid the separation and identification of structural isomeric/isobaric 
species (Giesbertz et al. 2015). The coverage of acylcarnitines in the current 
method is not as expansive as others. However, the detection of novel 
acylcarnitine species was not the aim of this work. The relatively smaller 
number of species were quantified with high confidence due to the large 
number of authentic and isotopically labelled internal standards used in the 
current work. 
3.4 Conclusions  
In conclusion the work in this chapter describes a fully validated method for 
the simultaneous quantification of acylcarnitines, BCAAs and BCKAs, key 
metabolites with established associations with obesity, insulin resistance and 
type 2 diabetes. Using the method of standard addition with isotopically 
labelled standards it was possible to address the matrix effect of biological 
samples to allow accurate and confident quantification of these key 
metabolites in both muscle and plasma. This method avoids laborious and 
tedious sample preparation and owing to the high sensitivity of this method, 
concentrations in samples are well above LOD and LOQ. The method was 
then applied to human samples and showed concentrations consistent with 
previous studies.  
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4 Chapter 4 Quantitative metabolomics in 
human skeletal muscle and plasma reveals 
distinct differences in key biomarkers of 
Type 2 diabetes 
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4.1 Introduction 
Elevated plasma acylcarnitines (Mihalik et al. 2010), branched chain amino 
acid (BCAAs) (Newgard et al. 2009) and branched chain keto acids (BCKAs) 
(Menni et al. 2013) have all been associated with insulin resistance and the 
development of Type 2 diabetes. Furthermore, their use as possible early 
biomarkers for the development of type 2 diabetes has been validated by 
population based studies that show these metabolites successfully predict 
future disease (Wang et al. 2011; Sun et al. 2016). Despite these robust 
relationships between plasma profiles and disease progression, little is known 
about the origin of the metabolites in plasma nor which tissue’s metabolism 
they reflect. Furthermore, it has not been established if they can be causative 
of insulin resistance in vivo or whether simply reflect an insulin resistant state. 
In contrast to short-chain acylcarnitines that can be produced from glucose, 
amino acids, and fatty acid degradation, medium- and long-chain 
acylcarnitines are derived exclusively from fatty acid metabolism. Long-chain 
species are mainly synthesized and metabolized in mitochondria; therefore, 
concentrations of long-chain acylcarnitines are used as markers of 
mitochondrial fatty acid oxidation. Indeed, the presence of acylcarnitines in 
plasma is routinely used a diagnostic measure of inborn errors of fatty acid 
metabolism (Rinaldo, Cowan, and Matern, 2009). 
It has been proposed that the plasma concentrations of acylcarnitines can 
predict the intracellular energy metabolism pattern and can be used as a 
marker of metabolic dysfunction in obesity and type 2 diabetes (Adams et al. 
2009; Mihalik et al. 2010) For example, elevated even number chain lengths 
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(C2-C20) of acylcarnitines have been proposed to reflect mitochondrial 
overload when lipid availability is in excess of the capacity of the mitochondria 
to utilise fatty acids, leading to ‘incomplete’ fatty acid oxidation and 
accumulation of acylcarnitines (due to reduced oxidation) in muscle and 
subsequently into the circulating pool in plasma (Koves et al. 2008). Whether 
or not acylcarnitines simply reflect the lipotoxcity associated with obesity and 
lipid accumulation in muscle or play some causative role in human remains 
unknown at present (Schooneman et al. 2013). Moreover, the majority of 
acylcarnitine profiling thus far in human studies has been limited to plasma 
concentrations and not tissue content (Adams et al. 2009; Mihalik et al. 2010). 
Despite the established association of intracellular lipid accumulation and 
intermediates with insulin resistance of glucose metabolism (Samuel, 
Petersen, and Shulman 2010), there are several lines of emerging evidence 
that plasma BCAAs and products of their catabolism such as BCKAs 
(produced from BCAA transamination) and odd number carbon chain lengths 
(C3-C5) acylcarnitines (products of oxidative metabolism of BCAAs) may be 
more closely associated with insulin resistance than lipid markers (Newgard  
et al. 2009; Menni et al. 2013). These findings have given rise to the 
hypothesis that BCAAs and associated metabolites may cause insulin 
resistance in skeletal muscle (White et al. 2016). Alternatively, it has since 
been suggested that altered skeletal muscle metabolism may contribute to 
those species in the circulation (Lerin et al. 2016; David et al. 2019). 
Whilst a number of studies have measured circulating concentrations of 
acylcarnitines, BCAAs and related metabolites (Mihalik et al. 2010; Newgard 
2012) and attempted to make inferences on skeletal muscle metabolism, it has 
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been demonstrated that plasma metabolite profiles do not accurately muscle 
tissue profiles (Schooneman et al. 2014). Therefore, studies investigating both 
tissue and plasma profiles are essential to draw conclusions from plasma 
profiles. This is vital given that more recent data has shown that acylcarnitines 
(Céline Aguer et al. 2015a), BCAAs and BCKAs (Zhou et al. 2019) can all 
impair insulin signalling in vitro. Therefore, quantitative assessments of these 
metabolites in human tissue are important to determine if (or at all) 
acylcarnitines, BCAA and BCKAs can contribute to insulin resistance in human 
skeletal muscle. 
In recent years, much attention has been paid to the development of LC-
MS/MS based methods for identification and quantification of acylcarnitines, 
BCAAs and BCKAs in biological tissues. Whilst these methods provide large 
coverage of acylcarnitines, they often require complicated and laborious steps 
of sample preparation which may limit them to one metabolite type. Although 
in recent years, more rapid and simpler methods have allowed for the 
simultaneous quantification of BCAAs and BCKAs in plasma, a method to 
quantify all three groups of these important and related metabolites (ie 
acylcarnitines, BCAAs and BCKAs) was lacking. In the previous chapter a 
quantitative method with a single and simple extraction protocol was 
developed and optimised to simultaneously measure all three metabolite types 




• To apply and validate the optimised method from the previous chapter, 
using plasma and skeletal muscle samples from both Type 2 diabetic 
patients and control subjects for absolute quantification of BCAAs, 
BCKAs and short-, medium- and long-chain acylcarnitines. 
• To compare the signature of all three types of metabolites between 
plasma and muscle and examine to what extent plasma concentrations 




4.2 Methods  
4.2.1 Participant characteristics  
The samples used in this chapter were obtained from two separate studies 
involving overweight/obese subjects and patients with type 2 diabetes. 
Samples from a total of ten overweight/obese patients with type 2 diabetes 
(T2D) and fourteen middle-aged normoglycemic controls (CON) were used in 
this study. Sample collection was approved by the University of Nottingham 
Faculty of Medicine and Health Sciences Research Ethics Committee 
(E15012015) and the NHS Research Ethics Committee (East Midlands REC 
reference No 14/EM/0136). Subject characteristics with details on sample 
amounts are shown in Table 4.1 
Table 4.1 Subject characteristics of CON and T2D participants and number of 
samples used for the analysis of each sample type. 
 CON (n=14) T2D (n=10) 
Age (years) 45.1 ± 1.9 47.7 ± 1.5 
BMI (Kg/m2) 31.9 ± 1.3 30.1 ± 1.3 
Fasting glucose 
(mmol/L) 
4.6 ± 0.1 6.2 ± 0.5 ** 
Fasting serum insulin 
(mU/L) 
19.6 ± 4.1 17.9 ± 2.3 
HOMA-IR 4.1 ± 0.9 5.0 ± 0.9 
Skeletal muscle biopsy (n) 14 10 
Plasma (n) 7 10 
Body mass index (BMI). **p < 0.01 Homeostatic Model Assessment of Insulin 
Resistance (HOMA-IR)   
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4.2.2 Sample collection 
In all cases subjects arrived at the laboratory at 08:00 after an overnight fast 
(10–12 h), having abstained from heavy exercise and alcohol for the previous 
48 h. Diabetic patients were instructed to not take any of their diabetic 
medication on the day of the experimental visit. Subjects then rested in bed in 
a semi-supine position, and an intravenous cannula was inserted retrograde 
into the superficial hand vein of one arm to obtain an arterialized venous blood 
sampling. Arterialization of the venous sample was achieved by heating the 
hand to 50-55o C using hot-air warming unit (Gallen and Macdonald 1990).  
An arterialised fasting state blood sample was obtained, and blood glucose 
concentration was determined immediately as described in chapter 2 section 
2.3.1. The blood sample was then dispensed into appropriate vacutainers for 
the isolation of plasma (chapter 2, section 2.3.3) and serum (chapter 2, section 
2.3.5) for the determination of plasma acylcarnitine, BCAAs and BCKAs and 
serum insulin (chapter 2, section 2.3.6). Skeletal muscle samples were 
obtained from the vastus lateralis in the fasted state using the Bergstrom 
needle biopsy technique (Bergström 1975) and immediately frozen in liquid 
nitrogen-cooled 2-methylbutane and subsequently stored in liquid nitrogen 
until analysis. 
4.2.3 Preparation of samples, calibrants and QCs for LC-MS 
analysis  
One portion of frozen skeletal muscle was freeze-dried and powdered, and a 
100 µL aliquot of plasma was processed and prepared for extraction as 
described in Chapter 3, section 3.2.2. Calibrants were prepared from stock 
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solutions (described in chapter 3 section 3.2.4) and diluted to produce 10-point 
standard curves to cover appropriate biological ranges for skeletal muscle and 
plasma. Calibrants were then spiked into 7.5 % BSA in PBS and processed in 
an identical manner to biological samples. 
Biological samples were extracted in batches with no more than 30 samples 
per batch. Within each batch at least 2 repeatability QC samples were also 
extracted in an identical manner to the biological samples. Repeatability QC 
samples were aliquots from a single homogeneous QC reference sample 
(either muscle or plasma) used to determine any variability in the extraction 
procedure between batches. For all the work presented in this thesis, samples 
within any analytical run were all extracted in the same day. All samples and 
calibrants were reconstituted in 100 µL of methanol:water (1:1, v:v), at this 
step, a 10 µL aliquot of each sample was used to create a pooled QC sample 
of all biological samples to be quantified. This pooled QC was injected 
repeatedly to account for any variation in retention times or MS performance 
over the duration of the analytical run.  
4.2.4 LC-MS setup and analysis  
Analytes were separated and analysed using both RP and HILIC 
chromatography linked to high resolution MS as described in chapter 3, 
section 3.2.3. For LC-MS analysis, the column was equilibrated with the mobile 
phase and a system suitability standard (SSD), comprising of an unextracted 
calibrant was injected for confirmation of chromatographic separation, MS 
detection and MS/MS fragmentation. Then, an appropriate number of solvent 
blanks (methanol:water 1:1) were injected to ensure no carry over from the 
SSD. The ten-point calibration curve was then injected followed by solvent 
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blanks to account for any carry over from the highest calibrant point. Prior to 
any biological sample injection, the column was conditioned with at least 5 
injections of the pooled QC and finally the first of the repeatability QCs. 
Biological samples were injected in a randomised order and interspersed with 
a pooled QC and the subsequent repeatability QC every ten samples. 
Following the injections of all biological samples, the calibration curve was 
injected again at the of the analytical run. All samples, QCs and calibrants 
were stored at -80o C between analysis. Samples were analysed on the C18 
column first and then on the HILIC column.  
To confirm that the method was suitable to quantify each set of biological 
samples with confidence, analytical acceptance criteria were applied to the 
calibrants and QC samples. The CV of both the pooled QC and calculated 
concentrations from the repeatability QC was assessed with at least 6 
replicates in every analytical run and variability within 15% for each analyte 
was deemed acceptable. The concentration of each biological sample was 
calculated from both calibration curves (ran at the beginning and end of each 
acquisition). 
4.2.5 Peak extraction and statistical analysis 
Raw data collected from LC-MS was processed on Thermo Xcalibur 
Processing Quan Browser (version 4.1) software for analyte quantification as 
described in chapter 3, section 3.2.10. Differences in muscle and plasma 
metabolite concentrations between CON and T2D were assessed using a 
Student’s unpaired t test. Due to sample availability, only 7 of the 14 subjects 
in CON had a corresponding plasma value and therefore correlations between 
muscle and plasma were only performed in these 7 subjects. Pearson’s 
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correlation coefficients were used to analyse associations between muscle 
and plasma analyte concentrations in only those subjects (from both groups) 
with both a muscle and corresponding fasting plasma sample (n = 17). 
Correlation analysis was also performed on data pooled from both groups to 
investigate associations between fasting blood glucose and plasma (n =14), 
and muscle analyte concentrations (n= 21). Biological data are mean ± SEM 
unless stated otherwise. Statistical significance was accepted at p < 0.05. 
When referring to chain lengths AC were grouped as short (C3-C5), medium 
(C6-C10) and long-chain (C12-C20). Summed BCAA refers to the summation of 
leucine, isoleucine and valine concentrations. Summed BCKA refers to the 
summation of α-ketoisocaproic (KIC), α-keto-β-methylvaleric acid (KMV) and 
α-ketoisovaleric acid (KIV) concentrations. 
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4.3 Results  
4.3.1 Assessment of method performance and QCs  
Within plasma, variation in the repeatability QC and the pooled QC (a measure 
of variation of the system) were within 10% for every analyte. For muscle 
analysis, all analytes repeatability QC and the pooled QC were less than 11%, 
except for C10 which had a repeatability QC variation of 16.5%. In general, 
variation in both types of QCs was greater in muscle than plasma, though it 
should be noted that muscle is a far more heterogenous in composition than 
plasma. The percentage difference between the two slopes was less than 8% 
for muscle analysis. For all standard curves regardless of matrix, the R2 was 
above 0.99. Taken together, the results from the QC analysis demonstrate the 
analytical method met all QC criteria to quantify all analytes across multiple 
batches accurately. Details of all analytical performance parameters is given 
in Table 4.2.
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Table 4.2. Assessment of the analytical run for the quantification of analytes in biological samples. Calibration curves were analysed 
at the beginning and end of each analytical run. Repeatability QCs are aliquots of one the same sample and pooled QCs are repeat 
injections of the same sample over the analysis time. Data for the second calibration curves for BCAA in muscle were not obtained 
due to technical difficulties with the LC-MS system. 






























N = 14 
C2 6.01 6.01 0.8 8.5 3.4 8.8 8.6 2.5 0.7 1.8 
C3 30.1 31.4 4.2 10.7 1.9 36.3 37.4 3.1 2.9 2.5 
C4 33.4 34.2 2.1 9.8 4.7 32.9 30.8 6.4 4 5.1 
C5 24.6 24.0 2.4 4.2 5.1 25.0 24.5 2.1 4.9 3.2 
C6 31.1 30.78 1.3 10.6 5.4 34.3 34.9 1.9 4.2 6.2 
C8 35.1 33.5 4.8 10.7 3.1 39.1 38.0 2.6 2.3 1.3 
C10 38.4 37.6 2.1 16.5 5.8 55.6 52.6 5.5 8.3 6.1 
C12 41.1 42.8 2.5 10.7 10.9 73.4 58.1 20.9 5.5 9.1 
C14 31.9 32.9 3.3 7.4 2.3 40.1 37.6 6.3 5.3 3.2 
C16 15.6 15.1 3.4 6.5 3.5 15.7 15.1 3.5 3.5 3.2 
KIC 0.75 0.80 7.3 6.6 5.1 0.86 0.82 5.5 2.6 1.7 
KMV 0.91 0.9 1.5 8.2 2.6 0.88 0.80 9.7 3.7 3.3 
KIV 0.73 0.73 0.7 7.3 2.7 0.73 0.69 6.2 2.3 1.6 
Leucine - - - 8.3 2.4 0.80 0.80 0.1 2.9 2.1 
Isoleucine - - - 3.4 2.2 0.80 0.80 1.4 3.3 4.8 
Valine - - - 5 4.6 0.51 0.49 2.3 3.5 1.7 
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4.3.2 Plasma metabolites  
4.3.2.1 Plasma BCAAs and BCKAs 
Plasma leucine (16%) and valine (15%) concentrations were higher in T2D vs 
CON, p = 0.04 and 0.03, respectively. There was also a trend for isoleucine 
concentration (p = 0.10) to be (13.6 %) higher in T2D vs CON. Plasma BCKAs 
were similar between T2D and CON. Numerical elevations in KIC and KIV 
approached statistical significance p = 0.09 and 0.13, respectively. The sum 
of the three BCKAs was also numerically but not significantly higher in T2D 
than CON (p = 0.13). Plasma BCAA and BCKA data are shown in Figure 4.1. 
 
4.3.2.2 Plasma carnitine and acylcarnitine profile  
There were no differences in plasma free carnitine or acetylcarnitine (C2) 
(Table 4.3). The sum of short-chain (but not medium- or long-chain) 
acylcarnitines were higher in T2D vs CON (p = 0.02) and this was driven by 
significant elevations in C3 (p = 0.01), iso C4 (p =0.04), C4 (p <0.001) and C5:1 
(p = 0.03) species. C4-DC, C5-OH and iso C5 tended to be higher in T2D (p = 
0.06, 0.08 and 0.10, respectively). There were no differences in any other 




4.3.3 Muscle metabolites  
4.3.3.1 Muscle BCAAs and BCKAs 
Muscle leucine (27%), isoleucine (21) and valine (26%) concentrations were 
higher in T2D than CON (p = 0.01, 0.04 and 0.01, respectively). Muscle BCKAs 
were not different between the two groups but there was a trend for lower 
levels of KIC in T2D than CON (p = 0.1). Muscle BCAA and BCKA data are 
shown in Figure 4.1. 
 
4.3.3.2 Muscle free carnitine and acylcarnitines  
Muscle free carnitine and acetylcarnitine concentrations were not different 
between groups. The sum of short-chain (but not medium- or long-chain) 
acylcarnitines were higher in T2D than CON (p = 0.02). This elevation was 
driven by increased concentrations in C3-DC (p = 0.02), C4-OH (p = 0.03), C4-
DC and C5:1 (p=0.01 for both) species. There were no differences between 
groups in the concentrations of medium- or long-chain species (Figure 4.2).  
An illustration of muscle BCAA catabolic flux is shown in Figure 4.3 and a 
diagram of the biochemical pathway of each BCAA’s catabolism indicating 
where each acylcarnitine species can be formed is shown in Figure 4.4. 
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Table 4.3 Free carnitine, acetylcarnitine and sum of short-, medium- and long-
chain acylcarnitine concentrations in human plasma and muscle samples from 
obese individuals with type 2 diabetes (T2D) and without T2D (CON) 
 CON T2D 
Plasma  n=7 n =10 
Free carnitine (µmol/L) 41.0 ± 3.9 43.0 ± 1.9 
Acetylcarnitine (C2) (µmol/L) 8.1 ± 0.5 8.5 ± 1.2 
Short-chain (C3-C5) (µmol/L) 0.7 ± 0.1 1.0 ± 0.1* 
Medium-chain (C6-C10) (µmol/L) 0.5 ± 0.1 0.5 ± 0.1 
Long-chain (C12-C18) (µmol/L) 0.6 ± 0.02 0.5 ± 0.1 
Muscle n=14 n=10 
Free carnitine (mmol/kg dry mass)  11.8 ± 0.6 13.3 ± 1.4 
Acetylcarnitine (C2) (mmol/kg dry mass) 1.5 ± 0.3 1.9 ± 0.3 
Short-chain (C3-C5) (µmol/kg dry mass) 40.9 ± 4.0 53.6 ± 4.2* 
Medium-chain (C6-C10) (µmol/kg dry mass) 10.2 ± 1.3 12.9 ± 3.8 
Long-chain (C12-C18) (µmol/kg dry mass) 54.3 ± 13.2 59.2 ± 19.9 




Figure 4.1 Muscle (A) and plasma (B) branched chain amino acid (BCAA) 
concentrations. Muscle (C) and plasma (D) branched chain keto acid (BCKA) 
concentrations. α-ketoisocaproic acid (KIC), α-keto-β-methylvaleric acid 
(KMV) and α-ketoisovaleric acid (KIV). CON, control. T2D, type 2 diabetic 
patients. Data are mean ± SEM. * p < 0.05 from CON. For muscle n = 14 and 
n = 10 for CON and T2D, respectively. For plasma n = 7 and n=10 for CON 




Figure 4.2 Acylcarnitine profile in muscle (A) and plasma (B). CON, control. 
T2D, type 2 diabetic patients. Data are mean ± SEM. * p < 0.05, *** p < 0.001 
from CON compared by t test. For muscle n = 14 and n = 10 for CON and T2D, 




Figure 4.3 Skeletal muscle quantitative concentrations of valine (A), isoleucine (B) 
and leucine (C) and subsequent metabolites formed during their respective 
catabolism to branched chain keto acids and metabolite specific acylcarnitine 
species. Muscle C2, acetylcarnitine, the final product of both leucine and isoleucine 
catabolism in muscle (D). α-ketoisocaproic acid (KIC), α-keto-β-methylvaleric acid 
(KMV) and α-ketoisovaleric acid (KIV). CON, control. T2D, type 2 diabetic patients. 
Data are mean ± SEM, n = 14 and n = 10 for CON and T2D, respectively. * P < 0.05 
CON vs T2D. A schematic of BCAA catabolism showing where each acylcarnitine 






Figure 4.4 Schematic diagram of each branched chain amino acid’s specific 
catabolic pathway. An abbreviation of quantified acylcarnitine species with the 
current analytical method is shown in bold next to the corresponding CoA ester 
from which it is formed. A question mark next to C4-OH and C4-DC denotes 
that these species can also be formed from other CoA esters from other 
metabolic pathways so may represent multiple species.  
KIV KMV KIC 
C4/Iso C4 ? Iso C5 C5 
C4-OH ? 
C3 C2 
C4 -DC ? 
C4 -DC ? 
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4.3.4 Correlations between muscle, plasma and fasting blood 
glucose 
All 3 BCAAs and C5:1 acylcarnitine were moderate-strongly correlated 
between muscle and plasma when data from both groups were pooled 
(leucine, r =0.58; p = 0.01; isoleucine, r = 0.72; p = 0.001; valine, r = 0.68; p = 
0.003; C5:1, r = 0.82; p < 0.001).  
Plasma BCAAs and C5:1, C3 and C5-OH were positively correlated with fasting 
blood glucose (Table 4.4), whereas Iso C4 showed a weaker correlation, r = 
0.5 (p = 0.07). Muscle C5:1 also correlated with fasting blood glucose (Table 
4.3), whereas the sum of intramuscular BCAA showed a weaker association r 
= 0.4 (p = 0.10) with fasting blood glucose.  
There were no correlations between any metabolite in either muscle or plasma 
and fasting serum insulin or HOMA-IR. 
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Table 4.4 Correlations between analytes and fasting blood glucose 
concentration on data pooled from both groups (n = 14 for plasma and n = 21 
for muscle). 
Analyte r p 
Plasma leucine 0.71 0.005 
Plasma isoleucine 0.75 0.002 
Plasma Valine 0.79 0.0007 
Plasma KIC 0.7 0.005 
Plasma KMC 0.69 0.006 
Plasma KIV 0.72 0.003 
Plasma C5:1 0.54 0.04 
Plasma C3 0.72 0.004 
Plasma C5-0H 0.54 0.04 
Muscle C5:1 0.45 0.04 
α-ketoisocaproic acid (KIC), α-keto-β-methylvaleric acid (KMV) and α-
ketoisovaleric acid (KIV).   
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4.4 Discussion  
The aim of this chapter was to apply and validate the analytical method that 
was developed in the previous chapter for the simultaneous quantitative and 
targeted profiling of acylcarnitines, BCAAs and BCKAs in both plasma and 
skeletal muscle. The results of this study reveal elevated plasma and muscle 
BCAA and short chain acylcarnitine in patients with T2D when compared with 
their obese non-diabetic counterparts. However, there were no differences in 
plasma and muscle BCKAs or medium- and long-chain acylcarnitines between 
groups.  
On average, the plasma BCAA concentrations were ~15 % higher in patients 
with T2D compared with normoglycaemic control subjects that were matched 
for age and BMI. These elevations are in line with several reports linking 
increased circulating BCAAs with insulin resistance across a range of 
population cohorts (Newgard et al. 2009; Fiehn et al. 2010; Alfaqih et al. 2018; 
Chen et al. 2016). The fact that plasma BCAA levels can be used to predict 
the future development of Type 2 diabetes (Wang et al. 2011) highlights the 
importance of accurate and validated measurements of these metabolites in 
at risk populations. In line with this, each plasma BCAA was strongly correlated 
with fasting blood glucose (an index of fasting insulin resistance) across all 
participants from both groups (r > 0.7 for each BCAA, Table 4.3). These 
findings extend upon much of the previous untargeted metabolomic 
approaches to provide quantitative assessment of changes in those 
metabolites. If quantitative methods could be applied to determine plasma 
BCAAs concentrations in subjects progressing from impaired fasting glucose 
to clinically diagnosed T2D then this could lead to the potential for BCAAs to 
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be used as diagnostic biomarkers in disease progression. However, large 
scale studies would be needed to validate this.  
Plasma levels of BCKAs (the reversible products of BCAA transamination) 
were not significantly different between T2D and CON but there was a trend 
for elevated KIC and KIV (arising from leucine and valine catabolism, 
respectively). BCKAs have also been associated with T2D and impaired 
fasting glucose (Menni et al. 2013). Indeed, despite the lack of significant 
elevations in the present study, each BCKA was positively correlated with 
fasting blood glucose. BCAA and BCKAs have both been independently 
associated with the development of insulin resistance and T2D suggesting that 
perturbations in BCAA catabolism are likely key sites of aberrant metabolism 
in insulin resistance states. In support of this statement elevated plasma short-
chain acylcarnitines were also observed in T2D in the current study. These 
species are produced when BCKAs are catabolised irreversibly and committed 
to their oxidative fate. Plasma C3, iso C4 and C5:1 (all BCAA derived) were all 
significantly elevated in T2D, which is consistent with previously published 
studies on obese (Newgard et al. 2009) and diabetic patients (Mihalik et al. 
2010; Bene et al. 2012) that demonstrated elevated C3 and C5 species in 
plasma, providing further evidence for increased BCAA catabolism in obese 
humans. Furthermore, in the present study as with BCAA plasma C3, C5:1 and 
C5-OH also showed positive correlations with fasting blood glucose. 
Collectively, the findings from this study provide further compelling evidence 
of the association of a BCAA-related plasma signature and insulin resistance 
in T2D.  
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The method used in the current study was also able profile a full range (short, 
medium, and long) of acylcarnitines. In contrast to previous studies (Adams et 
al. 2009; Mihalik et al. 2010), elevations of medium and long chain 
acylcarnitines (derived exclusively from fatty acid metabolism) in plasma were 
not observed in T2D patients. One possible explanation for these 
discrepancies could be related to the fact that the control group in this group 
was matched to the T2D group for age and obesity. It is possible that if a lean 
age-matched control group had also been included, then a further 
differentiation in the profile of other medium-or long-chain acylcarnitines may 
have surfaced. Indeed, the aforementioned study investigated a lean, obese 
and an obese with T2D group (Mihalik et al. 2010). In that study both the obese 
and T2D groups exhibited elevated plasma long-chain acylcarnitines 
compared to lean age matched control with no difference between the obese 
and obese T2D subjects. The accumulation of even chain acylcarnitines with 
obesity and T2D is thought to represent incomplete β-oxidation of fatty acid 
intermediates resulting in the formation of corresponding acylcarnitines and 
subsequent export into the plasma (Koves et al. 2008). Given that the control 
group in this study was also obese, the results in the current study most likely 
reflect the effect of insulin resistance per se rather than increased adiposity. It 
is important to note that not all studies profiling circulating fasting 
acylcarnitines have found differences between control and T2D subjects. On 
the contrary, reduced medium and long chain acylcarnitines have also been 
observed in T2D patients compared to healthy lean controls (Bene et al. 2012). 
This could suggest reduced rather than incomplete fatty acid oxidation in T2D. 
Clearly there are discrepancies in plasma acylcarnitines profiles across 
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different cohorts. This is important to consider as numerous studies have 
reported on elevated plasma acylcarnitines in human studies with the 
assumption that they reflect skeletal muscle metabolism (Mihalik et al. 2010). 
However, more recent studies measuring transorgan fluxes in pigs 
(Schooneman et al. 2015) and humans (G. Xu et al. 2016) have demonstrated 
that liver is the major contributor to the plasma pool under fasting conditions 
and plasma inadequately reflect skeletal muscle metabolism (Schooneman et 
al. 2014). Therefore, the inconsistent findings when measuring fasting 
circulating acylcarnitine profiles could be reconciled by accounting for liver 
metabolism. Interestingly, in the flux studies it was shown that liver and the gut 
can also produce C3 and C5 acylcarnitines and is releasing them into the blood 
during fasting states, suggesting liver may be the key site of origin of the 
elevated plasma acylcarnitines observed in the current study. 
The origin of elevated plasma BCAAs and associated short-chain 
acylcarnitines has been the subject of much research over the past decade. 
Although elevated circulating BCAA in obese subjects was observed many 
decades ago (Felig, Marliss, and Cahill 1969) it is only more recently that these 
metabolites have been implicated in the progression of insulin resistance 
(Newgard et al. 2009) Data from animal studies has led to the hypothesis that 
obesity leads to reduced adipose tissue and liver BCAA catabolism and spill 
over from the adipose tissue into the circulation (She, Van Horn, et al. 2007) 
Consequently, skeletal muscle may take up and catabolises this excess supply 
of BCAA and these BCAAs may compete with fatty acid oxidation within the 
mitochondria, the latter point being supported by the findings of elevated 
BCAA derived acylcarnitines in skeletal muscle of rodents fed a high fat diet, 
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supplemented with BCAAs (Newgard 2012). However, direct evidence for this 
in humans is lacking. One of the novel elements of the developed analytical 
method in the current work is that it enabled the quantitative assessment of 
BCAA catabolic products from the level of the BCAA to short chain 
acylcarnitines formed during catabolism (Figure 4.3). BCAA concentrations 
were several fold higher than their catabolic products, indeed valine was an 
order of magnitude higher than its short chain acylcarnitine products. 
Furthermore, leucine and isoleucine can both form Acetyl-CoA before entering 
the TCA/krebs cycle for complete oxidation. However, products of leucine and 
isoleucine catabolism were in the µmol/kg dry mass range where as 
acetylcarnitine which is formed form Acetyl-CoA was in the mmol/kg dry mass 
range (an order of magnitude higher). These quantitative assessments of 
BCAA catabolites  suggest only a minor contribution of BCAAs to energy 
provision, especially during the fasted state in humans. This is important to 
consider as Acetyl-CoA is the end product of β- oxidation of fatty acids and is 
likely the main source of Acetyl-CoA and acetylcarnitine, not BCAAs. In 
support of this, it has been demonstrated using stable isotope tracers in 
rodents that BCAAs only contribute ~ 5 % of total carbons to the TCA cycle 
and fatty acids are the major contributor of carbons to the TCA cycle in muscle 
(Neinast et al. 2020). Taken together, these findings argue against the 
suggested hypothesis that excessive BCAA catabolism in muscle and 
compete with fatty acid oxidation in muscle.  
Recent evidence has demonstrated that BCAA catabolism may be impaired in 
skeletal muscle of insulin resistant individuals (Lerin et al. 2016) and that 
skeletal muscle may directly contribute to the circulating BCAA pool following 
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the induction of insulin resistance in rats (David et al. 2019). However, data 
from our group has demonstrated that muscle BCAA derived short-chain 
acylcarnitines were more closely related with muscle insulin resistance and 
accumulated in excess (suggesting that catabolism is increased not impaired) 
during an euglycaemic-hyperinsulineamic clamp with concurrent lipid infusion, 
an experimental model of lipid-induced insulin resistance (Stephens et al. 
2014). Collectively, the human studies in the literature implicate skeletal 
muscle as an important site of origin of the elevated levels of circulating BCAA 
often observed in insulin resistant subjects and warrants further investigation. 
In agreement with the altered plasma profile of BCAA observed in patients with 
T2D in the present study, their intramuscular BCAA content was also ~25% 
higher when compared with CON. This was not accompanied by changes in 
their respective muscle BCKA content. However, there was trend for reduced 
muscle KIC in T2D. This could imply an impairment in muscle BCAA 
catabolism, leading to accumulation of BCAAs and possible export into the 
plasma and thus muscle may be a contributing pool of elevated BCAAs seen 
in plasma. In support of this notion, a strong correlation between plasma and 
skeletal muscle BCAA concentrations. However, to confirm to what extent 
muscle, or indeed any other tissue including adipose, contributes to the 
plasma pool of BCAA, studies of their arterio-venous balance across multiple 
organs are required.  
There were also significant elevations of some short-chain acylcarnitines 
(including C3-DC, C4-OH, C4-DC and C5:1) were also observed in skeletal 
muscle from individuals withT2D. C5:1 is formed from leucine metabolism, 
whereas C4-DC can be formed from both valine and isoleucine catabolism and 
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could possibly represent an inability to utilise succinate. It should also be noted 
that C4-OH (hydroxybutyryl/hydroxyisobutyryl) can be derived from either 
ketone (hydroxybutyryl) or valine catabolism (hydroxyisobutyryl). The current 
analytical method did not allow for sufficient discrimination between the two 
isomers. Given that in the current study other species (C4-DC) relating to 
valine catabolism were also elevated, a possible contribution of valine 
catabolism to the production of C4-OH species without chromatographic 
separation of the isomers cannot be ruled out. Interestingly, elevated 
hydroxyisobutyrate (which is formed during valine catabolism in the step after 
hydroxyisobutyryl-CoA and the production of C4-OH, see Figure 4.4) has been 
observed in diabetic muscle supporting the notion that BCAA catabolism may 
be elevated in diabetic skeletal muscle (Jang et al. 2016). Furthermore, 
hydroxyisobutyrate may also leave the muscle cell and drive vascular fatty acid 
transport into the muscle cell and promote lipid accumulation and 
subsequently insulin resistance. Taken together, these data suggest a degree 
of excess BCAA catabolism as a result of obesity related insulin resistance. 
The fact that intramuscular BCAA content remained elevated despite 
concomitant increases in their catabolic products could suggest that the 
accumulation of BCAA may be in excess of their catabolism and possibly 
through a feedback mechanism may be limiting further catabolism. From the 
available human data, it could be speculated that insulin resistance leading to 
excessive proteolysis and BCAA catabolism in muscle leading to the 
accumulation of short chain acylcarnitines in muscle, given that they likely 
contribute only minor amounts to muscle energy provision, overtime they may 
spill over into the circulation, in support of this muscle and plasma C5:1 had 
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the strongest of all correlations measured in this study and both muscle and 
plasma C5:1 correlated with fasting blood glucose. Despite studies measuring 
flux of acylcarnitines in pigs (Schooneman et al. 2015) and humans (G. Xu et 
al. 2016) have shown liver is the main contributor to fasting acylcarnitine 
profiles and muscle may be taking up these species, it should be noted that 
no studies have assessed how BCAA related metabolites or indeed medium 
and short chain acylcarnitines fluxes are altered in insulin resistant states in 
humans. Future studies should focus of measuring metabolite flux as well as 
metabolite concentrations. 
The origin of the increased intramuscular BCAAs remains uncertain. Insulin 
resistance may accelerate muscle protein breakdown and hence contribute to 
the free amino acid pool of BCAA. Indeed, post absorptive skeletal muscle 
breakdown rates are greater in patients with T2D but this was matched by 
increased synthesis (Bell et al. 2006). Therefore, the elevated muscle BCAA 
measured from a single biopsy giving a ‘snapshot’ of dynamic processes in 
could reflect greater muscle turnover in T2D. Free intramuscular amino acids 
were elevated following limb immobilisation (Glover et al. 2008) and it is well 
established that even short periods of muscle disuse can lead to the rapid 
development of muscle insulin resistance (Dirks et al. 2019). In addition, recent 
work has demonstrated leucine release from muscle following 1 week of 
muscle disuse (Wall et al. 2020). Given that physical inactivity is a major 
underlying factor in the development of insulin resistance and perturbed lipid 
metabolism (Chee et al. 2016), it is conceivable that alterations in muscle 
protein metabolism may contribute to the elevated plasma BCAAs seen in 
obese and insulin resistance individuals. Further investigations into the activity 
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of intracellular enzymes are required to elucidate the possible mechanisms. 
Recent work in animals has demonstrated that the activity of the reversible 
enzymatic reaction catalysed by the branched chain amino transferase 
(BCAT), which converts BCAA to their respective BCKA, is reduced with 
insulin resistance (David et al. 2019), which also increased phosphorylation 
(and hence inactivation) of the irreversible enzymatic reaction catalysed by the 
branched chain keto dehydrogenase complex (BCKDH), which converts 
BCKA into intermediates and ultimately the formation of short-chain 
acylcarnitines. How the state and expression of this enzyme complex differs 
in human skeletal muscle between insulin sensitive and insulin resistant 
individuals and in response to insulin stimulation remains to be determined. 
A limitation of this work and others that have characterised fasting 
concentrations of metabolites, is that it is difficult to assess if they simply reflect 
an insulin resistant state or were causative of insulin resistance in some way. 
In this cross-sectional analysis, it is only possible to conclude that T2D is 
associated with the elevated levels of metabolites observed in plasma and 
muscle. Whether these metabolites are causative of insulin resistance can 
only be established by measuring tissue concentrations of such metabolites in 
the presence of the insulin stimulated state. Currently, no study has 
characterised how theses metabolites change from the fasted to the insulin 
stimulated state in human skeletal muscle. 
4.5 Conclusions  
In conclusion the results of this work demonstrate significant perturbations in 
BCAA metabolism in patients with T2D which is likely to be associated with 
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insulin resistance per se rather than adiposity. These data are quantitative 
assessments of metabolites in both muscle and plasma and extend upon 
previous untargeted and/or semi quantitative published literature by 
suggesting that BCAAs and products of their catabolism are reflective of each 
other in plasma and muscle. This warrants further investigation into the role 
BCAAs may be playing in perturbed metabolism and the development of 
insulin resistance and T2D and their use as circulating biomarkers of the 
underlying processes. 
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5 Chapter 5 The effect of insulin on skeletal 
muscle branched chain amino acid and 
acylcarnitine profiles. A comparison of age 
and obesity.
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5.1 Introduction  
Elevations in plasma branched chain amino acids (BCAAs) in obesity and type 
2 diabetes (T2D) are well established in numerous experimental models 
(Siddik and Shin 2019). Despite this, the underlying mechanism(s), nor the 
organs(s) responsible for their elevated levels in plasma is currently unknown. 
Recent reports in humans and rodents have demonstrated that obesity and 
insulin resistance may directly perturb skeletal muscle BCAA metabolism 
(Lerin et al. 2016; David et al. 2019) and possibly even independent of 
changes in adipose and liver BCAA catabolic capacity (David et al. 2019). 
Thus, alterations in skeletal muscle BCAA metabolism, independent of 
concurrent aberrations in other tissues, may contribute to the elevated 
circulating BCAA observed in obese and insulin resistance states. In support 
of this notion, in the previous chapter (chapter 4) elevated plasma and muscle 
BCAAs were observed in patients with (T2D). Therefore, skeletal muscle may 
be major contributor to elevated BCAA concentrations seen in insulin resistant 
individuals. 
In contrast to the lipotoxicity model which suggests that accumulation of 
intermediates such diacylglycerides and ceramides arising from an imbalance 
between lipid delivery and reduced oxidation in muscle may directly impair 
insulin signalling (Samuel, Petersen, and Shulman 2010), other reports have 
suggested that excessive mitochondrial entry of lipids leading to the 
accumulation of acylcarnitines may be causative of insulin resistance (Koves 
et al. 2008). The majority of the support for the latter hypothesis has come 
from either rodent or in vitro work (Koves et al. 2008; Aguer et al. 2015) or 
from observations of elevated plasma acylcarnitine concentrations in humans 
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(Mihalik et al. 2010; Adams et al. 2009). Recent work from this group has 
shown that lipid infusion during a hyperinsulinaemic euglycaemic clamp, short 
chain acylcarnitines arising from BCAA catabolism were more closely 
associated with lipid induced insulin resistance than lipid derived medium or 
long chain acylcarnitines (Stephens et al. 2014). Based on these findings, it is 
possible that in pathophysiological states where muscle lipid content is 
elevated i.e obesity then BCAA catabolism may be increased in conditions 
where it would normally be supressed, such as during insulin infusion 
(Stephens et al. 2014). 
Ageing per se is also associated with insulin resistance and reduced glucose 
tolerance (Luzi, Castellino, and DeFronzo 1996). Insulin also exerts an 
inhibitory effect on protein breakdown and elderly individuals have been 
shown to have a blunted inhibition of muscle proteolysis in response to insulin 
(Wilkes et al. 2009). It is well established that ageing is also associated with a 
blunted anabolic response to amino acids (Cuthbertson et al. 2005; Wall et al. 
2015). Thus, with ageing per se there could be an increase in free amino acids 
from muscle breakdown and inability to incorporate readily available amino 
acids into muscle protein. Whether these amino acids contribute to excessive 
catabolism in muscle and how, if at all, their availability is associated with 
muscle insulin resistance is unknown. In chapter 3, a quantitative method to 
measure BCAA, BCKA and a range of acylcarnitines was developed. This 
method combined with measurements of BCKDH protein expression would 
allow the determination of BCAA catabolic flux and how factors such as age 
and increased adiposity may impact BCAA metabolism in skeletal muscle. 
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Despite the emerging lines of evidence implicating skeletal muscle as a major 
contributor to the plasma metabolite signature observed in insulin resistant 
individuals (i.e., elevated BCAA and a range of acylcarnitines), quantitative 
assessment skeletal muscle content of all these metabolites in obese, insulin 
resistant humans has not performed from a single analysis. Furthermore, how 
these metabolite concentrations change in the insulin stimulated state has not 
been investigated previously. Therefore, to extend beyond much of the 
published reports that have measured plasma profiles and made inferences 
about skeletal muscle (Mihalik et al. 2010) or the reports that have been limited 
to a single static measure in the fasted state and subsequently hypothesised 
that BCAA and acylcarnitines are causative of insulin resistance, 
measurement of these metabolites in the face of insulin are required. 
5.1.1 Aims  
The aim of this chapter was to investigate the effect of age and adiposity with 
a specific focus on intramuscular BCAA, BCKA and acylcarnitine 
concentrations and their respective responses to insulin to determine if any 
differences may corroborate with reports of perturbation in their metabolism 
seen in obese and insulin resistant states. 
A second aim was to provide further validation of the analytical method 
developed in chapter 3 to demonstrate its ability to detect expected 




5.2.1 Participant characteristics  
The samples used in the current study were part of a larger study and some 
of the data for the YL group has been published previously (Chee et al. 2016). 
The aim of that study was to assess the effect of ageing and adiposity on 
skeletal muscle lipid metabolism and insulin sensitivity as opposed to changes 
in BCAA metabolism.  
Samples from seven young lean (YL) and nine old lean (OL) and nine old 
obese (OO) healthy, recreationally active male volunteers were used in this 
cross-sectional study, which was approved by the University of Nottingham’s 
medical school ethics committee in accordance with the Declaration of Helsinki 
(medical ethics approval number E13102011BMS). All participants underwent 
medical screening, blood testing and gave written informed consent to 
participate in the study and they were made aware that they were free to 
withdraw at any point. Participants were excluded if they smoked, had diabetes 
or other metabolic disorders, cardiovascular disease, blood disorders or 
abnormal blood tests. Participant characteristics are presented in Table 5.1. 
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Table 5.1 Participant characteristics of young lean (YL), old lean (OL) and old 
obese (OO) male volunteers 
 YL OL OO 
n 7 9 9 
Age (years) 21.5 ± 1.0 70.7 ± 0.5 *** 68.8 ± 0.6 # 
Body mass (kg) 76.5 ± 4.5 70.7 ± 3.0 86.9 ± 2.2 ### 
BMI (kg/m2) 23.2 ± 1.0 23.4 ± 2.1 29.1 ± 2.1 ### 
Lean body mass (kg) 59.3 ± 3.8 51.6 ± 1.4* 55.3 ± 2.0 
Leg lean mass (kg) 21.8 ± 1.7 17.2 ± 0.8* 19 ± 0.7 
Fat mass (kg) 12.0 ± 1.8 14.5 ± 2.0 26.2 ± 1.1 ### 
FMI (kg/m2) 3.7 ± 0.6 4.8 ± 0.6 8.8 ± 0.5 ### 
Leg fat mass (kg) 5.4 ± 0.9 4.9 ± 0.5 7.4 ± 0.6 ## 
Trunk fat mass (kg) 5.6 ± 0.8 8.0 ± 1.4 16.6 ± 0.6 ### 
Fasting blood 
glucose (mmol/L) 
4.6 ± 0.1 4.6 ± 0.1 5.1 ± 0.2 
GDR 
(µmol/kg lean body 
mass/min) 
59.8 ± 3.6 43.6 ± 2.1** 27.7 ± 2.5 ### 
GDR = Glucose Disposal Rate during the euglycaemic-hyperinsulinaemic 
clamp. BMI= Body mass index. FMI = fat mass index. Data are mean ± SEM 
* p < 0.05, ** p < 0.01 and *** p < 0.001, OL compared to YL. # p < 0.05, ## p 




5.2.2 Experimental protocol  
Participants arrived at the laboratory at 0800 after an overnight fast. A DEXA 
scan (Lunar Prodigy,GE Healthcare, US) was performed to assess body 
composition (as described in chapter 2, section 2.2.4). They then rested semi 
supine on a bed while cannulae were inserted retrograde into a superficial vein 
on the back of the hand for arterialised blood sampling and forearm veins for 
insulin and glucose infusions. A 3-hour hyperinsulinaemic euglycaemic clamp 
at 60 mU m-2 min-1 was carried out to assess insulin sensitivity (protocol 
described in detail in chapter 2 section 2.2.1).  
5.2.3 Sample collection  
Skeletal muscle samples were obtained from the vastus lateralis using the 
Bergstrom needle biopsy technique (Bergström 1975) before and immediately 
after each clamp and immediately frozen in liquid nitrogen-cooled 2-
methylbutane and subsequently stored in liquid nitrogen until analysis. 
Unfortunately, blood samples were not available for the determination of 
plasma metabolites and therefore analysis was carried out in muscle only. 
5.2.4 BCAA, BCKA and acylcarnitine quantification  
BCAAs, BCKAs, free carnitine and range of acylcarnitines were extracted from 
freeze dried muscle tissue samples as described in chapter 3. Samples, 
calibrants and QCs were processed and analysed by LC-MS/MS with the 
same analytical parameters as described in chapter 4. Reproducibility of 
analytical run was assessed by 7 repeat injections of the same pooled QC 
same and extraction repeatability was assessed by 9 separate injections of 9 
aliquots of the same muscle biopsy sample. Raw data collected from LC-
 175 
MS/MS analysis was processed on Thermo Xcalibur Processing Quan 
Browser (version 4.1) software for analyte quantification as described in 
chapter 3.  
5.2.5 Western blotting  
Muscle protein was extracted from one wet portion of frozen skeletal muscle 
using the mRNA extraction described in Chapter 2 (section 2.4.3) Following 
protein quantification using the Pierce bicinchoninic acid (PCA) assay, 30 µg 
of protein was loaded onto fixed 10% acrylamide gel and separated using 
electrophoresis. Proteins were transferred overnight to a polyvinylidene 
difluoride membrane. Protein expression was assessed using rabbit polyclonal 
antibodies for total BCKDH (E1α polypeptide) (Cat. No. # ab138460) and 
phospho S293 BCKDH (Cat. No. # ab200577), purchased from Abcam (Abcam, 
Cambridge, UK). Membranes were incubated overnight at 4oC with primary 
antibodies diluted 1:2,500 in 5% BSA/TBS-T (w/v). Specific signal was 
detected with a horseradish peroxidase-conjugated secondary antibody 
(1:5,000) swine anti-rabbit horse- radish peroxidase diluted in 5% BSA/TBS-
T. Following addition of ECL Prime, protein expression was then visualised in 
a dark room using X-ray film and normalized to -actin (1:5,000, Cat. No. 
#A2066; Sigma, Dorset, UK). 
5.2.6 Statistical analysis  
The aim of this chapter was to independently compare the effect of age and 
obesity per se on muscle BCAA and acylcarnitine metabolism. Therefore, 
differences in group participant characterises were compared with separate 
students unpaired t test (YL vs OL and OL vs OO). The within and between 
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group differences in the fasted state and in response to the insulin clamp were 
determined using two separate, two-way mixed ANOVAs (group x pre/post 
insulin). This design does not permit the direct comparison of YL with the OO 
group. When a significant main effect was observed, a Sidak post hoc test was 
performed to identify individual differences. Statistical significance was set at 
p < 0.05, and all values are presented as means ± SEM. 
When referring to chain lengths, AC were grouped as short (C3-C5), medium 
(C6-C10) and long-chain (C12-C20). Summed BCAA refers to the summation of 
leucine, isoleucine and valine concentrations. Summed BCKA refers to the 
summation of α-ketoisocaproic (KIC), α-keto-β-methylvaleric acid (KMV) and 
α-ketoisovaleric acid (KIV) concentrations. 
. 
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5.3 Results  
5.3.1 Participants  
YL and OL were matched for BMI and FMI but OL had lower total and leg lean 
mass and a lower glucose disposal rate during the 3-hour clamp (p<0.05, see 
Table 5.1 for level of significance). 
OO had higher BMI, FMI, total body, leg, trunk and total fat mass compared to 
OL. Glucose disposal during the 3-hour clamp was also markedly reduced in 
OO compared to OL (p<0.05, see Table 5.1 for levels of significance). 
5.3.2 Analytical method parameters  
For all analyte standard curves, the R2 was above 0.99. The CV of the pooled 
QC ranged from 0.5 – 7.3 % for all metabolites (n = 7). The CV of the extraction 
repeatability QC was below 12 % for all analytes except for KIV which was 
17.7 % (n = 9). The analytical method met all the quality control criteria 
required for accurate quantification of metabolites. 
5.3.3 Effect of age and insulin (YL vs OL groups) 
BCAA and BCKAs 
ANOVA revealed significant ageing (p = 0.04), insulin (p < 0.001) and 
interaction (p = 0.05) effects on muscle total BCCA content. Fasting muscle 
total BCAA content was 35% lower in OL vs YL (p = 0.005) and insulin resulted 
in a decrease in total BCAA content by 54 % in YL and 43 % in OL (p < 0.001) 
(Figure 5.1D). Similarly, there were significant ageing (p = 0.02), insulin (p < 
0.001) and their interaction (p = 0.04) effects on muscle leucine. Muscle 
leucine content (Figure 5.1A) followed a similar pattern and was 37 % lower in 
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OL vs YL in the fasted state (p = 0.003) and was reduced 65 and 58 % 
following insulin in YL and OL, respectively (p < 0.001). Fasting muscle 
isoleucine content was 36% lower in OL vs YL (group effect p = 0.04) and 
declined (72%) in both groups following insulin infusion (insulin effect p < 
0.001) (Figure 5.1B). There was a main effect of age (p = 0.04) on muscle 
valine, which was 33 % lower in OL vs YL in fasted state (p = 0.008) there was 
also a main effect of insulin (p < 0.001), however post hoc analysis revealed 
that the decline in valine content was only present in YL (p < 0.001). Total 
valine reduced by 42 % in YL but only 25 % in OL (interaction effect p = 0.06) 
(Figure 5.1C).There were no differences between YL and OL in the fasting 
state muscle content of any of the three BCKAs or their sum (Figure 5.1E-H). 
Insulin infusion resulted in the reduction in the content of KIC and KMV in YL 
only (insulin effect for both metabolites p = 0.03) but there was no effect of 
insulin on KIV content in either group.  
Acylcarnitine content  
There were no significant differences between groups for any single BCAA 
derived acylcarnitines species. However, ANOVA revealed a main effect of 
interaction (p = 0.01) and insulin (p = 0.002) on the sum of short chain 
acylcarnitines derived from BCAA metabolism was higher in the fasted state 
in YL vs OL (p = 0.01) and insulin suppressed their abundance in YL (p = 
0.001) only (Figure 5.2A) There were no significant differences in fasting 
medium chain acylcarnitines (Figure 5.2B) and insulin reduced their 
concentration in both groups (insulin effect p < 0.001). There was trend for 
fasting long chain acylcarnitines (interaction effect p = 0.08) to be higher in YL 
compared to OL (Figure 5.2C), and insulin suppressed long chain acylcarnitine 
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content in YL only (insulin effect p = 0.002). There a main effect of age on 
muscle acetylcarnitine (age effect p = 0.01) which was higher in YL than OL in 
the fasted state (p = 0.03) and was reduced following insulin stimulation in the 
YL group only (insulin effect p = 0.003). (Figure 5.3A). A full profile of muscle 
acylcarnitine concentrations in the fasted and insulin stimulated state can be 
seen in Appendix C 
5.3.4 Effect of increased adiposity (OL vs OO groups) 
BCAAs and BCKAs 
There was a main of adiposity (p = 0.02) and insulin (p < 0.001) on muscle 
isoleucine content. Fasting muscle isoleucine content (Figure 5.1B) was 17 % 
higher in OO vs OL (p = 0.02) and declined (72 %) in both groups (p < 0.001). 
ANOVA revealed a strong tend for a main effect of adiposity and an adiposity 
and insulin interaction on muscle leucine (p = 0.06 for both). Fasting muscle 
leucine content was 19 % higher in OO vs OL (Figure 5.1A) and declined 57 
and 66 % in OL and OO, respectively with insulin infusion (p < 0.01). There 
was a strong trend for an adiposity and insulin interaction effect on muscle 
valine. Fasting valine was also 19% higher in OO vs OL and declined 45 % in 
OO (p < 0.001) but only 24 % in OL. (Figure 5.1C). Fasting muscle total BCAA 
content was 19% higher in OO vs OL (interaction effect p= 0.06) and declined 
56 and 43 % in OO and OL, respectively (p<0.001). There were no differences 
between OL and OO in the fasting muscle content of any of the three BCKAs 
or their sum (Figure 5.1E-H). Insulin reduced the content of KIC and KMV in 
OO (P = 0.01) but not in OL and there was a significant interaction effect for 
KIV (p = 0.03) which revealed a significant reduction in OO following insulin (p 
=0.04). 
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Acylcarnitine content  
ANOVA revealed a significant interaction effect of adiposity and insulin on total 
short chain acylcarnitines derived from BCAA metabolism (p = 0.01). Fasting 
muscle content was higher in OO than OL (p = 0.006; Figure 5.2A) and insulin 
resulted in their suppression in OO only (p = 0.002). Specifically, muscle 
succinyl/methylmanoylcarnitine (C4-DC) (Figure 5.3B) was also elevated in the 
fasted state in OO when compared to OL (p = 0.004) and was suppressed in 
OO only with insulin infusion (p= 0.003). The numerical elevations in total 
medium and long chain acylcarnitines (Figure 5.2B-C) in OO when compared 
to OL did not reach statistical significance (group effect p = 0.05 and p = 0.09, 
respectively). Insulin infusion suppressed both medium and long chain 
acylcarnitines in OO (insulin effect p = 0.003 and p = 0.03, respectively). 
Muscle acetylcarnitine was not different between the two groups in the fasted 




Figure 5.1 5.2 Muscle leucine (A), isoleucine (B) valine (C) and total branched chain 
amino acid (BCAA) content (D) in the fasted state and post insulin infusion. Muscle 
KIC (E), KMV (F), KIV (G) and total branched chain keto acid (BCKA) content (H) in 
the fasted state and post insulin infusion. * p < 0.05, OL significantly different from 
YL. # p < 0.05 OO significantly different from OL; ^ P < 0.05, ^^ p < 0.01 and ^^^ P < 
0.001 significantly different from the corresponding fasting value. Significance values 
on figures are of post hoc analysis of significant main effects of age, adiposity, insulin 
and interactions (see text). Data are mean ± SEM; n = 7 YL, n = 9 OL and n = 9 OO.  
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Figure 5.2 Muscle total short (C3-C5) chain (A), medium (C6-C10) chain (B) and long 
(C12-C20) chain (C) acylcarnitine content in YL, OL and OO subjects in the fasted state 
and post insulin infusion. * p < 0.05 OL different from YL. ## OO different from OL. ^ 
P < 0.05, ^^ p < 0.01 and ^^^ p < 0.001 significantly different from the corresponding 
fasting value. Significance values on figures are of post hoc analysis of significant 
main effects of age, adiposity, insulin and interactions (see text). Data are mean ± 
SEM; n = 7 YL, n = 9 OL and n = 9 OO.  
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Figure 5.3 Muscle acetylcarnitine (A) and the total of both succinyl and 
methylmanoylcarnitine, C4-DC (B) in YL, OL and OO in the fasted state and 
post insulin infusion. * p < 0.05, OL significantly different from YL. # p < 0.05 
OO significantly different from OL ^ P < 0.05, and ^^ p < 0.01 significantly 
different from the corresponding fasting value. Significance values on figures 
are of post hoc analysis of significant main effects of age, adiposity, insulin 
and interactions (see text). Data are mean ± SEM; n = 7 YL, n = 9 OL and n 
= 9 OO.  
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5.3.5 Muscle BCKDH phosphorylation status 
There were no differences between YL and OL or OL and OO in the 
phosphorylation of the E1a component of the BCKDH complex in the fasted 
state (Figure 5.4). Furthermore, there was no effect of the insulin clamp on the 
degree of phosphorylation in any of the groups. 
 
Figure 5.4.Muscle pS293 phosphorylated E1α component of the branched 
chain keto acid dehydrogenase complex in the fasted state and post insulin 
infusion. Data are mean ± SEM; n = 5 YL, n = 6 OL and n = 8.  
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5.4 Discussion  
The main findings from this chapter were that ageing is associated with a 
reduction in fasting intramuscular BCAA content which was observed when 
comparing young and old lean (albeit slightly more insulin resistant) subjects. 
Interestingly, the old lean group appeared to exhibit an attenuated suppression 
of BCAA catabolism in the insulin stimulated state. Moreover, when the old 
lean group was compared to an age matched overweight and more insulin 
resistant group, fasting BCAA content was elevated in skeletal muscle of the 
latter group. Thus, insulin resistance alone cannot explain the decrease in 
content observed between the old lean group. However, in the acutely insulin 
stimulated state the overweight group suppressed BCAA, BCKA and short 
chain acylcarnitines (markers of BCAA catabolism) to a greater extent than the 
old lean group. These results appear to dissociate age and adiposity-induced 
insulin resistance from perturbed/excessive muscle BCAA catabolism. 
The total muscle BCAA content was approximately 30% lower in older lean 
subjects compared to their younger BMI matched counterparts. Although total 
and leg lean mass was also lower in the former group, the BCAA content was 
expressed per kg of muscle tissue. Therefore, the differences observed are 
likely independent of differences of body composition and reflective of some 
level of age-related alterations in muscle protein metabolism that may cause 
a reduction in the muscle free amino acid pool. Assuming that were no 
differences in muscle uptake and release of BCAA in the fasted state and 
given that short chain acylcarnitines (markers of BCAA oxidation) were also 
significantly lower in the old lean group, the differences could be explained by 
altered post-absorptive muscle protein turnover rates. Post absorptive leg 
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protein breakdown rates do not appear to be different between young and 
older subjects (Wilkes et al. 2009). However, a cross-sectional, retrospective 
study comparing in vivo post-absorptive muscle protein synthesis (MPS) rates 
determined with stable isotope methodologies between 34 healthy young (22 
± 1 y) and 72 older (75 ± 1 y) men (the largest comparison to date) has shown 
numerically (but not statistically) higher values in the elderly in fasting muscle 
protein synthesis rates at a more advanced age (Wall et al. 2015). This may 
in part, explain the reduced fasting muscle BCAA content in the older subjects 
compared to their younger counterparts observed in the current study. It has 
not/cannot be determined to what extent muscle free BCAA content relates to 
muscle protein synthesis or breakdown and inferences about dynamic 
processes from static measures should be made with caution. However, work 
from this group using the same analytical method has demonstrated that 
increased incorporation of dietary protein into skeletal muscle measured using 
a stable isotope tracer approach was accompanied by lower muscle BCAA 
content (possibly due to BCAAs being driven towards protein synthesis) 
(Tsintzas et al. 2020). This suggests an inverse relationship between muscle 
free BCAA content and protein synthesis in the postprandial state, although 
the nature of this relationship in the post-absorptive state is not currently 
known. 
With insulin infusion, in the absence of any concurrent amino acid infusion to 
maintain euaminoacidaemia (as is the case in the current study), there is a 
resultant hypoaminocidaemia due to an insulin mediated reduction in 
proteolysis as well as an increased amino acid cellular uptake (Castellino et 
al. 1987). Consequently, the lower availability of amino acids in both the 
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circulation leads to a decline in muscle protein synthesis due to a reduction in 
substrate availability. However, because the insulin-induced decline in protein 
degradation exceeds the decrease in protein synthesis, a net protein anabolic 
effect ensues. In the current study, where no exogenous amino acids were 
administered, it is likely that the reduction in muscle BCAA content in YL can 
be attributed mainly to an insulin-stimulated reduction in muscle proteolysis. 
In the YL group BCKAs (a measure of BCAA transamination) and short chain 
acylcarnitines (a measure of their oxidation) were all suppressed during the 
insulin clamp. Indeed, previous reports demonstrating reduced leucine 
turnover, oxidation and endogenous appearance in the circulation resulting in 
a less negative net whole body (Castellino et al. 1987; Luzi, Castellino, and 
DeFronzo 1996) and leg (Wilkes et al. 2009) leucine balance in healthy young 
individuals during an insulin infusion.  
In response to insulin infusion in OL however, BCAA content was decreased 
in both groups to a similar concentration as YL but the magnitude of the decline 
was lower in older than younger subjects (evidence by the significant 
interactions effects). Of the three BCAAs, valine did not (significantly) 
decrease in OL and the reduction of the BCKAs KIC and KMV were also not 
observed in OL when compared to YL. This may suggest that valine 
metabolism should be considered separately and studies using phenylalanine 
and leucine as an index of total muscle amino acid metabolism may not 
accurately reflect valine metabolism. In addition, short chain acylcarnitines, 
specific products of BCAA oxidation did not decrease following insulin infusion 
in OL suggesting some level of ongoing BCAA oxidation in OL in the insulin-
stimulated state. The lack of plasma samples and arteriovenous balance 
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measurements in this analysis precluded the ability to assess the net efflux of 
BCKAs or indeed BCAAs into the circulation. Nevertheless, these results 
highlight a differential fate of intramuscular BCAAs with age in response to 
insulin. These findings are in agreement with a previous study that 
demonstrated that older individuals matched for body composition and fasting 
glucose and insulin concentrations still exhibited an attenuated inhibition of 
proteolysis in response to insulin (Wilkes et al. 2009). Thus, ageing per se 
appears to be characterised by both lower muscle protein accretion in the 
postprandial state (Cuthbertson et al. 2005; Wall et al. 2015) and impaired 
ability to supress proteolysis in the presence of insulin. These findings may in 
part explain the reduction in lean body and leg mass in the OL group. Whilst 
the reduced GDR rate during the 3 hour glucose clamp in OL vs YL confirms 
the previously reported age associated decline in whole body glucose disposal 
compared to young individuals (Defronzo 1979; Boirie et al. 2001). It should 
be noted that age per se does not necessarily cause insulin resistance (Chee 
et al. 2016). Much of the ‘age’ related reduction in muscle metabolic quality, 
that is, fatty acid oxidation and glucose disposal may be a result of inactivity 
per se (Chee et al. 2016). Unfortunately, data regarding habitual physical 
activity was not available for the subjects used in the current study. However, 
future work should aim to replicate the findings of the current study in physical 
activity matched cohorts. 
The finding that adiposity and increased insulin resistance also increased 
fasting intramuscular BCAA accumulation and some of their catabolites (short 
chain acylcarnitines) in older individuals when compared to age matched lean 
subjects could be a result of several factors. Given that the accumulation was 
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evident in the fasted state suggests that these elevations are likely to be a 
consequence of factors other than simply differences in dietary protein and 
energy intake. Previous studies have reported on whole body and skeletal 
muscle protein turnover in obese subjects. Lower muscle postabsorptive 
protein synthetic rates have been observed by some (Guillet et al. 2009) but 
not others (Murton et al. 2015; Beals et al. 2016) when comparing age 
matched lean and obese men. However, the same reports have all shown a 
reduced synthetic response to dietary amino acids. Therefore, the elevated 
BCAA muscle content could represent a chronic, lower postabsorptive 
incorporation of amino acids into muscle protein (and potential increases in 
protein breakdown) in the background of worsened insulin resistance resulting 
in a greater amount of intramuscular free amino acid content. 
Interestingly, muscle C4-DC acylcarnitine was elevated in the OO group when 
compared to OL. With the current analytical method used, this species 
represents the sum of both methylmanoylcarnitine and succinylcarnitine. The 
conversion of methylmanoyl-CoA to succinyl-CoA via the action of 
methylmanoyl-CoA mutase (mut) is the route by which isoleucine and valine 
catabolic products enter the TCA cycle or complex 2 of the electron transport 
chain. A recent report found reduced mRNA levels of mut and other BCAA 
catabolic enzymes in skeletal muscle of overweight insulin resistant individuals 
with T2D along with lower relative (not quantitative) expression of BCKAs and 
some TCA intermediates and accumulation of medium chain acylcarnitines 
(Lerin et al. 2016). This led to the hypothesis that reduced BCAA catabolic flux 
with insulin resistance resulted in reduced anaplerosis of TCA intermediates 
from BCAAs and consequential accumulation of medium and long chain 
 190 
acylcarnitines, as a result of the inability to completely oxidise fatty acids, 
which may in turn impair insulin signalling (Lerin et al. 2016). In addition, 
denervation of rat hindlimb (a rodent model of inactivity) also resulted in 
reduced mRNA expression of muscle BCAA catabolic enzymes. Furthermore, 
rodents with a heterogenous mut knockout had increased body weight 
following 20 weeks of high fat and developed insulin resistance. However, 
there several limitations to consider with these findings. Firstly, the data was 
based on untargeted metabolomics with no quantitative assessment of 
metabolites and mRNA data does not always reflect actual protein content. 
Secondly, the knockout model resulted in a whole effect and was not specific 
to muscle. Given that quantitative flux data in rodents (Neinast et al. 2020) and 
humans (Tan et al. 2020) has shown that obesity and insulin resistance is a 
state of accelerated BCAA catabolism challenges the aforementioned study. 
In the previous chapter, this species was also elevated in muscle of obese 
T2D patients (along with other BCAA derived acylcarnitines, assessed 
quantitatively) and was also shown to be elevated in the plasma of obese 
diabetic subjects (Mihalik et al. 2010). It is more likely that there is a degree of 
increased BCAA catabolism with insulin resistance and adiposity. 
It should be noted that succinyl-CoA itself is a TCA intermediate and previous 
reports have shown a reduced oxidative capacity in muscle of obese 
individuals and T2D patients (Colberg et al. 1995). The enzyme activity of 
succinate dehydrogenase was also significantly reduced in all muscle fibre 
types of those populations compared to lean controls. Therefore, the 
accumulation of succinylcarnitine could be reflective of reduced oxidative 
capacity of muscle in OO. 
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It could be speculated that with both obesity and insulin resistance where both 
reduced postprandial incorporation of meal derived amino acids into muscle 
protein (Beals et al. 2016) may lead to the accumulation of intramuscular 
BCAAs and related metabolites. This effect may be further compounded by 
reduced physical activity (Glover et al. 2008; Wall et al. 2020). Consequently, 
BCAA and related metabolites may spill over from muscle into the circulation. 
If obesity induced insulin resistance progresses to clinically overt T2D this may 
further exacerbate BCAA metabolism/catabolism through increased 
proteolysis. Given that both YL and OO had elevated short chain acylcarnitines 
compared to OL but only OO showed an accumulation of C4-DC, a distal step 
in BCAA catabolism, supports the notion that obesity and insulin resistance 
could be associated with a degree of mismatch between BCAA catabolism 
and utilisation within the TCA cycle. The current work is the first study to 
quantitively assess products of BCAA catabolism in human muscle in 
overweight/obese individuals. The application of the current analytical method 
in combination with stable isotope tracers to quantitatively determine fluxes 
through the BCAA and fatty acid metabolism are required to determine the 
impact the two substrates may have on each other. 
In response to insulin infusion, muscle BCAA content was reduced in both OL 
and OO. Furthermore, there was also a reduction in some BCKAs (notably 
KIC and KMV) and BCAA derived short chain acylcarnitines in (displaying the 
same responses to insulin as the YL, despite lower insulin-stimulated glucose 
disposal) following insulin infusion in OO suggesting a decrease in catabolic 
flux in line with the decline in BCAA content. The fact that insulin failed to 
suppress those BCKAs and short chain acylcarnitines in the OL group could 
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suggest that the OO group was paradoxically more sensitive to the insulin-
induced suppression of muscle proteolysis and BCAA oxidative flux. A recent 
report investigating specifically leg muscle amino acid metabolism 
demonstrated that leg protein breakdown was not different between obese and 
lean older men in the postabsorptive state. There was however a blunted 
synthetic response to insulin and amino acids but importantly a concurrent 
inhibition of leg protein breakdown resulted in an equal net protein balance 
when compared to lean controls (Murton et al. 2015). This is in contrast to 
previous reports showing that in obese individuals there was an impairment in 
the ability of insulin to supress whole body proteolysis as evidenced by a lower 
BCAA net balance compared to lean controls (Luzi, Castellino, and DeFronzo 
1996; Chevalier et al. 2005; Guillet et al. 2009). The lack of muscle specific 
data in obese individuals make the findings of this study difficult to determine 
why the OO reduced markers of catabolism in response to insulin yet an aged 
matched lean group did not. 
Upon insulin infusion medium and long-chain acylcarnitines were suppressed 
in OO group to similar values of the OL group despite the markedly reduced 
whole body glucose disposal in the former group. A study from this group 
demonstrated that during lipid infusion in combination with a 
hyperinsulinaemic euglycaemic clamp, the accompanying insulin resistance of 
glucose uptake was not associated with an accumulation of muscle 
acylcarnitines (Stephens et al. 2014). Rather, insulin resistance was 
accompanied by increased acetyl-CoA, the final product of β – oxidation and 
an allosteric inhibitor of the PDC. These findings provided evidence that in 
humans, excessive and not incomplete fatty acid oxidation causes insulin 
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resistance. It should be noted that evidence suggesting acylcarnitines directly 
impair insulin signalling stems from studies using cell culture models (Koves 
et al. 2008; Adams et al. 2009; Aguer et al. 2015). Though the potential role of 
acylcarnitines per se limiting glucose disposal in humans cannot be ruled out 
completely, it is likely that a number of factors (including accumulation of DAGs 
and ceramides) may contribute to insulin resistance seen with excessive fatty 
acid availability. The finding that some but not all ceramide and DAG species 
were elevated in the OO group (Chee et al. 2016) supports the latter notion.  
Previous studies from this group have shown that short chain acylcarnitines 
arising from excessive BCAA catabolism were closely associated with the 
reduced glucose disposal seen with lipid infusion during a euglycaemic 
hyperinsulinaemic clamp (Stephens et al. 2014). The results from this chapter 
do not show excessive BCAA catabolism under hyperinsulinaemic conditions 
despite a lower glucose disposal in OO. Therefore, it could be suggested that 
without a concomitant elevation in fatty acid availability an aggravating impact 
on muscle BCAA catabolism may not occur. Fatty acids have been shown to 
increase the activity of the BCKDH complex in rodents (Paul and Adibi 1992) 
and therefore the sustained presence of fatty acids (achieved with lipid 
infusion) may be required to increase BCAA catabolism. In the current study 
no change in the phosphorylation status of muscle BCDKH was observed 
before or after insulin infusion. Given that the OO had markedly lower GDR 
compared to OL, its is likely that there was some degree of elevated lipid 
availability during the clamp but without an assessment of the amount of fat 
oxidised it is uncertain as what level of increased fatty acid oxidation is 
required to increase BCAA catabolism. Of note, in a recent study in rodents 
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that utilised a stable isotope approach to measure BCAA metabolism in a 
range of organs, it was shown that mice fed a high fat diet did not elevate 
BCAA oxidation in muscle, but hyperphagic diabetic (db/db) mice did (Neinast 
et al. 2018). This may suggest that the severity of obesity and insulin 
resistance (such as in diagnosed T2D) may be a determining factor in the 
extent of the excess BCAA catabolism in muscle. 
5.5 Conclusion  
In conclusion age and obesity appear to have differential effects on skeletal 
muscle BCAA accumulation and metabolism in humans. The independent 
impact of age may be greater than the effect of obesity per se and future 
studies involving cohorts with a wide age range should account for this. The 
fact that muscle medium and long chain acylcarnitines were not associated 
with reduced glucose disposal rate (an index of insulin resistance) seen with 
increased overweight/obesity provide further evidence that those species may 
not be involved in the development of muscle insulin resistance. Further 
studies matching middle aged and older aged subjects for lean body mass are 
required to determine if the observed differences in muscle BCAA content 
persist independent of body composition. Studies investigating muscle BCAA 
metabolism in combination with fatty acid tracers are required to understand 
how one substrate may be impacted the other.
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6 Chapter 6. The effect of Type 2 diabetes 
and age on whole body fat oxidation and 
BCAA metabolism.
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6.1 Introduction  
Perturbations in BCAA metabolism have long been associated with obesity 
and insulin resistance (Felig, Marliss, and Cahill 1969). Interest in the 
interaction between BCAA and insulin resistance has been renewed in recent 
years based on the findings that a BCAA related signature was more closely 
associated with insulin resistance than lipid markers (Newgard 2012). 
Furthermore, baseline circulating BCAA concentrations were able to predict 
the future onset of type 2 diabetes (T2D) many years before disease 
progression (Wang et al. 2011). Moreover, Mendelian randomization analysis 
suggested a causal link between genetic variants associated to impaired 
BCAA catabolism and higher risk of T2D (Lotta et al. 2016). Therefore, there 
is growing evidence that high levels of BCAAs and related intermediate 
metabolites are not only T2D biomarkers but may also contribute to the 
pathogenesis of insulin resistance and T2D. Despite these associations, the 
mechanisms by which altered BCAA metabolism may precede and contribute 
to the development of skeletal muscle insulin resistance are unknown. 
Animal work suggests that obesity is associated with reduced BCAA 
catabolism in adipose tissue and liver (She et al. 2007; Herman et al. 2010; 
Zhou et al. 2019). Consequently, this may reroute systemic BCAAs to skeletal 
muscle where excessive BCAA oxidation may compete with fatty acids 
oxidation in the mitochondria (Newgard 2012; White et al. 2016). However, 
there is no evidence of reduced BCAA catabolism in human adipose tissue 
(Lackey et al. 2013b; Piro et al. 2020). Furthermore, the contribution of adipose 
tissue to BCAA catabolism in humans is likely to be small and the contribution 
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of BCAAs to mitochondrial oxidation is quantitatively minor in skeletal muscle 
(Wagenmakers, Salden, and Veerkamp 1985; Neinast et al. 2020). 
Previous work from this group has demonstrated that under lipid infusion in 
combination with hyperinsulinaemic-euglycaemic clamp conditions, BCAA-
derived short chain acylcarnitines were positively associated with insulin 
resistance to tissue glucose disposal (Stephens et al. 2014). More recently, it 
has been shown that 3-hydroxyisobutyrate (3-HIB), a catabolite of valine, is 
elevated in muscle of rodent and patients with T2D and this catabolite can 
leave the muscle cell and increase trans-endothelial flux of fatty acids into 
muscle in a paracrine manor (Jang et al. 2016). In chapter 4, fasting levels of 
short chain acylcarnitines from BCAA catabolism were increased in both 
muscle and plasma of patients with T2D. Therefore, it could be hypothesised 
that increased muscle BCAA catabolism, secondary to lipid-induced insulin 
resistance could lead to accumulation of BCAA catabolites in muscle which 
may in turn exacerbate the pre-existing insulin resistance. This may provide 
the mechanistic link between the associations of a BCAA related signature 
with obesity and insulin resistance previously observed. Indeed, more reports 
have demonstrated that higher BCAA levels do not have a casual effect on 
insulin resistance, rather insulin resistance drives higher fasting BCAAs (Wang 
et al. 2017; Mahendran et al. 2017) Alternatively, it has also been suggested 
that reduced BCAA catabolism in muscle may reduce muscle fatty acid 
oxidation through reduced anaplerosis of TCA intermediates (Lerin et al. 
2016). These findings were based largely on mRNA expression data and 
untargeted metabolite profiling.  
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In chapter 5, it was demonstrated that ageing and adiposity-induced insulin 
resistance exert differential effects on fasting muscle BCAA content, and the 
ability of insulin to suppress BCAA catabolism. These findings suggest that 
against the background of ageing, BCAA content may not always reflect insulin 
resistance. To date, no studies have quantitatively assessed markers of fatty 
acid and BCAA metabolism simultaneously in humans and how their 
relationship may be perturbed in T2D. 
6.1.1 Aims 
• To assess the effect of a chronic state of glucose dysregulation and 
insulin resistance on whole body meal derived fat oxidation in 
middle-aged patients with T2D and age- and adiposity-matched 
controls using an isotopically labelled fatty acid drink. 
• To investigate how ageing can modify this effect in a separate group 
of older patients with T2D with similar disease duration. 
• To determine how any differences in fatty acid handling may be 
related to perturbed skeletal muscle metabolism in both the fasting 
state and in response to endogenous insulin responses during an 
oral glucose tolerance test (OGTT). 
. 
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6.2 Methods  
6.2.1 Participants 
Seven middle-aged (MA-T2D) and 7 older-aged patients (OA-T2D) with T2D, 
matched for disease duration and metformin use, and 7 middle-aged 
normoglycemic controls (MA-CON) were recruited and volunteered to 
participate in this cross-sectional study that was part of bigger study 
investigating the effect of carnitine feeding on muscle metabolism (see chapter 
2 for details on patient recruitment). The T2D selected for this study were also 
matched for body composition to allow the comparison of age per se between 
the two T2D groups and diabetes per se between the two middle aged 
groups.The study was approved by the NHS Research Ethics Committee East 
Midlands, Nottingham and met the regulations outlined in the Declaration of 




Table 6.1 Participant characteristics of middle aged controls (MA-CON), 
middle aged Type 2 Diabetic patients (MA-T2D) and older aged Type 2 
Diabetic patients (OA-T2D). 
 MA-CON MA-T2D OA-T2D 
n 7 7 7 
Age (years) 44.4 ± 3.5 45.4 ± 1.3 63.4 ± 0.6 ### 
Body mass (kg) 98.7 ± 2.9 95.7 ± 3.9 90.8 ± 5.2 
BMI (kg/m2) 31.2 ± 1.5 30.5 ± 1.3 29.6 ± 1.3 
Fat free mass (kg) 64 ± 2.2 62.1 ± 1.3 58.7 ± 2.4 
Arm lean mass (kg) 7.8 ± 3.7 7.6 ± 5.4 6.6 ± 3.6 
Leg lean mass (kg) 20 ± 1.3 19.8 ± 1.1 18.3 ± 1.0 
Fat mass (kg) 33.3 ± 2.4 33.8 ± 4.0 30.2 ± 2.9 
Trunk fat mass (kg) 20.1 ± 2.0 20.3 ± 2.4 19.0 ± 1.8 
Arm fat mass (kg) 2.9 ± 0.3 3.2 ± 0.5 2.9 ± 0.2 
Leg fat mass (kg) 9.4 ± 0.3 9.4 ± 1.2 8.0 ± 1.0 
Body fat percentage 
(%) 
34.1 ± 2.0 34.7 ± 2.9 34.0 ± 1.3 
Fasting blood glucose 
(mmol/L) 
4.4 ± 0.2 6.8 ± 0.7 ** 5.8 ± 0.3 
Fasting serum insulin 
(mU/L) 
14.0 ± 2.2 18.2 ± 2.6 19.3 ± 3.6 
Years since diagnosis  3.7 ± 0.9 5.6 ± 1.7 
Metformin treatment 
(mg/d) 
 786 ± 241 1000 ± 327 
Data are mean ± SEM ** p < 0.01, MA-T2D compared to MA-CON. ### p < 
0.001, OA-T2D vs MA-T2D. 
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6.2.2 Experimental protocol 
This study consisted of a 3-day metabolic monitoring period to assess body 
composition and determine free-living dietary fat oxidation followed by a 
laboratory visit day in which subjects underwent a 2-hour OGTT. Blood 
samples were obtained before, during and after the OGTT, whereas muscle 
samples were obtained before and after the OGTT.  
6.2.2.1 Body composition and free-living measurements  
On the first day of the metabolic monitoring period the participant’s body 
composition was assessed by DEXA (chapter 2, section 2.2.4). Throughout 
the metabolic monitoring period, subjects recorded all food intake in a food 
diary. Physical activity levels (step counts) were also assessed for all 3 days 
of the metabolic monitoring period using pedometers (Actiheart, CamNtech 
inc., Cambridge, UK). On the day before the laboratory visit (day 3 of the 
metabolic monitoring period), subjects attended the laboratory in a fasted state 
between 8.00am and 9.00am, having refrained from all exercise including 
cycling commutes for 24 h before the visit. Subjects voided their bladder into 
an experimental container and then were weighed and asked to rest on a semi-
reclined position. Following this, 15 mg/kg [2H31] palmitate and 0.2g/kg 18O-
water stable-isotope tracers were suspended in a nutritionally balanced meal 
replacement drink (330 kcal: 44g carbohydrate, 11g fat, and 14g protein). The 
[2H31] palmitate was added to the meal replacement drink first, which was 
heated to 50° C to ensure the palmitate dissolved, after which the 18O-water 
was added. Subjects were allowed 10 minutes to consume the drink; all 
subjects consumed the drink in this time and in full. Upon completion, a timer 
was started to accurately determine 10 h after the drink was ingested. Subjects 
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were then provided with a container to collect all urine for the next 10 h upon 
leaving the lab. The container was kept cool with ice-packs (~4°C) until 
delivered to the lab on the following morning (laboratory visit). 
The ingestion of [2H31]palmitate was to determine free-living dietary fat 
oxidation in humans. This method has several advantages over the traditional 
13C method, including that tracer is not lost through the TCA cycle and that the 
stable-isotope tracer can be used in free-living conditions. Following oral 
ingestion, 2H labelled fatty acids such as [2H31]-palmitate are metabolised to 
acetyl CoA releasing NADH. The 2H is liberated as water (2H2O) when this 
NADH is oxidised during oxidative phosphorylation in the mitochondria, and 
the remaining 2H label is released as 2H2O during the oxidation of acetyl CoA 
in the TCA cycle. The 2H2O from both pathways mixes with body water, which 
is then excreted as urine, where it can be measured either laser-based 
spectroscopy (Votruba, Zeddun, and Schoeller 2001; A et al. 2004). 
 
6.2.2.2 OGTT 
Participants arrived at the laboratory at 08:00 after an overnight fast (10–12 h) 
having consumed a standardised meal the night before. In order to control for 
the effects of dietary factors and exercise on whole body and muscle 
metabolism during the 3-day metabolic monitoring period, the volunteers were 
provided with prescribed meals (55% of energy from carbohydrate, 30% fat, 
15% protein) based on estimated daily energy requirements and asked to 
refrain from strenuous exercise. The meals were based on habitual foods 
recorded in the diet diaries to help ensure compliance.Diabetic patients were 
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instructed to not take any of their diabetic medication on the day of the 
experiment visit. Subjects then rested in bed in a semi-supine position, and an 
intravenous cannula was inserted retrograde into the superficial hand vein of 
one arm for arterialized venous blood sampling. Arterialization of the venous 
sample was achieved by heating the hand to 50-55oC using hot-air warming 
unit (Gallen and Macdonald 1990). Indirect calorimetry was performed prior to, 
and during the final 20 minutes of the OGTT (Cosmed Quark RMR, Rome, IT). 
Subjects then underwent a standard 2h OGTT, consuming 75g dextrose 
dissolved in 300ml water 
An overview of the metabolic monitoring period and the OGTT is shown 
schematically in Figure 6.1 
 
 
Figure 6.1 Schematic overview of the 3-day metabolic monitoring period (top 
timeline) and the oral glucose tolerance test (OGTT) during the laboratory visit 
(bottom timeline). CGM refers to continuous glucose monitoring of free-living 
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glycaemic profile, but this data was not analysed as a part of the current 
chapter. Dual-Energy X-Ray Absorptiometry (DEXA). 
6.2.3 Sample collection and analysis  
Prior to the measurement of enrichment, all urine samples were made 
acellular. Samples were thawed on ice, transferred to 1.5ml centrifuge tubes, 
and were then centrifuged at 21,130 RCF for 30 minutes at 4°C (Eppendorf 
5424R, Hamburg, Germany). The supernatant was removed and transferred 
to a glass auto-sampler tube by passing through a 0.25 μm filter. Samples 
were then kept at 4°C throughout analysis. Urine samples were analysed for 
2H/1H and 18O/16O isotope ratios by infrared spectroscopy (Elemtex Ltd, UK) 
to calculate dietary fat oxidation and total body water, respectively (Votruba et 
al. Int J Obes 2001;25:1240-4). 
Arterialized venous blood samples were collected at every 15 minutes 
throughout the OGTT and analysed for glucose, insulin and FFA (as described 
in Chapter 2, section 2.3). Skeletal muscle samples were obtained from the 
vastus lateralis in the fasted state and immediately following the 2 h OGTT 
using the Bergstrom needle biopsy technique (Bergström 1975) and 
immediately frozen in liquid nitrogen-cooled 2-methylbutane and subsequently 
stored in liquid nitrogen until analysis. Muscle and plasma samples at time 0 
and 120 mins were analysed for BCAA, BCKA, free carnitine, acylcarnitine 
content (as described in chapter 3, section 3.2.2) and muscle protein 
expression of total BCKDH E1α and phospho S293 BCKDH as described in 
chapter 5 (section 5.3.4). 
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6.2.4 Statistical analysis  
The aim of this chapter was to independently compare the effect of T2D and 
age per se on fat and BCAA metabolism. Therefore, differences in group 
participant characterises were compared with separate students paired t test 
(MA-CON vs MA-T2D and MA-T2D vs OA-T2D). The within and between 
group differences in the fasted state and in response to OGTT were 
determined using two separate, two way ANOVAs (2 factors of group (T2D 
and age) and OGTT) This design does not permit the comparison of MA-CON 
with the OA-T2D group. When a significant main effect was observed, a Sidak 
post hoc test was performed to identify individual differences. Statistical 
significance was set at P < 0.05, and all values are presented as means ± 
SEM. When referring to chain lengths AC were grouped as short (C3-C5), 
medium (C6- C10) and long-chain (C12-C20). Summed BCAA refers to the 
summation of leucine, isoleucine and valine concentrations. Summed BCKA 
refers to the summation of α-ketoisocaproic (KIC), α-keto-β-methylvaleric acid 
(KMV) and α-ketoisovaleric acid (KIV) concentrations. 
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6.3 Results  
6.3.1 Participant characteristics and free-living measurements  
Subjects were well matched for body composition and there were no 
differences between total and regional lean or fat mass between groups as 
assessed by DEXA. MA-T2D and OA-T2D were well matched for years since 
diagnosis and metformin usage. The average daily energy intake in the 3 days 
prior to the OGTT test day was not different between any groups. Although, 
MA-CON had a numerically higher total energy intake this was not different to 
MA-T2D or OA-T2D. The macronutrient composition (expressed as 
percentage of total energy intake) and physical activity level was not different 
between groups (Table 6.2). 
Table 6.2 Average energy intake and percentage contribution of each 
macronutrient for the 3 days prior to OGTT 
 MA-CON MA-T2D OA-T2D 
Average energy intake (Kcal)  2722 ± 338 2077 ± 280 2071 ± 169 
Carbohydrate (%) 43 ± 1 43 ± 3 38 ± 2  
Fat (%) 37 ± 2 37 ± 2 38 ± 3 
Protein (%) 18 ± 2 21 ± 4 16 ± 2 
Actiheart activity counts 8.1 ± 2.5 11.1 ± 4.2 9.1 ± 2.9 
Data are mean ± SEM. n = 7. Actiheart activity counts are a daily average of 
a 3-day period. 
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6.3.2 Dietary fat oxidation  
MA-T2D had a higher (10 hour) dietary-derived fat oxidation compared to MA-
CON (p = 0.03). There was trend (p =0.08) for meal derived fat oxidation to be 
lower in OA-T2D when compared to MA-T2D. Differences in meal derived fatty 
acid oxidation are shown in Figure 6.2. 
 
Figure 6.2 10-hour meal derived fat oxidation from a meal replacement drink 
as assessed by % deuterium recovery from urine samples * p < 0.05 MA-T2D 
compared to MA-CON. Data are mean ± SEM. n = 6.  
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6.3.3 Response to OGTT 
6.3.3.1 Glucose 
MA-CON vs MA T2D 
Fasting glucose was higher in MA-T2D vs MA-CON (Table 6.1) and increased 
in response to OGTT in both groups but was higher in at each time point from 
30 mins, reaching a peak at 75 minutes at concentrations of 9.3 and 14.5 
mmol/L in MA-CON and MA-T2D, respectively (Figure 6.3A). Whereas plasma 
glucose declined in MA-CON, it remained significantly elevated for the 
remainder of the OGTT in MA-T2D (interaction effect p < 0.001). At the end of 
the OGTT, plasma glucose decreased to 7.0 and 12.6 mmol/L in MA-CON and 
MA-T2D, respectively. Accordingly, the total iAUC for glucose was significantly 
greater in MA-T2D compared to MA- CON over the 120-minute period (p = 
0.004) (Figure 6.4 A). 
MA-T2D vs OA- T2D 
There was no difference in fasting blood glucose concentrations between MA-
T2D and OA-T2D or at any time point during the OGTT (Figure 6.3A). A peak 
glucose concentration of 12.9 mmol/L was reached at 90 mins and did not 
decline thereafter such that glucose concentration was 11.4 mmol/L at the end 
of the OGTT in OA-T2D. There was no difference in iAUC of glucose during 
OGTT between the 2 groups (Figure 6.4 A). 
6.3.3.2 Serum Insulin  
MA-CON vs MA T2D 
There was no significant difference in fasting insulin concentrations between 
the two groups. There was a sharp rise in insulin concentration in MA-CON 
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and as with glucose, concentrations peaked at 75 minutes at a concentration 
of 136.2 mU/L (Figure 6.3B). In contrast, the insulin response was blunted in 
MA-T2D which did not reach statistical significance (main effect of diabetes p 
= 0.08). Insulin concentrations reached peak values of 66.7 mU/L at 90 mins 
(Figure 6.3B). Post hoc analysis revealed that insulin concentrations were not 
significantly different to the fasting value at any point during the OGTT in MA-
T2D (interaction effect p = 0.06). However, the iAUC for insulin (Figure 6.4 B) 
was significantly lower in MA-T2D when compared to MA-CON during OGTT 
(p = 0.03). 
MA-T2D vs OA-T2D 
There were no differences in fasting insulin concentrations and no difference 
in the insulin response to OGTT between MA-T2D and OA-T2D (Figure 6.2B). 
Serum insulin levels reached a peak concentration of 78.7 mU/L at 105 
minutes in OA-T2D but levels were no different to MA-T2D at any time point. 
Accordingly, there were no differences in iAUC for insulin between the two 
groups (Figure 6.4 B). 
6.3.3.3 Plasma FFA 
MA-CON vs MA T2D 
There were no differences in fasting plasma FFA concentrations between 
groups (Figure 6.3C). OGTT resulted in a suppression of FFAs such that final 
concentrations were 10-fold lower in MA-CON but only 4-fold lower after OGTT 
in MA-T2D (interaction effect p = 0.01) indicating attenuated suppression of 
FFA in MA-T2D compared to MA-CON. 
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MA-T2D vs OA-T2D 
Fasting FFA concentrations did not differ between the two groups and despite 
lower numerical values throughout the OGTT there was no difference in the 
FFA response to OGTT between the two groups (Figure 6.3C). 
The glucose, insulin and FFA response to OGTT are shown in Figure 6.3 
6.3.3.4 Energy expenditure  
There were no differences in fasting or OGTT energy expenditure between 
any of the groups. There was significant effect of OGTT in all groups on fat 
oxidation which declined during OGTT in all groups. The indirect calorimetry 
data are shown in Table 6.3. 
Table 6.3 Indirect calorimetry data for the three groups during the fasted state 
and final 20 minutes of OGTT. Data are mean ± SEM. n = 5 for MA-CON and 
n = 7 for MA- and OA- T2D. 
 MA -CON MA -T2D 0A-T2D 




103 ± 7 106 ± 7 104 ± 2 105 ± 3 95 ± 5 101 ± 5 
Fat oxidation 
(kj/kg lbm/min) 
91 ± 26 59 ± 14 84 ± 13 58 ± 7 83 ± 13 46 ± 12 
Fat % of EE 83 ± 21 55 ± 13 80 ± 23 54 ± 6 84 ± 10 44 ± 10 
Data are mean ± SEM. n = 5 for MA-CON and n = 7 for MA- and OA-T2D; 





Figure 6.3 Plasma glucose (A), serum insulin (B) and plasma free fatty acid 
(C) concentrations during an oral glucose tolerance test. * p < 0.05, ** P < 
0.01 and *** P < 0.001 MA-T2D different from MA-CON There was also a 
main effect of interaction (p = 0.01) for plasma FFA between MA-CON and 
MA-T2D. Data are mean ± SEM. n = 7.  
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Figure 6.4 Incremental area under the curve (iAUC) for plasma glucose (A) 
and serum (B) responses over the 120-minute oral glucose tolerance. Data 
are mean ± SEM n =7. * p < 0.05 and ** P < 0.01 MA-T2D different from MA-
CON.  
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6.3.4 Muscle metabolites 
6.3.4.1 BCAA and BCKA 
MA-CON vs MA-T2D 
ANOVA revealed a main effect of T2D (p = 0.003) and OGTT (p < 0.001) on 
total muscle BCAAs. Fasting total BCAA was 49% higher in MA-T2D 
compared to MA-CON (p = 0.008) and declined 32 % (p = 0.04) and 45 % (p 
< 0.001) with OGTT in MA-CON and MA-T2D, respectively (Figure 6.5 H). 
There was a main effect of T2D and OGTT (p <0.001 for both) and strong trend 
for their interaction (p = 0.06) for both muscle leucine and isoleucine. Fasting 
muscle leucine was 55% higher in MA-T2D vs MA-CON (p < 0.001) and 
declined 43 % (p = 0.002) and 51% (p < 0.001) with OGTT in MA-CON and 
MA-T2D, respectively (Figure 6.5 A). Fasting muscle isoleucine was 47% 
higher in MA-T2D vs MA-CON (p = 0.006) and declined 43 % (p < 0.001) and 
54% (p < 0.001) with OGTT in MA-CON and MA-T2D, respectively (Figure 6.5 
B). There was a main of T2D (p = 0.009) and OGTT (p = 0.002) on muscle 
valine. Fasting concentrations were 46 % higher in MA-T2D (p = 0.003) and 
declined numerically but not significantly 23 % and 38% % (p = 0.005) with 
OGTT in MA-CON and MA-T2D, respectively (Figure 6.5 C). 
There were no differences in the fasting intramuscular concentrations of any 
of the three BCKAs (Figure 6.5E-H). There was a main effect of OGTT on 
muscle KIC and post hoc analysis revealed a trend for a decline in 
concentration in MA-CON (p = 0.07). Muscle KMV was reduced following 
OGTT in MA-T2D but not in MA-CON (interaction effect p=0.02). 
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MA-T2D vs OA-T2D 
There was strong trend for fasting muscle leucine to be (20%) lower and its 
suppression during OGTT to be lower in OA-T2D compared to MA-T2D 
(interaction effect p = 0.06) (Figure 6.5A). Fasting concentrations declined 51 
% (p < 0.001) and 34% (p = 0.08) in MA-T2D and OA-T2D, respectively. There 
was significant interaction effect for muscle isoleucine (p = 0.04) driven by 
(20%) lower fasting isoleucine (p = 0.05) and attenuated suppression during 
OGTT in OA-T2D (38, p = 0.001) %vs MA-T2D (54%, p <0.001) (Figure 6.5B). 
There were no differences in fasting muscle valine or total BCAA content 
between groups (despite an 18% numerical increase for both) and OGTT 
reduced their content (p = 0.004 and p = 0.04 for MA-T2D and OA-T2D, 
respectively) (Figure 6.5C-D). There were no differences between groups in 
any of the BCKAs in the fasted state and there was no effect of OGTT in either 




Figure 6.5 Skeletal muscle leucine (A) isoleucine (B) valine (C) and total branched 
chain amino acid (BCAA) (D), KIC (D) KMV (E) and KIC (F) and total branched chain 
keto acid (BCKA) in the fasted stated and post OGTT. ** p < 0.01 and *** p < 0.001 
MA-T2D compared to MA-CON. ^ p < 0.05, ^^ p < 0.01 and ^^^ p < 0.001 post OGTT 
different from corresponding fasting value. Data are mean ± SEM n =7  
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6.3.4.2 Carnitine and acylcarnitines 
MA-T2D vs OA-T2D 
There were no differences between groups in free carnitine at either time point 
(Table 6.4). Muscle acteylcarntine content did not differ in the fasted state but 
there was a main effect of OGTT (p = 0.006). (Table 6.4). Independent t tests 
revealed no significant difference in any single acylcarnitine species between 
the two groups in the fasted state or after OGTT. When short, medium, and 
long chain-chain acylcarnitines were summed there was no differences 
between groups in the fasted state or post OGTT (Table 6.4). OGTT 
significantly reduced total short (p=0.01) and long (p=0.04) but not medium 
chain acylcarnitines in both groups. 
MA-T2D vs OA- T2D 
There were no differences between groups in fasting free carnitine content 
and there was no effect of OGTT (Table 6.4). Fasting muscle acetylcarnitine 
content was not different between groups in the fasting or post OGTT state. 
Total fasting short, medium and long chain acylcarnitines did not differ 
between groups and ANOVA revealed a significant main effect of OGTT for 
short (p=0.001) and long (p=0.04) chain acylcarnitines and a trend (p=0.06) 
for medium chains but specific post hoc comparisons were not significant. 
A full profile of muscle acylcarnitine concentrations in the fasted and post 




Table 6.4 Skeletal muscle free carnitine, acetylcarnitine and the sum of short, medium, and long chain acylcarnitines in the fasted 
state and in response to oral glucose tolerance test (OGTT). 
 MA -CON MA -T2D OA -T2D 
 Fasting Post OGTT Fasting Post OGTT Fasting Post OGTT 
Free carnitine  
(mmol/kg dm) 
11.4 ± 0.7 12.7 ± 1.6 13.4 ± 2 11.9 ± 1.9 13.9 ± 0.8 13.8 ± 1.8 
Acetylcarnitine 
(mmol/kg dm) 
1.8 ± 0.5 0.6 ± 0.1 1.7 ± 0.3 0.9 ± 0.2 1.7 ± 0.6 0.6 ± 0.1 
Short chain acylcarnitine (C3-C5) 
(µmol/kg dm) 
47 ± 4.7 39.8 ± 4.2 54 ± 6.0 38 ± 6.9  60 ± 8.1 43 ± 8.6 
Medium chain acylcarnitine (C6-C10) 
(µmol/kg dm) 
10.3 ± 1.9 9.7 ± 2.4 13.0 ± 4.8 8.7 ± 2.0 16.9 ± 4.0 5.7 ± 0.7 
Long chain acylcarnitine (C12-C18) 
(µmol/kg dm) 
67.7 ± 24.5 22.5 ± 6.1 66.7 ± 28.3 23.3 ± 8.5 78.7 ± 40.8 10.5 ± 1.6 
Data are mean ± SEM. n = 7. OGTT significantly reduced total short- (p<0.02) and long- (p<0.05) acylcarnitines and acetylcarnitine 
(p<0.02) regardless of group
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6.3.5 Plasma metabolites  
6.3.5.1 BCAA and BCKAs 
MA-CON vs MA-T2D 
There was a main effect of T2D and OGTT (p < 0.001 for both main effects) 
on total and each individual BCAA. Fasting plasma leucine was (19%) higher 
in MA-T2D (p= 0.02) and concentrations reduced in both groups (p < 0.001 
and p = 0.003 for MA-CON and MA-T2D, respectively) but post OGTT 
concentration was 43% higher in MA-T2D (p = 0.002) (Figure 6.6A). Fasting 
plasma isoleucine was also (19%) higher in MA-T2D (p = 0.02) and 
concentrations reduced in both groups (p < 0.001 and p = 0.001 for MA-CON 
and MA-T2D, respectively) but post OGTT concentration was 36 % higher in 
MA-T2D (p = 0.01) (Figure 6.6B). Fasting plasma valine was (19%) higher in 
MA-T2D (p = 0.01) and concentrations reduced in both groups (p < 0.001 and 
p = 0.001 for MA-CON and MA-T2D, respectively) but post OGTT 
concentration was 28% higher in MA-T2D (p = 0.01) (Figure 6.6C).  
There were main effects of T2D (p = 0.04) and OGTT (p < 0.001) on both 
plasma KIC and KMV. Fasting plasma KIC and KMV and KIV concentrations 
(Figure 6.6E-G) were not different between the two groups. However, OGTT 
reduced plasma KIC (p = 0.002) and KMV (p = 0.003) in MA-CON resulting in 
lower post OGTT KIC (p = 0.01) and KMV (p = 0.03) concentrations when 
compared to MA-T2D. Plasma KIV was not different between groups in the 




MA-T2D vs OA- T2D 
There were no differences in fasting or post OGTT concentrations of each 
BCAA between groups (Figure 6.6A-C). Post OGTT concentrations for all 3 
BCAAs were significantly reduced relative to fasting concentrations (OGTT 
effect p < 0.001 for both groups for each BCAA). There were no differences in 
fasting or post OGTT plasma BCKAs concentrations between groups (Figure 
6.6E-G). Only KIC and KMV concentrations reduced (p<0.0001 for both) 
following OGTT (p = 0.005 and p = 0.002 for MA-T2D and OA- T2D, 
respectively for KIC, and p = 0.008 and p = 0.002 for MA-T2D and OA- T2D, 




Figure 6.6 Plasma leucine (A) isoleucine (B) valine (C) and total branched 
chain amino acid (BCAA) (D), KIC (D) KMV (E) and KIC (F) and total branched 
chain keto acid (BCKA) in the fasted stated and post OGTT * p < 0.05 and ** 
p < 0.01, MA-T2D compared to MA-CON. ^ p < 0.05, ^^ p < 0.01 and ^^^ p < 
0.001 post OGTT different from fasting value. Data are mean ± SEM n =7  
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6.3.5.2 Free carnitine and acylcarnitines  
MA-CON vs MA-T2D 
There were no differences in fasting or post OGTT values between groups for 
free carnitine and acetylcarnitine concentrations (Table 6.5). Acetylcarnitine 
declined from fasting values in both groups after OGTT (p < 0.001). Fasting 
plasma total short chain acylcarnitines were higher in MA-T2D (p = 0.003) and 
remained elevated post OGTT (p =0.02) compared to MA-CON (main effect of 
T2D p=0.005; Table 6.5). This elevation was driven by significantly higher 
fasting (p < 0.001) and post OGTT (p=0.001) C3 acylcarnitine and elevated 
fasting (p=0.03) and post OGTT (p=0.03) iso C5 in the former group (T2D effect 
p = 0002 and interaction effect p=0.02; Figure 6.7). In addition, elevated fasting 
C4 (p = 0.01) and C5:1 (T2D effect p = 0.03 and interaction effect p=0.004) were 
also observed in MA-T2D when compared to MA-CON. Plasma iso C4 was 
higher in MA-T2D post OGTT (p = 0.04 and main T2D effect p= 0.03) (Figure 
6.7). There were no significant T2D or interaction effects for plasma total 
medium and long chain acylcarnitines (Table 6.5). OGTT reduced the 
concentrations of total medium and long chain acylcarnitines to a similar extent 
in both groups (OGTT effect p=0.003 and p<0.001, respectively).  
MA-T2D vs OA-T2D 
There were no differences in fasting or post OGTT values between groups for 
free carnitine and acetylcarnitine concentrations (Table 6.5). Plasma 
acetylcarnitine declined from similar fasting values in both groups (OGTT 
effect p < 0.001). Total short chain acylcarnitines were lower in OA-T2D than 
MA-T2D in the fasted state and post OGTT (age effect p=0.008; Table 6.5). 
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This was driven by lower fasting (p < 0.001) and post OGTT (p = 0.004) C3 
(age effect p < 0.001), lower fasting iso C5 (group effect p = 0.02) levels (Figure 
6.7). OGTT reduced plasma total medium and long chain acylcarnitines to a 
similar extent in both groups (OGTT effect p < 0.001 for both groups). 
A full profile of plasma acylcarnitine concentrations in the fasted and post 
OGTT state can be seen in Appendix E 
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Figure 6.7. Plasma short chain acylcarnitine profile in the fasted state (A) and 
post OGTT (B). * p < 0.05, ** p < 0.01 and *** p < 0.001 MA-T2D compared to 
MA-CON. # p < 0.05, OA-T2D different to MA-T2D. ^ p < 0.05, ^^ p < 0.01 and 
^^^ p < 0.001 post OGTT different from fasting value. Data are mean ± SEM n 
=7
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Table 6.5 Plasma free, acetylcarnitine and the sum of short, medium and long chain acylcarnitines in the fasted state and in response 
to oral glucose tolerance test (OGTT).  
 MA -CON MA -T2D OA -T2D 
 Fasting Post OGTT Fasting Post OGTT Fasting Post OGTT 
Free carnitine 
(µmol/L) 
41.0 ± 3.9 43.5 ± 2.4 41.9 ± 1.5 42.6 ± 1.7 41.9 ± 2.9 41.5 ± 2.4 
Acetylcarnitine  
(µmol/L) 
8.1 ± 0.5 4.4 ± 0.4  7.8 ± 1.1 4.5 ± 0.6  7.0 ± 0.5 4.1 ± 0.3  
Short chain acylcarnitine (C3-C5)  
(µmol/L) 
0.7 ± 0.1 0.7 ± 0.04 1.0 ± 0.1 ** 1.0 ± 0.04* 0.8 ± 0.02 ## 0.7 ± 0.02# 
Medium chain acylcarnitine (C6-C10)  
(µmol/L) 
0.5 ± 0.1 0.3 ± 0.03 0.4 ± 0.1 0.32 ± 0.04 0.6 ± 0.1 0.4 ± 0.03 
Long chain acylcarnitine (C12-C18) 
(µmol/L) 
0.6 ± 0.02 0.4 ± 0.03 0.46 ± 0.01 0.32 ± 0.04 0.5 ± 0.03 0.3 ± 0.02 
Data are mean ± SEM. n = 7. * p < 0.05 and ** p < 0.01 MA-T2D different to the corresponding MA-CON value. # p < 0.05 and ## p 
< 0.01 OA-T2D different to corresponding MA-T2D value. OGTT reduced plasma acetylcarnitine (p < 0.001), total short , medium 
and long chain acylcarnitine in all groups (p < 0.05).
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6.3.6 BCKDH protein expression 
There were no differences in the ratio of phosphorylated amount of the 
E1α subunit of the BCKDH complex between MA-CON and MA-T2D 
or MA-T2D and OA-T2D in the fasted state. ANOVA for MA-CON vs 
MA-T2D revealed a main effect of OGTT (p=0.02) indicating an 
increase regardless of treatment.  
 
Figure 6.8 Muscle pS293 phosphorylated E1α component of the 
branched chain keto acid dehydrogenase complex. Post OGTT values 
for OA-T2D are missing due to insufficient sample number. Data are 
mean ± SEM. n = 6.  
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6.4  Discussion  
T2D is characterised by derangements in glucose, lipid and protein 
metabolism. The use of an isotopically labelled fat drink and the application of 
the analytical method developed and validated in the previous experimental 
chapters in this thesis enabled an integrative assessment of multiple 
substrates at the whole-body level and in skeletal muscle. The findings from 
the current study reveal that compared to their middle aged, obese control 
subjects, patients with T2D exhibited an increased meal derived fat oxidation 
and an attenuated ability to suppress plasma FFA with OGTT. This was 
accompanied by marked elevations in plasma and muscle BCAA content and 
plasma (but not muscle) short chain acylcarnitines providing further evidence 
that excessive muscle fatty acid oxidation may contribute to increased BCAA 
catabolism in humans. Interestingly, these responses appear to be reversed 
in the older aged T2D group.  
The T2D patients in the current study clearly demonstrated the twin defects 
that define the condition (Kahn, Hull, and Utzschneider 2006). Compared to a 
well-matched group for body composition, the middle-aged diabetic group 
displayed hyperglycaemia and a lower insulin response to OGTT, reflecting an 
impairment in β-cell function and insulin release. Aging per se did not appear 
to exacerbate these defects but the differences in fatty acid and amino acid 
metabolism highlight that despite being matched for body composition and 
disease duration, T2D in older age appears to represent a different metabolic 
phenotype compared to middle aged patients suggesting that careful 
considerations should be made when assessing T2D in large cohorts across 
a large age range. 
 227 
In response to dietary fat intake, adipose tissue provides an appropriate site 
of fat storage (Frayn 2002). Reduced adipose tissue storage of fatty acids from 
chylomicron TAG (i.e. dietary fat) has been observed in obese individuals 
(McQuaid et al. 2011) and is proposed to be the pathophysiological basis of 
diversion of fatty acid to other organs such as liver and skeletal muscle and 
even the pancreatic β-cell (R Taylor 2013), resulting in tissue insulin 
resistance. Indeed, increased accumulation of liver and intramuscular lipid 
content differentiates insulin resistant and insulin sensitive obese phenotypes 
(Stefan et al. 2009). The finding from the current study that dietary derived 
fatty acid oxidation was elevated in middle aged diabetics could reflect an 
impairment of adipose tissue function resulting in inappropriate fat ‘spill over’ 
to ectopic organs. Increased postprandial fat delivery to, and extraction by 
muscle of postprandial TAG has been observed in insulin resistant men (van 
Hees et al. 2011). Uptake and utilisation of this elevated circulating fatty acid 
may consequently compete with glucose for oxidation in the classic concept 
of the glucose-fatty acid cycle proposed by Randle and colleagues (Randle et 
al. 1963). Therefore, in times where fatty acids should be routed towards 
esterification and storage, they are oxidised ectopically as fuel in the presence 
of concomitantly available glucose. This notion is supported by recent findings 
in rodents with lipodystrophy (a state defined by a lack of adipose tissue and 
early onset of diabetes), which provides insight into the immediate 
consequences of surplus fat ingestion. In response to a high formulation fat 
ingestion, lipodystrophic mice displayed marked increases in fatty acid 
oxidation to match fat intake which was accompanied by worsening of 
hyperglycaemia and hyperinsulinemia and liver TAG accumulation (Girousse 
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et al. 2018). These findings highlight the deleterious consequences of the 
inability to appropriately store meal derived fatty acid and support the findings 
of increased meal fatty acid oxidation seen in the current study. When 
combined with the observation of an attenuated suppression of endogenous 
FFA mobilisation during OGTT in the middle-aged T2D group, these findings 
suggest excessive postprandial fat delivery to ectopic sites such as muscle, 
liver and pancreas, impairing insulin action in the middle-aged but not older 
group with T2D. The finding that muscle acetylcarnitine (which could be 
formed from excess acetyl CoA produced from continued fat delivery to, and 
oxidation by, the muscle) was less suppressed with OGTT in the MA-T2D 
group further supports this notion. Taken together it is clear that the MA-T2D 
group is burdened by an inappropriate increase in both exogenous and 
endogenous delivery of fatty acids to skeletal muscle in the postprandial 
(insulin stimulated) state.  
The absence of a middle-aged lean group precluded the ability to assess the 
effect of obesity per se on metabolism. However, when compared to age and 
body composition matched obese controls, T2D per se is characterised by 
marked increases in fasting muscle and circulating BCAA concentrations as 
well circulating BCAA derived short-chain acylcarnitines This is consistent with 
findings from chapter 4, in which a larger cohort of subjects with a wider age 
range were studied. In the current work, the MA-CON group were also obese 
(BMI 31.2) yet muscle BCAAs were ~50% higher in MA-T2D, suggesting that 
elevations in BCAA in humans may be a consequence rather than a cause of 
insulin resistance and diabetes. Although plasma BCAAs were also elevated 
with diabetes, the lack of arterial-venous differences measurements across 
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the muscle precludes the ability to judge any direction of flux to/from the tissue. 
However, the increase in plasma BCAAs was modest (~20%) and it is unlikely 
that muscle uptake of circulating BCAAs (resulting from reduced catabolism in 
other tissues) would be the sole cause of such markedly elevated muscle 
BCAA content.  
These findings are important as longitudinal and cross sectional studies have 
suggested that BCAA and related catabolites could be implicated in the 
progression of insulin resistance (T. J. Wang et al. 2011) but have often 
compared only lean and obese individuals in the fasted state (Newgard et al. 
2009). Therefore, if elevated BCAAs caused insulin resistance in obese 
individuals, it would be expected an increase in their circulating or tissue 
concentration would precede the development of insulin resistance and T2D. 
In this study, all groups were well matched for body composition, dietary 
intake, and physical activity. Thus, the increase in BCAA in muscle and plasma 
is likely to reflect the insulin resistant state. The findings from this study extend 
upon much of previous work measuring fasting metabolite profiles (Newgard 
et al. 2009; Lerin et al. 2016).  
In response to OGTT there was a clear impairment of the suppression of 
plasma BCAA and BCKAs (KIC AND KMV) in the MA-T2D compared to the 
MA-CON group, which could be indicative of on-going whole body proteolysis 
and possibly oxidation and this response did not appear to be exacerbated by 
age. This is line with the blunted insulin response to OGTT in MA-T2D and 
OA-T2D and is reflective of the lower levels of circulating insulin and its potent 
inhibition of muscle protein breakdown (Tessari et al. 1986). However, BCAA 
content in muscle declined to similar concentrations in all groups and without 
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the calculation of flux across the muscle it is not possible to make any 
inferences on the extent to which muscle may have contributed to persistent 
elevations of intramuscular BCAA post OGTT. Therefore, a role of impaired 
insulin-stimulated uptake of BCAA during OGTT cannot be ruled out. It is likely 
that multiple organs are contributing to plasma metabolite concentrations and 
there is likely to be exchange of these metabolites between multiple tissues. 
Emerging evidence from human studies have demonstrated that obesity and 
insulin resistance is associated with increased whole body (Tan et al. 2020) 
and visceral adipose tissue BCAA oxidation (Piro et al. 2020) rather than 
impaired BCAA catabolism as seen in rodent studies (Zhou et al. 2019). Given 
that in the MA-T2D group there was a significant reduction in plasma BCAA 
derived acylcarnitines yet still remained significantly elevated compared to the 
MA-CON post OGTT suggests a degree of ongoing catabolism. These findings 
question the validity of previous rodent studies suggesting reduced BCAA 
catabolism with insulin resistance and their application to human metabolism. 
One reason for this discrepancy of findings may be due to the fact that skeletal 
muscle comprises a much smaller percentage of the total body mass in rats 
(Wolfe 2017). Therefore, proteolysis of skeletal muscle and its contribution to 
circulating pools may not be significant in that model.  
The ability to quantitively assess fat oxidation and BCAA content in the present 
study enabled exploration of possible interactions between the two respective 
pathways. The finding that the elevations in meal derived fat oxidation in MA-
T2D vs MA-CON is mirrored by elevated muscle and plasma BCAA content 
suggests a potential cause and effect relationship. Previous work from our 
group has shown that muscle BCAA derived short chain acylcarnitines were 
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negatively correlated with insulin-stimulated glucose disposal and muscle 
glycogen storage during lipid infusion in combination with a hyperinsulinaemic-
euglycaemic clamp, an acute experimental model that drove high muscle fat 
oxidation even in the presence of high levels of circulating insulin (Stephens 
et al. 2014). Furthermore, plasma short chain acylcarnitine and muscle C5:1 
positively correlated with fasting blood glucose in chapter 4. The fact that short 
chain acylcarnitines were not elevated in muscle of MA-T2D but were in 
chapter 4 (where a greater number of subjects were studied n = 10) may be 
due a lack of statistical power in the present study. Taken together with the 
former report, these findings point to a novel locus of interaction between 
excessive fatty acids and perturbed BCAA metabolism. Therefore, it could be 
suggested that the findings from the longitudinal studies implicated BCAA 
catabolites with the progression of insulin resistance (Wang et al. 2011; Menni 
et al. 2013) could simply be the reflection of deranged muscle metabolism. It 
could be proposed that obesity (with a possible contribution of inactivity) 
related alterations in BCAA metabolism leads to an accumulation of BCAA in 
muscle and possible spill over into the circulation. Overtime, as insulin 
resistance is exacerbated and clinically overt T2D develops BCAA catabolism 
is increased due to the complete loss of insulin sensitivity/release as observed 
in this study. Coupled to an aggravating effect of increased muscle lipid 
availability due to impaired adipose tissue lipid trafficking (McQuaid et al. 2011; 
Brøns and Grunnet 2017), a positive feedback cycle may be set in motion, 
whereby lipid induced insulin resistance promotes BCAA catabolism which 
worsens insulin resistance. Under these circumstance short chain 
acylcarnitines may too, spill over into the circulation over time. Although organ 
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flux studies have shown liver is the main contributor to fasting acylcarnitine 
profiles (Schooneman et al. 2015; G. Xu et al. 2016), no studies have 
determined how muscle flux changes in insulin resistance states, particularly 
when muscle is burdened with excess lipids as described in this work. Studies 
in larger cohorts are required to confirm these assumptions. It is also important 
to highlight that both T2D groups in this study had a deficiency in glucose-
stimulated insulin release, which is different to the experimental model used in 
the previous section in which exogenous insulin was administered under 
clamp conditions without a concomitant elevation of circulating fatty acids 
through infusion.  
BCAA and fatty acids both require esterification to form acylcarnitines to 
transport their respective CoA adducts across mitochondrial membranes. It 
has been suggested that excessive BCAA catabolism may compete with fatty 
acid oxidation in the mitochondria leading to incomplete fatty acid oxidation 
and the accumulation of medium- and long-chain acylcarnitines (Newgard 
2012; White et al. 2016). However, more recent studies using stable isotope 
tracers to measure the fate of BCAA in rodents have shown that the fractional 
contribution of BCAA to the TCA in skeletal muscle is smaller (5%–6%) than 
that of fatty acids so that even a large increase in BCAA oxidation is not likely 
to significantly compete with fatty acids (Neinast et al. 2018). Alternatively, 
impairments in BCAA catabolism in muscle may impair fatty acid oxidation by 
reduced anaplerosis and replenishment of intermediates required for fatty acid 
oxidation, leading to the accumulation of medium and long chain acylcarnitines 
(Lerin et al. 2016). However, in the current study there were no observed 
differences in muscle or plasma free carnitine content between any groups 
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and no accumulation in muscle of medium or long chain acylcarnitines (even 
in chapter 4 where more subjects were studied). Together with the finding that 
fatty acid oxidation was increased in MA-T2D, these findings suggest that in 
humans, increased and not incomplete oxidation of fatty acids (in the insulin 
stimulated state) is associated with insulin resistance and T2D.  
The experimental design of the current study also allowed for a comparison of 
age per se on T2D. Strikingly, despite a similar attenuation of insulin secretion 
and resultant hyperglycaemia during the OGTT, the older aged T2D patients 
did not exhibit many of the adverse effects seen with T2D per se in middle 
aged group. For example, given an attenuate insulin response to OGTT in MA-
T2D compared MA-CON it could have been argued that the higher meal 
derived fat oxidation (in MA-T2D vs MA-CON) was due simply to a reduced 
insulin response and not adipose tissue dysfunction. However, the finding that 
OA-T2D could supress plasma FFA for same insulin response as MA-T2D 
would suggest a dysfunction in MA-T2D and a different phenotype of disease. 
Consequently OA-T2D are not burdened by post prandial fatty acid delivery 
and the mechanism underlying the T2D is different to the mechanisms in MA-
T2D. Indeed, age per se is associated with an increased risk of T2D, even 
when controlling for body composition, by some level of age related decline in 
pancreatic β- cell function possibly mediated by a degree of age specific 
inflammation (De Tata 2014; Löhr et al. 2018) which could explain the 
differences between the T2D groups (i.e there may be an age related decline 
in pancreatic function rather than impaired adipose tissue function in the OA-
T2D group). 
 234 
Consistent with the findings from the previous chapter, intramuscular BCAA 
content appears to decline with age in the diabetic populations, regardless of 
the insulinaemic and glycaemic responses to OGTT and therefore 
postprandial insulin resistance. In chapter 5, the young lean group had higher 
total and leg lean mass so it could be argued that the reduced BCAA content 
simply reflected lower lean leg mass. However, in the current study, subjects 
were closely matched for lean mass yet an age-related decline in muscle 
BCAA content was still present in the fasted state. A novel finding of this study 
was that plasma short chain acylcarnitines of BCAA catabolism were also 
lower in the OA-T2D group compared to MA-T2D. This could reflect an age 
related reduction of whole body protein/BCAA turnover (Morais et al. 1997) 
despite the presence of insulin resistance. However, it could also provide 
further support for the notion mentioned above, with regards to an aggravating 
effect of excessive fatty acid oxidation on muscle BCAA metabolism in the MA-
T2D group. It is tempting to speculate that the absence of excessive lipid 
supply in the OA-T2D group prevented perturbations of BCAA metabolism. 
This was the first study to assess fat oxidation and BCAA flux and provides 
the framework for future studies to tease out the effect of age and fatty acid 
availability on BCAA metabolism.  
Given that there were no differences in plasma BCAA concentrations between 
the two T2D groups despite lower muscle BCAA content in the older T2D 
group suggests that plasma BCAA concentrations may not accurately reflect 
muscle tissue metabolism in ageing. Furthermore, older age was associated 
with reduced plasma BCAA-derived short chain acylcarnitines suggesting that 
these species are not accurate biomarkers of insulin resistance and T2D in the 
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context of ageing. In response to the OGTT however, the OA-T2D did not 
display a significant reduction in muscle BCKAs, suggesting some ongoing 
muscle BCAA catabolism which is consistent with the findings in chapter 5. 
Furthermore, there were no differences between MA-T2D and OA-T2D in 
plasma BCAAs or BCKAs reduction in response to OGTT. These findings are 
difficult to reconcile but may in part be explained by the notion that there are 
differential sensitivities of insulin on glucose, fatty acid and BCAA metabolism 
(Boirie et al. 2001) and each aspect should be considered as a separate entity 
with regards to insulin resistance, particularly in the face of 
perturbed/differential fatty acid availability. 
The finding that neither elevated whole body meal derived fat oxidation nor 
attenuated suppression of endogenous fat delivery during the OGTT was 
reflected in differences in plasma fatty acid derived (medium and long chain) 
acylcarnitine profiles between groups may suggest that the measurement of 
these species lack sufficient sensitivity to accurately determine tissue level 
substrate oxidation. These findings argue against previous reports that have 
measured plasma acylcarnitines and attempted to draw conclusions about 
muscle metabolism (Mihalik et al. 2010). Furthermore, it has been 
demonstrated in rodents, that in response to an OGTT the only tissue that 
appeared to reflect plasma acylcarnitine profiles was the heart (Makrecka-
Kuka et al. 2017) providing further evidence that plasma acylcarnitines may 
not be an appropriate biomarker for skeletal muscle insulin resistance. 
No differences in phosphorlayion status of the BCKDH complex was observed 
in the current study. The BCKDH complex is also regulated by intracellular 
energy status; a high NADH/NAD ratio as would occur when fatty acid 
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oxidation is high could inhibit BCAA oxidative flux in muscle leading to efflux 
into the plasma as an alternative fate. High lipid availability leading to insulin 
resistance has also been shown to impair muscle protein synthesis in humans 
(Stephens et al. 2015; Smiles et al. 2019) which could in part be contributing 
to accumulation of intramuscular BCAA. How strategies to improve insulin 
sensitivity through the modulation of muscle fatty acid metabolism impact upon 
BCAA levels requires investigation. 
6.5 Conclusion  
In conclusion, excessive lipid availability and oxidation in the postprandial 
(insulin stimulated) state appears to differentiate middle aged obese 
individuals from T2D patients. This is accompanied by marked elevations in 
circulating and muscle BCAA content and may in part being contributing to 
perturbed BCAA metabolism. Remarkably, age per se does not appear to 
exacerbate any of these derangements in metabolism in T2D, rather it appears 
to reverse some of the effects seen in the middle aged T2D group. These 
discrepancies cannot be explained by differences in disease duration, body 
composition, physical activity, or energy intake. Taken together these findings 




7 Chapter 7 General Discussion
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7.1 Overview of findings  
A primary aim of this thesis was to develop a targeted analytical method for 
the absolute quantification of a number of circulating metabolites strongly 
associated with insulin resistance and type 2 diabetes (T2D). In recent years, 
BCAAs, fatty acids and associated catabolites have been implicated in the 
development of insulin resistance. However, much of the mechanistic 
investigation has been performed in animal or cell-based models which may 
not encapsulate various physiological aspects of human metabolism. 
Furthermore, investigations in humans have been limited to either the fasted 
state or analysis of plasma profiles, providing little insight into tissue 
metabolism. 
In chapter 3, a liquid chromatography coupled to high resolution mass 
spectrometry (LC-MS) method was developed, optimised and validated in 
accordance with the FDA analytical guidelines for method development (FDA 
and CDER 2018). The method met the major validation criteria required for the 
accurate assessment of metabolite concentrations from biological tissues. 
Application of the developed LC-MS method to healthy human samples 
demonstrated that calculated concentrations of metabolites were strongly 
consistent with numerous well-established methods for individual metabolites. 
In chapter 4, the method was validated in plasma and skeletal muscle of 
patients with T2D. The method confirmed previous findings that a circulating 
BCAA related signature is more closely associated with insulin resistance and 
T2D than markers of fatty acid metabolism (i.e. medium and long chain 
acylcarnitines) (Newgard 2012). A novel finding was that skeletal muscle 
BCAA and short chain BCAA-derived acylcarnitines were also elevated in 
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muscle and plasma of patients with T2D providing evidence for a possible 
association between muscle and plasma profiles. 
In chapter 5, it was revealed that ageing, despite being accompanied with a 
slight degree of insulin resistance, appeared to reduce intramuscular BCAA 
content, whereas the presence of increased adiposity and worsening of insulin 
resistance appeared to increase fasting muscle BCAA content. Thus, against 
a background of ageing and adiposity there appears to be a dissociation 
between BCAA content and insulin resistance. These findings were confirmed 
in chapter 6 where groups of individuals with and without T2D were well 
matched for body composition, energy intake and physical activity. In addition, 
the work in chapter 6 revealed that the perturbed BCAA metabolism in T2D 
was mirrored by increased meal derived fatty acid oxidation in middle aged but 
not older aged T2D patients. These findings revealed that regardless of insulin 
resistance age per se may represent a distinct phenotype of BCAA 
perturbation. 
7.2 Development of a targeted method  
In chapter 3, the commonly cited challenges associated with quantifying 
metabolites from biological samples using LC-MS based methodologies were 
systematically addressed. These challenges included chromatographic and 
mass spectrometry optimisation, ensuring accurate and precise measured 
concentrations of the analytes in the complex biological matrices and the 
ability to measure all the analytes in a single biological sample.  Utilising 
isotopically labelled analytes and the standard addition method, analytical 
parameters of linearity (R2 >0.99), precision, accuracy, recovery, stability, and 
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reproducibility were all confirmed in both human plasma and skeletal muscle 
tissue. These results confirmed the appropriateness of the extraction protocol 
used throughout this thesis. Due to laborious nature of the standard addition 
method, the internal standard method in an appropriate proxy matrix substitute 
of muscle and plasma (7.5% BSA in PBS) was also optimised and validated 
against the same analytical criteria for industry (Fda and Cder 2018). 
Assessment of metabolite concentrations from both methods had very close 
agreement (within 5 % for most metabolites). Collectively, these results 
demonstrate the method developed in chapter 3 provides a robust and 
accurate assessment of metabolite concentrations in human biological 
samples. 
The advantage of the developed method was that it provided accurate 
concentrations of a large range of metabolites (BCAAs, BCKA, free carnitine 
and >40 acylcarnitines) from one single extraction protocol. The use of both 
reversed phase and HILIC chromatography enabled the detection of multiple 
metabolites that span different orders of magnitude in abundance. For 
example, free carnitine is in the mmol/kg (dry mass) range whereas 
acylcarnitines are in the nmol/ kg (dry mass) range. Thus, from one extraction 
protocol and two analytical acquisitions, an accurate assessment of 
carbohydrate, fatty and BCAA metabolites in skeletal muscle can be 
ascertained. 
7.3 The effect of T2D per se on BCAA metabolism 
The developed method revealed striking differences in a BCAA related 
signature between a middle-aged group with T2D and an age matched obese 
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group without T2D. Circulating BCAA and short chain acylcarnitines derived 
from BCAA catabolism were all significantly elevated with T2D, consistent with 
earlier reports (Newgard et al. 2009). Moreover, they correlated significantly 
with fasting blood glucose concentrations. Furthermore, BCKAs, despite not 
being statistically elevated in the T2D group also correlated with blood 
glucose. Collectively, these findings demonstrated marked alterations in 
BCAA catabolism which are likely a consequence of T2D. When investigating 
skeletal muscle, T2D was characterised by marked increases in muscle BCAA 
content and BCAA derived acylcarnitines. Interestingly muscle and plasma 
BCAA and C5:1 (derived from leucine) was positively correlated, suggesting 
that muscle may also be contributing to circulating profiles. This is in contrast 
to speculative rodent literature which have implied that muscle simply acts as 
a ‘sink’ for BCAAs which accumulate secondary to reduced adipose tissue and 
liver BCAA catabolism (She, Van Horn, et al. 2007; Herman et al. 2010; White 
et al. 2016; Zhou et al. 2019). However, evidence in humans has shown that 
BCAA catabolism is not impaired but is increased, both in adipose tissue (Piro 
et al. 2020) and at the whole body level (Tan et al. 2020). Together with the 
findings within this thesis, this questions the validity of rodent models and 
questions the proposed notion that increasing BCAA catabolism is a viable 
treatment for insulin resistant states (Zhou et al. 2019).  
7.4 The effect of age on BCAA metabolism  
One consistent finding in this thesis was that age is negatively correlated with 
fasting BCAA content, regardless of increased insulin resistance. In chapter 5, 
total BCAA content was ~ 30 % lower in older lean subjects compared to a 
younger lean but more insulin sensitive group. In chapter 6, despite being 
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equally insulin resistant an older aged T2D group had 20 % lower BCAA 
content compared to middle aged T2D patients (Figure 7.1). Interestingly, 
ageing also appears to be associated with attenuated suppression of muscle 
BCAA catabolism regardless of insulin sensitivity. The impact, if any, of this 
reduced attenuation of BCAA catabolism on total skeletal muscle protein 





Figure 7.1 Fasting muscle total branched chain amino acid (BCAA) content 
measured using targeted metabolomics across increasing age and degrees of 
insulin resistance from all the groups measured throughout this thesis. Age 
per se appears to reduce muscle BCAA content whereas insulin resistance 
per se appears to increase muscle BCAA content. The young lean (n=7) and 
old lean (n=9) group were matched for BMI, but the old lean had less overall 
lean mass and were slightly less insulin sensitive. The old obese (n=9) and old 
lean group were matched for age, but the obese group were markedly less 
insulin sensitive as assessed by glucose disposal under clamp conditions. The 
middle-aged obese group (n=7) were matched for body composition with the 
middle-aged type 2 diabetic (T2D) group (n=7) but were more insulin sensitive. 
The older aged T2D group (n=7) were matched for body composition and 
equally insulin resistant as the middle aged T2D group. Data are mean ± SEM. 
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7.5 Acylcarnitines and insulin resistance  
Fatty acid derived acylcarnitines have been implicated as potential causative 
markers of insulin resistance (Koves et al. 2008). Numerous studies have 
profiled circulating plasma acylcarnitines and found elevations in obese and 
insulin resistant individuals (Adams et al. 2009; Mihalik et al. 2010). Whilst in 
vitro evidence has shown that acylcarnitines can cause muscle insulin 
resistance (Céline Aguer et al. 2015b), there is a dearth of evidence linking 
fatty acid derived acylcarnitines and insulin resistance in humans. For any 
acylcarnitine species to cause insulin resistance in muscle, it would be 
expected that their accumulation will precede the development of insulin 
resistance. Throughout the experimental chapters in this thesis, it has been 
shown that medium and long chain acylcarnitines are suppressed in the insulin 
stimulated state despite markedly lower glucose disposal, dissociating them 
from the development of insulin resistance. In chapter 5, a young lean and 
highly insulin sensitive group had higher fasting muscle medium and long 
chain acylcarnitine content compared to older lean (matched for body fatness) 
albeit slightly less insulin sensitive group. Furthermore, no differences in fasted 
fatty acid derived acylcarnitines in plasma was observed between insulin 
sensitive and insulin resistant obese individuals. Moreover, medium and long 
chain acylcarnitines did not reflect the differences in meal derived fat oxidation 
and circulating FFA during OGTT between the middle-aged individuals with 
and without T2D in chapter 6. Therefore, unless tissue acylcarnitine flux is 
calculated using stable isotope tracers (which will be the basis of future work), 
assumptions on changes in fatty acid oxidation and insulin sensitivity based 
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on static acylcarnitine concentrations should be avoided and are not 
appropriate.  
Conversely, short chain, BCAA derived acylcarnitines were elevated in muscle 
of patients with T2D and obese insulin resistant subjects (chapter 5). These 
findings confirm previous work from this group which has shown muscle short 
chain acylcarnitines appear to be more closely associated with insulin 
resistance (Stephens et al. 2014). Striking elevations of these species were 
evident in plasma which persisted in the insulin stimulated state. Again, age 
per se appeared to cause a decline in these species in the circulation despite 
a similar insulin release in response to OGTT. What role these species have 
in the development of insulin resistance remains unknown. 
7.6 Potential impact of fat oxidation on BCAA 
metabolism 
In chapter 6, the fate of meal derived fat was quantitatively assessed in middle 
aged obese individuals with and without T2D as well as an older aged T2D 
group, matched for disease duration. The middle-aged T2D group displayed 
higher meal derived fatty acid oxidation and a reduced ability to suppress 
circulating FFA flux during an OGTT, as well as markedly higher muscle BCAA 
content compared to the other groups. These findings extend upon previous 
work from this group which showed elevated fatty acid availability and 
oxidation in muscle resulted in the accumulation of BCAA derived short chain 
acylcarnitines which were negatively correlated with insulin-stimulated glucose 
disposal and glycogen storage (Stephens et al. 2014). In support of this, short 
chain acylcarnitines correlated with fasting blood glucose in chapter 4. 
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Therefore, a proposed model from this thesis would be, ectopic fat spill over 
into skeletal muscle (and other insulin sensitive tissues) can lead to the 
development of insulin resistance and an increased muscle BCAA catabolic 
flux which may exacerbate insulin resistance. Indeed, it has been 
demonstrated that catabolites of valine can leave the muscle cell and further 
drive fatty acids into the cell in a paracrine fashion (Jang et al. 2016). Thus, a 
vicious cycle is set in motion which results in further perturbations of BCAA 
metabolism and increased insulin resistance. Overtime, catabolites of BCAA 
degradation may also spill over into the circulation, supported by the finding 
that C5:1 acylcarnitine concentrations were positively correlated between 
muscle and plasma in chapter 4. Further time course work is required to 
investigate these proposed mechanisms. The differences in fatty acid 
trafficking (i.e. postprandial delivery) may in part explain the reductions in 
muscle BCAA and circulating short chain acylcarnitines seen in the older aged 
T2D group in chapter 6. 
7.7 Limitations of the current work  
One limitation of the analytical method developed in chapter 3 is that it was 
unable to distinguish between structural isomers of certain species that 
ultimately surfaced as key sites of interaction between BCAA and lipid 
metabolism. Therefore, despite high levels of confidence in metabolite 
concentrations in tissue, the results from muscle should still be interpreted with 
caution. For example, the intramuscular concentrations of the species C4-OH 
can be derived from both ketone bodies and valine catabolism and the species 
C4-DC can be produced from both methylmalonyl-CoA and succinyl-CoA, 
which can be generated in valine and isoleucine catabolism, respectively. 
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Furthermore, the distinction of C4 acylcarnitine in muscle was not possible, as 
this species can be derived from lipid and valine metabolism. Future work 
should aim to refine this method further to enable chromatographic separation. 
Nevertheless, the current analytical method was able to extract and quantify a 
wide range of metabolites with one simple extraction protocol from multiple 
biological matrices. It is likely that modifications in the extraction protocol, 
which may include derivatisation of acylcarnitines could improve 
chromatographic performance but compromise the range of analyte coverage.  
Another limitation of this work is that all comparisons in the experimental 
chapters are cross sectional in nature and therefore it is difficult to assess how 
the significant elevations in metabolites observed throughout the experimental 
chapters contribute to, or simply reflect metabolic changes associated with, 
age and insulin resistance. Nevertheless, prior to the work in chapter 3, a 
simple yet accurate and quantitative method to measure these metabolites in 
human samples was lacking. This analytical method can now be used in 
interventional studies to assess how these metabolites may change over time. 
The finding that short chain acylcarnitines increased in muscle of T2D patients 
in chapter 4 (with 10 subjects) but not in chapter 6 (with 7 subjects) could point 
to a lack of statistical power to detect differences in muscle content. Indeed, 
when assessing the absolute concentrations, acylcarnitines are several fold 
and sometimes an order of magnitude lower in abundance in muscle 
compared to BCAAs which were observed to be different in both chapters. 
Interestingly, differences in short chain acylcarnitines were observed in 
plasma regardless of subject number. This could be explained by the larger 
heterogeneity in tissue samples compared to plasma. Future work should aim 
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to address this by using larger cohorts. The work in this thesis is the first to 
quantify these metabolites simultaneously in human skeletal muscle and 
plasma and can be used for power calculations for future studies. 
7.8 Future directions  
The metabolite data presented throughout this thesis represent only 
‘snapshots’ of dynamic processes. However, the findings from the present 
thesis do extend upon much of previous work that has only measured BCAAs 
and acylcarnitines in the fasted state and mostly in plasma. Future work should 
investigate tissue level flux of these metabolites to ascertain how impairments 
in tissue metabolism are related to their plasma profile. The finding that muscle 
and plasma C5:1 was strongly correlated between both pools, and this species 
was also significantly corelated with fasting blood glucose, provides novel 
evidence of a potential cross talk between muscle and the circulating pool. 
This is in contrast to medium and long chain acylcarnitines derived from fatty 
acid metabolism which do not appear to accurately reflect different states of 
insulin sensitivity. 
In chapter 6, meal derived fatty acid oxidation was elevated when assessed 
using stable isotope tracers, but this was not reflected in differences of any of 
the measured acylcarnitines. It is largely unknown how fatty acid flux relates 
to acylcarnitine flux, but it is likely that the former is perhaps orders of 
magnitude greater than the later. The analytical method developed in chapter 
3 has limits of detection and quantification well below the biological range of 
BCAA and acylcarnitine abundance. Therefore, the current method can be 
applied to samples to not only measure concentration but also tracer 
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enrichments of acylcarnitines. This would provide novel insights into human 
fatty acid flux under diverse metabolic circumstances. The method is at 
present being developed further to measure tracer enrichment in muscle 
samples. 
With the analytical method developed in the current thesis, it was not possible 
to distinguish subcellular localisation of metabolites. This may be of relevance 
as acylcarnitines are produced in the mitochondria and then exported into the 
cytoplasm and finally can be exported into the circulation. Given that 
acylcarnitnes have been shown to induce insulin resistance in vitro but not in 
vivo suggests that factors beyond simply their abundance may underlie their 
propensity to cause insulin resistance. For example, the accumulation of other 
lipid metabolites such as DAGs and ceramides have been associated with 
insulin resistance but the findings have been inconsistent across multiple 
different methodologies and experimental models (Bosma et al. 2012), and 
even augmenting their total abundance in muscle does not always result in 
insulin resistance (Timmers et al. 2012). These inconsistencies may be 
reconciled by determining the subcellular and membrane localisation of these 
metabolites (Kahn et al. 2021). A new emerging technology, ORBI-SIMS has 
since been able to combine the high spatial resolution of secondary ion mass 
spectrometry (sims; under 200 nm for inorganic species and under 2 mm for 
biomolecules) with the high mass-resolving power of an orbitrap (>240,000 at 
m/z 200). This allows exogenous and endogenous metabolites to be 
visualized in 3D with subcellular resolution (Passarelli et al. 2017). Application 
of such methods to skeletal muscle may provide the answers to the 
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inconsistent findings across different experimental models of insulin resistance 
and diabetes when assessing the role of acylcarnitines. 
A consistent finding from metabolite profiling in human skeletal muscle was 
that the acylcarnitine species C4-DC was elevated in both T2D and 
overweight/obese individuals. Given that this metabolite has also been 
identified in plasma samples of T2D patients (Mihalik et al. 2010) may suggest 
this species could be considered as a novel biomarker of tissue insulin 
resistance. It is likely that highly sensitive measurements such as magnetic 
resonance spectroscopy would need to be developed to tracer the fate of 
BCAA derived metabolites into the mitochondria. 
7.9 Conclusions 
Largely association-based evidence renewed research interest in the potential 
role of altered BCAA metabolism in the development of insulin resistance and 
T2D. However, research into the cellular mechanisms to substantiate this 
hypothesis is lacking. The work in this thesis investigated muscle BCAA 
metabolism using quantitative metabolomics in both the fasting and 
postprandial/insulin stimulated state in ageing, obesity and T2D. Collectively, 
the results demonstrate that perturbed BCAA metabolism is likely a 
consequence of altered carbohydrate and fat metabolism that underlies the 
development of insulin resistance rather than directly contributing to these 
metabolic changes and not a cause of insulin resistance in humans. Moreover, 
combined with the use of stable isotope tracer assessment of dietary fatty acid 
oxidation, these findings provide further human in vivo evidence that insulin 
resistance is a state characterised by increased fatty acid oxidation and BCAA 
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catabolism, as opposed to incomplete and/or impaired catabolism of these 
metabolic fuels as suggested by previous rodent studies and human 
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115.0400 Negative 2.5 3.8 NCE KIV 
120.0568 Negative 2.5 3.8 NCE 13CKIV 
129.0557 Negative 4.5 6 NCE KIC/KMV 







204.123 Positive 1 4 NCE C2 
207.1418 Positive 1 3 NCE D-C2 
218.1387 Positive 3.4 4.4 NCE C3 
221.1575 Positive 3.4 4.4 NCE D-C3 
230.1387 Positive 4 5 NCE C4:1 
232.1543 Positive 4.4 5.4 NCE C4 
235.1732 Positive 4.4 5.4 NCE D-C4 
244.1538 Positive 5 6 NCE C5:1 
246.1700 Positive 5.3 6.2 NCE C5 
248.1125 Positive 2 7 NCE C3-DC 
248.1488 Positive 3 6 NCE C4-OH 
255.2265 Positive 5.3 6.2 NCE D-C5 
258.1700 Positive 5 6 NCE C6:1 
260.1856 Positive 6.4 7.4 NCE C6 
262.1649 Positive 3.5 4.5 NCE C5-OH 
266.1385 Positive 5 6 NCE C1-PHE 
274.2013 Positive 7 8 NCE C7 
276.1438 Positive 3.5 4.5 NCE C5-DC 
276.1806 Positive 4.5 5.5 NCE C6-0H 
286.2014 Positive 7 8 NCE C8:1 
 300 
288.2169 Positive 8 9 NCE C8 
291.2358 Positive 8 9 NCE D-C8 
304.211 Positive 6.5 7.5 NCE C8-OH 
310.2013 Positive 8 9 NCE C10:3 
314.2326 Positive 9 10 NCE C10:1 
316.2482 Positive 9 10 NCE C10 
332.2431 Positive 8 11 NCE C10-OH 
344.2795 Positive 10 11 NCE C12 
368.2795 Positive 10 11 NCE C14:2 
370.2952 Positive 10 11 NCE C14:1 
372.3108 Positive 10.5 11.5 NCE C14 
381.3673 Positive 10.5 11.5 NCE D-C14 
396.3108 Positive 10 11 NCE C16:2 
398.3262 Positive 10.5 11.5 NCE C16:1 
400.3421 Positive 11.4 12.4 NCE C16 




416.3376 Positive 10.5 11.5 NCE C16-0H 
422.3260 Positive 10.5 11.5 NCE C18:3 
424.3421 Positive 11 12 NCE C18:2 
426.3578 Positive 11 12.3 NCE C18:1 
428.3734 Positive 12 13 NCE C18 
444.3684 Positive 11 13 NCE C18:0H 
448.3421 Positive 11 12 NCE C20:4 
456.4047 Positive 13.2 14 NCE C20 
342.263 Positive 9 10 NCE C12:1 
388.2628 Positive 9.5 10.5 NCE C14:3 
394.2947 Positive 9.8 11 NCE C16:3 
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Appendix B Free carnitine concentration  
 
Association between the calculated concentration of free carnitine in human 
skeletal muscle from the established radioactive assay and the newly 
developed LC-MS/MS method in chapter 3. Data for concentrations from the 









Appendix C Muscle acylcarnitine profiles  
Muscle short chain acylcarnitines  
 
Full profile of skeletal muscle short chain (C3-C5) acylcarnitines during the 
fasted state (A) and following the 3-hour clamp (B). Data are mean ± SEM. n 
= 7, YL. n = 9, OL n= 9, OO 
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Muscle medium chain acylcarnitines  
 
Full profile of skeletal muscle medium chain (C6-C10) acylcarnitines during 
the fasted state (A) and following the 3-hour clamp (B). Data are mean ± SEM. 








Muscle long chain acylcarnitines 
 
Full profile of skeletal muscle long chain (C12-C18) acylcarnitines during the 
fasted state (A) and following the 3-hour clamp (B). Data are mean ± SEM. n 







Appendix D Muscle acylcarnitine profiles  
Muscle short chain acylcarnitines 
 
Full profile of skeletal muscle short chain (C3-C5) acylcarnitines during the 
fasted state (A) and following a 2-hour oral glucose tolerance test (B). Data 
are mean ± SEM. n = 7 
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Muscle medium chain acylcarnitines 
 
Full profile of skeletal muscle medium chain (C6-C10) acylcarnitines during 
the fasted state (A) and following a 2-hour oral glucose tolerance test (B). Data 
are mean ± SEM. n = 7 
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Muscle Long chain acylcarnitines 
 
Full profile of skeletal muscle long chain (C12-C18) acylcarnitines during the 
fasted state (A) and following a 2-hour oral glucose tolerance test (B). Data 
are mean ± SEM. n = 7 
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Appendix E Plasma acylcarnitine profiles  
Plasma medium chain acylcarnitines 
 
Full profile of plasma medium chain (C6-C10) acylcarnitines during the fasted 
state (A) and following a 2-hour oral glucose tolerance test (B). Data are mean 
± SEM. n = 7 
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Plasma long chain acylcarnitines 
 
Full profile of plasma long chain (C12-C18) acylcarnitines during the fasted 
state (A) and following a 2-hour oral glucose tolerance test (B). Data are mean 
± SEM. n = 7 
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Appendix F PIP reflective statement 
Note to examiners: 
This statement is included as an appendix to the thesis in order that the thesis 
accurately captures the PhD training experienced by the candidate as a 
BBSRC Doctoral Training Partnership student. 
The Professional Internship for PhD Students is a compulsory 3-month 
placement which must be undertaken by DTP students. It is usually centred 
on a specific project and must not be related to the PhD project. This reflective 
statement is designed to capture the skills development which has taken place 
during the student’s placement and the impact on their career plans it has had. 
I completed my PIP at Maastricht University in the Netherlands under the 
supervision of Professor Luc Van Loon and Dr Jorn Trommelen. I chose to 
travel to Maastricht University because of its reputation and expertise in 
utilising stable isotope tracers to investigate human metabolism. I wished to 
gain insight into how such studies were designed and conducted. In addition, 
I was able to expand upon my analytical skillset by spending time in stable 
isotope research centre (SIRC) and learned many new laboratory 
techniques. 
My primary responsibilities involved the set up and running of two human 
studies which utilised stable isotope tracers. The first investigated how 
different types of protein (whey and casein) consumed prior to sleep 
impacted upon muscle protein synthesis during recovery from endurance 
type exercise. This study involved exercising participants in the evening and 
collecting blood samples throughout the night. This study had obvious 
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challenges (not least staying awake) but most importantly I gained a 
thorough appreciation of costs involved in conducting studies using stable 
isotopes and the diligence required at every step so that any risk of wasting 
expensive tracer is mitigated. The second study involved investigating the 
effect of consuming different amounts (moderate or large) of proteins and 
measuring muscle protein synthesis over a 12-hour recovery period 
following resistance exercise. This was my first experience of conducting 
resistance training in a research setting and I learned how to accurately 
assess maximal strength. 
I also spent time in the SIRC and was introduced to the technique of gas 
chromatography linked isotope ratio mass spectrometry (GC-IRMS). This 
was particularly exciting as I had only read about this technique and did not 
have any working appreciation of how to operate the instrument. I got to 
speak at length with mass spec technicians and provided my own input into 
how to overcome a number of analytical challenges often faced when using 
mass spec. I also spent time in lab learning the protein extraction protocol 
used to prepare samples for GC-IRMS analysis.  
Upon completion of the studies, my supervisor gave me thorough 
explanation of how the numerous calculations are performed from the stable 
isotope infusions studies we ran, and I was able to understand how 
numerical data generated from lab analysis in the SIRC is used to compute 
muscle and whole-body synthetic, breakdown and oxidation rates. This was 
my primary objective, and I was delighted to achieve it. 
Indirectly, I also learned a lot from other PhD students in the department 
who I shadowed during lab days. For example, I did not have any previous 
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experience of using deuterated water to assess energy expenditure and 
protein synthesis. Although I had read literature about this technique, I had 
no real understanding of how it was applied and how the analysis is 
performed. Luckily, I shared an office with 3 incredibly bright students who 
explained the basis of this technique and calculations. 
Though I had not anticipated it, I also had the opportunity to supervise a 
number of under and post graduate students through their final year 
projects. I thoroughly enjoyed this experience and learned a lot as a result. 
Another unanticipated skill I developed during my time working with Jorn 
was how to communicate science succinctly to lay audiences. Jorn has a 
large social media (something I generally avoid) presence and has 
understood how to exploit it to its full potential to disseminate his research 
to the public. In the Netherlands, this is becoming a crucial question that 
researchers grant providers ask, what is the wider impact this research will 
have on the public? Admittingly, I had no appreciation of this before working 
with Jorn, but I realised that the way in which the lay public interact and 
understand the type of science I am interested in, is drastically different to 
how I do. 
From a personal perspective I learned a lot from living in a new country for 
3 months. I met a vast range of people and was able to put my 
conversational German skills to good use, whilst trying my best to pick up 
some Dutch. Most importantly, it gave me a new perspective on research 
and how other groups in this area of research operate. 
 
